




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07C 315/00		A2	(11) International Publication Number: WO 99/47497
			(43) International Publication Date: 23 September 1999 (23.09.99)
(21) International Application Number: PCT/CA99/00212		(81) Designated States: AE, AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, UA, US, UZ, VN, YU, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).	
(22) International Filing Date: 12 March 1999 (12.03.99)			
(30) Priority Data: 60/077,990 13 March 1998 (13.03.98) US 9815856.1 21 July 1998 (21.07.98) GB			
(71) Applicant (for all designated States except US): MERCK FROSST CANADA & CO. [CA/CA]; 16711 Trans-Canada Highway, Kirkland, Quebec H9H 3L1 (CA).		Published Without international search report and to be republished upon receipt of that report.	
(72) Inventors; and (75) Inventors/Applicants (for US only): GAREAU, Yves [CA/CA]; (CA). LABELLE, Marc [CA/CA]; (CA). JUTEAU, Helene [CA/CA]; (CA). GALLANT, Michel [CA/CA]; (CA). LACHANCE, Nicolas [CA/CA]; (CA). BELLEY, Michel [CA/CA]; 16711 Trans-Canada Highway, Kirkland, Quebec H9H 3L1 (CA).			
(74) Agent: MURPHY, Kevin, P.; Swabey Ogilvy Renault, Suite 1600, 1981 McGill College, Montreal, Quebec H3A 2Y3 (CA).			

(54) Title: CARBOXYLIC ACIDS AND ACYLSULFONAMIDES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT



(57) Abstract

Compounds of formula (I), as well as pharmaceutically acceptable salts, hydrates and esters thereof, are disclosed. The compounds are useful for treating or preventing prostaglandin mediated diseases. Pharmaceutical compositions containing such compounds and methods of treatment are also included.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

5

CARBOXYLIC ACIDS AND ACYLSULFONAMIDES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT

BACKGROUND OF THE INVENTION

10

The present invention relates to compounds which are useful for treating or preventing prostaglandin mediated diseases, methods of treatment and pharmaceutical compositions containing such compounds. The compounds are structurally different from conventional NSAIDs and opiates, and are antagonists of the pain and inflammatory effects of E-type prostaglandins.

15

Two review articles describe the characterization and therapeutic relevance of the prostanoid receptors as well as the most commonly used selective agonists and antagonists: *Eicosanoids: From Biotechnology to Therapeutic Applications*, Folco, Samuelsson, Maclouf, and Velo eds, Plenum Press, New York, 1996, chap. 14, 137-154 and *Journal of Lipid Mediators and Cell Signalling*, 1996, 14, 83-87. An article from *The British Journal of Pharmacology* (1994, 112, 735-740) suggests that Prostaglandin E₂ (PGE₂) exerts allodynia through the EP₁ receptor subtype and hyperalgesia through EP₂ and EP₃ receptors in the mouse spinal cord.

20

25

Thus, selective prostaglandin ligands, agonists or antagonists, depending on which prostaglandin E receptor subtype is being considered, have anti-inflammatory, antipyretic and analgesic properties, and in addition inhibit hormone-induced uterine contractions. Moreover, the compounds have anti-cancer effects.


30

The compounds have a reduced potential for gastrointestinal toxicity, a reduced potential for renal side effects, a reduced effect on bleeding times and a lessened ability to induce asthma attacks in aspirin-sensitive asthmatic subjects.

35

5 SUMMARY OF THE INVENTION

The present invention relates to compounds represented by formula I:



I

10 as well as pharmaceutically acceptable salts, hydrates and esters thereof, wherein:

HET represents a 5-12 membered monocyclic or bicyclic aromatic ring system containing 0-3 heteroatoms selected from O, S(O)_n and N(O)_m wherein m is 0 or 1 and n is 0, 1 or 2;

15 A is a one or two atom moiety and is selected from the group consisting of: -W-, -C(O)-, -C(R⁷)₂-W-, -W-C(R⁷)₂-, -CR⁷(OR²⁰)-, -C(R⁷)₂-, -C(R⁷)₂-C(OR²⁰)R⁷-, -C(R⁷)₂-C(R⁷)₂- or -CR⁷=CR⁷-, wherein W represents O, S(O)_n or NR¹⁷, with n as previously defined and R¹⁷ as defined below;

20 X represents a 5-10 membered monocyclic or bicyclic aryl or heteroaryl group having 1-3 heteroatoms selected from O, S(O)_n and N(O)_m, and optionally substituted with R¹⁴ and R¹⁵, and A and B are attached to the aryl or heteroaryl group ortho relative to each other;

Y represents O, S(O)_n, NR¹⁷, a bond or -CR¹⁸=CR¹⁸-;

25 B represents -(C(R¹⁸)₂)_p-Y-(C(R¹⁸)₂)_q-

wherein p and q are independently 0-3, such that when Y represents O, S(O)_n, NR¹⁷ or -CR¹⁸=CR¹⁸-, p + q = 0-6, and when Y represents a bond, p + q is 1-6;

Z is OH or NHSO₂R¹⁹;

30 R¹ R² and R³ independently represent H, halogen, lower alkyl, lower alkenyl, lower alkynyl, lower alkenyl-HET(R^a)₄₋₉-, (C(R⁴)₂)_pSR⁵-, (C(R⁴)₂)_pOR⁸-, (C(R⁴)₂)_pN(R⁶)₂-, CN, NO₂-, (C(R⁴)₂)_pC(R⁷)₃-, CO₂R⁹-, CON(R⁶)₂ or (C(R⁴)₂)_pS(O)_nR¹⁰, wherein n and p are as previously defined;

35 each R⁴ is independently H, F, CF₃ or lower alkyl,

5 or two R^4 groups are taken in conjunction and represent a ring of up to six atoms, optionally containing one heteroatom selected from O, $S(O)_n$ or $N(O)_m$;

each R^5 is independently lower alkyl, lower alkenyl, lower alkynyl, CF_3 , lower alkyl-HET, lower alkenyl-HET or $-(C(R^{18})_2)_pPh(R^{11})O-$
 10 2;

each R^6 is independently H, lower alkyl, lower alkenyl, lower alkynyl, CF_3 , Ph, Bn and when two R^6 groups are attached to N they may be taken in conjunction and represents a ring of up to 6 atoms, optionally containing an additional heteroatom selected from O, $S(O)_n$ or
 15 $N(O)_m$;

each R^7 is independently H, F, CF_3 or lower alkyl, and when two R^7 groups are presents, they may be taken in conjunction and represent an aromatic or aliphatic ring of 3 to 6 members containing from 0-2 heteroatoms selected from O, $S(O)_n$ and $N(O)_m$;

20 each R^8 represents H or R^5 ;

each R^9 is independently H, lower alkyl, lower alkenyl, lower alkynyl, Ph or Bn;

each R^{10} is independently lower alkyl, lower alkenyl, lower alkynyl, CF_3 , $Ph(R^{11})O-3$, $CH_2Ph(R^{11})O-3$ or $N(R^6)_2$;

25 each R^{11} is independently lower alkyl, SR^{20} , OR^{20} , $N(R^6)_2$, $-CO_2R^{12}$, $-CON(R^6)_2$, $-C(O)R^{12}$, CN, CF_3 , NO_2 or halogen;

each R^{12} is independently H, lower alkyl or benzyl;

each R^{13} is independently H, halo, lower alkyl, O-lower alkenyl, S-lower alkyl, $N(R^6)_2$, CO_2R^{12} , CN, CF_3 or NO_2 ;

30 R^{14} and R^{15} are independently lower alkyl, halogen, CF_3 , OR^{16} , $S(O)_nR^{16}$ or $C(R^{16})_2OR^{17}$;

each R^{16} is independently H, lower alkyl, lower alkenyl, Ph, Bn or CF_3 ;

each R^{17} is independently H, lower alkyl or Bn;

35 each R^{18} is independently H, F or lower alkyl, and when two R^{18} groups are present, they may be taken in conjunction and represent a ring of 3 to 6 members comprising carbon atoms and optionally one heteroatom chosen from O, $S(O)_n$ or N;

- 5 each R¹⁹ is lower alkyl, lower alkenyl, lower alkynyl, CF₃,
HET(Ra)₄₋₉, lower alkyl-HET(Ra)₄₋₉ or lower alkenyl-HET(Ra)₄₋₉;
 each R²⁰ is independently H, lower alkyl, lower alkenyl,
lower alkynyl, CF₃ or Ph(R¹³)₂
and
10 each Ra is independently selected from the group consisting
of:
H, OH, halo, CN, NO₂, amino, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl,
C₁₋₆alkoxy, C₂₋₆alkenyloxy, C₂₋₆alkynyloxy, C₁₋₆alkylamino,
di-C₁₋₆alkylamino, CF₃, C(O)C₁₋₆alkyl, C(O)C₂₋₆alkenyl, C(O)C₂₋
15 6alkynyl, CO₂H, CO₂C₁₋₆alkyl, CO₂C₂₋₆alkenyl, and CO₂C₂₋₆alkynyl,
 said alkyl, alkenyl, alkynyl and the alkyl portions of
alkylamino and dialkylamino being optionally substituted with 1-3 of:
hydroxy, halo, aryl, C₁₋₆alkoxy, C₂₋₆alkenyloxy, C₂₋₆alkynyloxy, CF₃,
C(O)C₁₋₆alkyl, C(O)C₂₋₆alkenyl, C(O)C₂₋₆alkynyl, CO₂H, CO₂C₁₋₆alkyl,
20 CO₂C₂₋₆alkenyl, CO₂C₂₋₆alkynyl, NH₂, NHC₁₋₆alkyl and N(C₁₋₆alkyl)₂.

Pharmaceutical compositions are also included which are
comprised of a compound of formula I in combination with a
pharmaceutically acceptable carrier.

- 25 A method of treating or preventing a prostaglandin
mediated disease is also included which is comprised of administering
to a mammalian patient in need thereof, a compound of formula I in an
amount which is effective for treating or preventing a prostaglandin
mediated disease.

30 DETAILED DESCRIPTION OF THE INVENTION

- The present invention relates to carboxylic acids and
acylsulfonamides, which are ligands at prostaglandin receptors, as well
as a method for treating or preventing a prostaglandin mediated disease
comprising administering to a patient in need of such a treatment of an
35 amount of compound of Formula I which is effective for treating or
preventing a prostaglandin mediated disease.

 The invention described in this patent application is
described using the following definitions unless otherwise indicated.

5 HET represents a 5-12 membered aromatic ring system containing 0-3 heteroatoms selected from O, S(O)_n and N wherein n is 0, 1 or 2. HET may be substituted with up to three substituents on the aromatic ring system, R¹, R² and R³. "Aromatic ring systems" as used herein includes aryl and heteroaryl groups such as benzene,
10 naphthalene, biphenyl, pyridine, quinoline, isoquinoline, furan, benzofuran, thiophene, benzothiophene, oxazole, thiazole, imidazole, benzothiazole, triazole, 1,2,5-thiadiazole, thienopyridine, indole, tetrazole, imidazole, benzoxazole, 1,2-methylenedioxybenzene and pyrrole.

15 HET² is a subset of HET and represents a member selected from the group consisting of: phenyl, thienyl, naphthyl, furanyl, thiazolyl, imidazolyl and indolyl.

Aryl refers to aromatic 6-10 membered groups having 1-2 rings and alternating (resonating) double bonds. Examples include
20 phenyl, biphenyl and naphthyl.

Heteroaryl refers to aromatic 5-12 membered groups having alternating (resonating) double bonds and containing from 1-4 heteroatoms selected from O, S(O)_n and N. Examples include the following: : quinoline, furan, benzofuran, thiophene, benzothiophene,
25 thiazole, benzothiazole, 1,2,5-thiadiazole, thienopyridine, oxazole, indole, isoindole, pyridine, isoquinoline, imidazole, thiazole, triazole, 1,3-methylene dioxobenzene, pyrrole and naphthyridine,

Heterocyclyl refers to non-aromatic 5-12 membered cyclic groups having 1-4 heteroatoms selected from O, S(O)_n and N. Examples
30 of heterocyclic groups are piperidine, piperazine, pyrrolidine, tetrahydrofuran, tetrahydropyran and morpholine.

X represents a 5-10 membered monocyclic or bicyclic aryl or heteroaryl group having 1-3 heteroatoms selected from O, S(O)_n and N(O)_m, and optionally substituted with R¹⁴ and R¹⁵, and A and B are
35 attached to the aryl or heteroaryl group X in positions which are ortho relative to each other. Examples are selected from the group consisting of: phenyl, naphthyl, biphenyl, quinoline, furan, benzofuran, pyridyl, pyrrole, thiophene, benzothiophene, thiazole, benzothiazole, 1,2,5-

5 thiadiazole, triazole, 1,2-methylenedioxybenzene, thienopyridine, oxazole and indole.

The terms alkyl, alkenyl, and alkynyl mean linear, branched, and cyclic structures and combinations thereof.

"Lower alkyl" means alkyl groups of from 1 to 7 carbon
10 atoms. Examples of lower alkyl groups include methyl, ethyl, propyl, cyclopropyl, isopropyl, butyl, s- and t-butyl, pentyl, cyclopentyl, hexyl, cyclohexyl, heptyl, and the like. When propyl and butyl are recited without the isomeric form being specified, these include all isomers thereof.

15 "Lower alkenyl" means alkenyl groups of 2 to 7 carbon atoms. Examples of lower alkenyl groups include vinyl, allyl, isopropenyl, pentenyl, hexenyl, heptenyl, 1-propenyl, 2-butenyl, 2-methyl-2-butenyl, cyclopropen-1-yl, cyclohexen-3-yl and the like. When cis or trans is not specified, both are intended in pure form as well as in
20 the form of a mixture of isomers.

"Lower alkynyl" means alkynyl groups of 2 to 7 carbon atoms. Examples of lower alkynyl groups include ethynyl, propargyl, 3-methyl-1-pentynyl, 2-heptynyl, 2-(cyclopropyl)ethenyl, 3-(cyclobutyl)-1-propynyl and the like.

25 Halogen (halo) includes F, Cl, Br and I.


The following abbreviations have the indicated meanings:

	AIBN	=	2,2'-azobisisobutyronitrile
	B.P.	=	benzoyl peroxide
	Bn	=	benzyl
30	CCl ₄	=	carbon tetrachloride
	D	=	-O(CH ₂) ₃ O-
	DAST	=	diethylamine sulfur trifluoride
	DCC	=	dicyclohexyl carbodiimide
	DCI	=	1-(3-dimethylaminopropyl)-3-ethyl 35 carbodiimide
	DEAD	=	diethyl azodicarboxylate
	DIBAL	=	diisobutyl aluminum hydride
	DME	=	ethylene glycol dimethylether
	DMAP	=	4-(dimethylamino)pyridine
40	DMF	=	N,N-dimethylformamide
	DMSO	=	dimethyl sulfoxide
	Et ₃ N	=	triethylamine
	LDA	=	lithium diisopropylamide

5	m-CPBA	=	metachloroperbenzoic acid
	NBS	=	N-bromosuccinimide
	NSAID	=	non-steroidal anti-inflammatory drug
	PCC	=	pyridinium chlorochromate
	PDC	=	pyridinium dichromate
10	Ph	=	phenyl
	1,2-Ph	=	1,2-benzenediyl
	Pyr	=	pyridinediyl
	Qn	=	7-chloroquinolin-2-yl
	Rs	=	-CH ₂ SCH ₂ CH ₂ Ph
15	r.t.	=	room temperature
	rac.	=	racemic
	THF	=	tetrahydrofuran
	THP	=	tetrahydropyran-2-yl
20	<u>Alkyl group abbreviations</u>		
	Me	=	methyl
	Et	=	ethyl
	n-Pr	=	normal propyl
	i-Pr	=	isopropyl
25	n-Bu	=	normal butyl
	i-Bu	=	isobutyl
	s-Bu	=	secondary butyl
	t-Bu	=	tertiary butyl
	c-Pr	=	cyclopropyl
30	c-Bu	=	cyclobutyl
	c-Pen	=	cyclopentyl
	c-Hex	=	cyclohexyl

It is intended that the definition of any substituent (e.g., R⁵,
 35 R⁶, etc.) in a particular molecule be independent of its definition
 elsewhere in the molecule. Thus, -N(R⁶)₂ represents -NHH, -NHCH₃, -
 NHC₆H₅, and the like.

In one aspect of the invention, the invention relates to a
 40 compound represented by formula I:



I

as well as pharmaceutically acceptable salts, hydrates and esters
 thereof, wherein:

5 HET represents a 5-12 membered monocyclic or bicyclic aromatic ring system containing 0-3 heteroatoms selected from O, S(O)_n and N(O)_m wherein m is 0 or 1 and n is 0, 1 or 2;

A is a one or two atom moiety and is selected from the group consisting of: -W-, -C(O)-, -C(R⁷)₂-W-, -W-C(R⁷)₂-, -CR⁷(OR²⁰)-,
 10 -C(R⁷)₂-, -C(R⁷)₂-C(OR²⁰)R⁷-, -C(R⁷)₂-C(R⁷)₂ or CR⁷=CR⁷, wherein W represents O, S(O)_n or NR¹⁷, with n as previously defined and R¹⁷ as defined below;

X represents a 5-10 membered monocyclic or bicyclic aryl or heteroaryl group having 1-3 heteroatoms selected from O, S(O)_n and
 15 N(O)_m, and optionally substituted with R¹⁴ and R¹⁵, and A and B are attached to the aryl or heteroaryl group ortho relative to each other;

Y represents O, S(O)_n, NR¹⁷, a bond or -CR¹⁸=CR¹⁸-;

B represents -(C(R¹⁸)₂)_p-Y-(C(R¹⁸)₂)_q-

wherein p and q are independently 0-3, such that when Y represents O,
 20 S(O)_n, NR¹⁷ or -CR¹⁸=CR¹⁸-, p + q = 0-6, and when Y represents a bond, p + q is 1-6;

Z is OH or NHSO₂R¹⁹;

R¹ R² and R³ independently represent H, halogen, lower alkyl, lower alkenyl, lower alkynyl, lower alkenyl-HET(R^a)₄₋₉, -
 25 (C(R⁴)₂)_pSR⁵, -(C(R⁴)₂)_pOR⁸, -(C(R⁴)₂)_pN(R⁶)₂, CN, NO₂, -(C(R⁴)₂)_pC(R⁷)₃, -CO₂R⁹, -CON(R⁶)₂ or -(C(R⁴)₂)_pS(O)_nR¹⁰, wherein n and p are as previously defined;

each R⁴ is independently H, F, CF₃ or lower alkyl,
 or two R⁴ groups are taken in conjunction and represent a ring of up to
 30 six atoms, optionally containing one heteroatom selected from O, S(O)_n or N(O)_m;


each R⁵ is independently lower alkyl, lower alkenyl, lower alkynyl, CF₃, lower alkyl-HET, lower alkenyl-HET or -(C(R¹⁸)₂)_pPh(R¹¹)₀₋₂;

35 each R⁶ is independently H, lower alkyl, lower alkenyl, lower alkynyl, CF₃, Ph, Bn and when two R⁶ groups are attached to N they may be taken in conjunction and represents a ring of up to 6 atoms,

- 5 optionally containing an additional heteroatom selected from O, S(O)_n or N(O)_m;
- each R⁷ is independently H, F, CF₃ or lower alkyl, and when two R⁷ groups are presents, they may be taken in conjunction and represent an aromatic or aliphatic ring of 3 to 6 members containing
- 10 from 0-2 heteroatoms selected from O, S(O)_n and N(O)_m;
- each R⁸ represents H or R⁵;
- each R⁹ is independently H, lower alkyl, lower alkenyl, lower alkynyl, Ph or Bn;
- each R¹⁰ is independently lower alkyl, lower alkenyl, lower
- 15 alkynyl, CF₃, Ph(R¹¹)₀₋₃, CH₂Ph(R¹¹)₀₋₃ or N(R⁶)₂ ;
- each R¹¹ is independently lower alkyl, SR²⁰, OR²⁰, N(R⁶)₂, -CO₂R¹², -CON(R⁶)₂, -C(O)R¹², CN, CF₃, NO₂ or halogen;
- each R¹² is independently H, lower alkyl or benzyl;
- each R¹³ is independently H, halo, lower alkyl, O-lower
- 20 alkenyl, S-lower alkyl, N(R⁶)₂, CO₂R¹², CN, CF₃ or NO₂ ;
- R¹⁴ and R¹⁵ are independently lower alkyl, halogen, CF₃, OR¹⁶, S(O)_nR¹⁶ or C(R¹⁶)₂OR¹⁷ ;
- each R¹⁶ is independently H, lower alkyl, lower alkenyl, Ph, Bn or CF₃;
- 25 each R¹⁷ is independently H, lower alkyl or Bn;
- each R¹⁸ is independently H, F or lower alkyl, and when two R¹⁸ groups are present, they may be taken in conjunction and represent a ring of 3 to 6 members comprising carbon atoms and optionally one heteroatom chosen from O, S(O)_n or N;
- 30 each R¹⁹ is lower alkyl, lower alkenyl, lower alkynyl, CF₃ , -HET(R^a)₄₋₉, lower alkyl-HET(R^a)₄₋₉ or lower alkenyl-HET(R^a)₄₋₉;
- each R²⁰ is independently H, lower alkyl, lower alkenyl, lower alkynyl, CF₃ or Ph(R¹³)₂
- and
- 35 each R^a is independently selected from the group consisting of: H, OH, halo, CN, NO₂, amino, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl,

- 5 C₁₋₆ alkoxy, C₂₋₆alkenyloxy, C₂₋₆alkynyloxy, C₁₋₆alkylamino, di-C₁₋₆alkylamino, CF₃, C(O)C₁₋₆alkyl, C(O)C₂₋₆alkenyl, C(O)C₂₋₆alkynyl, CO₂H, CO₂C₁₋₆alkyl, CO₂C₂₋₆alkenyl, and CO₂C₂₋₆alkynyl,
- said alkyl, alkenyl, alkynyl and the alkyl portions of alkylamino and dialkylamino being optionally substituted with 1-3 of:
- 10 hydroxy, halo, aryl, C₁₋₆ alkoxy, C₂₋₆alkenyloxy, C₂₋₆alkynyloxy, CF₃, C(O)C₁₋₆alkyl, C(O)C₂₋₆alkenyl, C(O)C₂₋₆alkynyl, CO₂H, CO₂C₁₋₆alkyl, CO₂C₂₋₆alkenyl, CO₂C₂₋₆alkynyl, NH₂, NHC₁₋₆alkyl and N(C₁₋₆alkyl)₂.

- In another embodiment of the invention, the invention
- 15 relates to compounds represented by formula I:



I

as well as pharmaceutically acceptable salts, hydrates and esters thereof, wherein:

- 20 HET represents a 5-12 membered monocyclic or bicyclic aromatic ring system containing 0-3 heteroatoms selected from O, S(O)_n and N(O)_m wherein m is 0 or 1 and n is 0, 1 or 2;

- A is a one or two atom moiety and is selected from the group consisting of: -W-, -C(O)-, -C(R⁷)₂-W-, -W-C(R⁷)₂-, -CR⁷(OR²⁰)-, -C(R⁷)₂-, -C(R⁷)₂-C(OR²⁰)R⁷-, -C(R⁷)₂-C(R⁷)₂ or CR⁷=CR⁷, wherein W represents O, S(O)_n or NR¹⁷, with n as previously defined and R¹⁷ as defined below;
- 25

- X represents a 5-10 membered monocyclic or bicyclic aryl or heteroaryl group having 1-3 heteroatoms selected from O, S(O)_n and N(O)_m, and optionally substituted with R¹⁴ and R¹⁵, and A and B are
- 30 attached to the aryl or heteroaryl group ortho relative to each other;

Y represents O, S(O)_n, NR¹⁷, a bond or -CR¹⁸=CR¹⁸;

B represents -(C(R¹⁸)₂)_p-Y-(C(R¹⁸)₂)_q-

- 5 wherein p and q are independently 0-3, such that when Y represents O, S(O)_n, NR¹⁷ or -CR¹⁸ = CR¹⁸-, p + q = 0-6, and when Y represents a bond, p + q is 1-6;

Z is OH or NHSO₂R¹⁹;

- 10 R¹, R² and R³ independently represent H, halogen, lower alkyl, lower alkenyl, lower alkynyl, lower alkenyl-HET(R^a)₄₋₉, -(C(R⁴)₂)_pSR⁵, -(C(R⁴)₂)_pOR⁸, -(C(R⁴)₂)_pN(R⁶)₂, CN, NO₂, -(C(R⁴)₂)_pC(R⁷)₃, -CO₂R⁹, -CON(R⁶)₂ or -(C(R⁴)₂)_pS(O)_nR¹⁰, wherein n and p are as previously defined;

- each R⁴ is independently H, F, CF₃ or lower alkyl,
15 or two R⁴ groups are taken in conjunction and represent a ring of up to six atoms, optionally containing one heteroatom selected from O, S(O)_n or N(O)_m;

- each R⁵ is independently lower alkyl, lower alkenyl, lower alkynyl, CF₃, lower alkyl-HET, lower alkenyl-HET or -(C(R¹⁸)₂)_pPh(R¹¹)₀₋₂;
20

- each R⁶ is independently H, lower alkyl, lower alkenyl, lower alkynyl, CF₃, Ph, Bn and when two R⁶ groups are attached to N they may be taken in conjunction and represents a ring of up to 6 atoms, optionally containing an additional heteroatom selected from O, S(O)_n or
25 N(O)_m;

- each R⁷ is independently H, F, CF₃ or lower alkyl, and when two R⁷ groups are presents, they may be taken in conjunction and represent an aromatic or aliphatic ring of 3 to 6 members containing from 0-2 heteroatoms selected from O, S(O)_n and N(O)_m;

- 30 each R⁸ represents H or R⁵;

each R⁹ is independently H, lower alkyl, lower alkenyl, lower alkynyl, Ph or Bn;

each R¹⁰ is independently lower alkyl, lower alkenyl, lower alkynyl, CF₃, Ph(R¹¹)₀₋₃, CH₂Ph(R¹¹)₀₋₃ or N(R⁶)₂;

- 35 each R¹¹ is independently lower alkyl, SR²⁰, OR²⁰, N(R⁶)₂, -CO₂R¹², -CON(R⁶)₂, -C(O)R¹², CN, CF₃, NO₂ or halogen;

each R¹² is independently H, lower alkyl or benzyl;

- 5 each R¹³ is independently H, halo, lower alkyl, O-lower alkenyl, S-lower alkyl, N(R⁶)₂, CO₂R¹², CN, CF₃ or NO₂ ;
 R¹⁴ and R¹⁵ are independently lower alkyl, halogen, CF₃, OR¹⁶, S(O)_nR¹⁶ or C(R¹⁶)₂OR¹⁷ ;
 each R¹⁶ is independently H, lower alkyl, lower alkenyl, Ph,
 10 Bn, CHF₂ or CF₃;
 each R¹⁷ is independently H, lower alkyl or Bn;
 each R¹⁸ is independently H, F or lower alkyl, and when two R¹⁸ groups are present, they may be taken in conjunction and represent a ring of 3 to 6 members comprising carbon atoms and optionally one
 15 heteroatom chosen from O, S(O)_n or N;
 each R¹⁹ is lower alkyl, lower alkenyl, lower alkynyl, CF₃ , HET²(Ra)₄₋₉, lower alkyl-HET²(Ra)₄₋₉ or lower alkenyl-HET²(Ra)₄₋₉, wherein HET² represents a member selected from the group consisting of: phenyl, thienyl, naphthyl, furanyl, thiazolyl, imidazolyl and indolyl;
 20 each R²⁰ is independently H, lower alkyl, lower alkenyl, lower alkynyl, CHF₂ , CF₃ or Ph(R¹³)₂
 and
 each Ra is independently selected from the group consisting of:
 25 H, OH, halo, CN, NO₂, amino, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₁₋₆ alkoxy, C₂₋₆alkenyloxy, C₂₋₆alkynyloxy, C₁₋₆alkylamino, di-C₁₋₆alkylamino, CF₃, C(O)C₁₋₆alkyl, C(O)C₂₋₆alkenyl, C(O) C₂₋₆alkynyl, CO₂H, CO₂C₁₋₆alkyl, CO₂C₂₋₆alkenyl, and CO₂C₂₋₆alkynyl,
 said alkyl, alkenyl, alkynyl and the alkyl portions of
 30 alkylamino and dialkylamino being optionally substituted with 1-3 of: hydroxy, halo, aryl, C₁₋₆ alkoxy, C₂₋₆alkenyloxy, C₂₋₆alkynyloxy, CF₃, C(O)C₁₋₆alkyl, C(O)C₂₋₆alkenyl, C(O)C₂₋₆alkynyl, CO₂H, CO₂C₁₋₆alkyl, CO₂C₂₋₆alkenyl, CO₂C₂₋₆alkynyl, NH₂, NHC₁₋₆alkyl and N(C₁₋₆alkyl)₂.
 35 An embodiment of the present invention which is of particular interest is represented by formula I wherein HET represents a member selected from the group consisting of: benzene, naphthalene, biphenyl, pyridine, quinoline, isoquinoline, furan, benzofuran,

5 thiophene, benzothiophene, oxazole, thiazole, imidazole, benzothiazole, triazole, 1,2,5-thiadiazole, thienopyridine, indole, tetrazole, imidazole, benzoxazole, 1,2-methylenedioxybenzene and pyrrole.

More particularly, an embodiment of the present invention is represented by formula I wherein HET is selected from the group
10 consisting of: benzene, biphenyl, naphthylene, indole, thiophene, benzofuran and quinoline. Within this subset of compounds of the invention, all other variables are as originally described with respect to formula I.

Another embodiment of the present invention that is of
15 particular interest is represented by formula I wherein A represents a one or two atom moiety and is selected from the group consisting of: S, S(O), SO₂, CH₂, -C(O)-, -OCH₂-, -CHOH-, -C(OH)(CH₃)- and -CH₂O-. More particularly, A is selected from the group consisting of: S, S(O), SO₂, CH₂, -C(O)-. Within this subset of compounds of the invention, all
20 other variables are as originally described with respect to formula I.

Another embodiment of the present invention that is of particular interest is represented by formula I wherein X represents phenyl optionally substituted with R¹⁴ and R¹⁵. Within this subset of compounds of the invention, all other variables are as originally
25 described with respect to formula I. More particularly, X represents phenyl and R¹⁴ and R¹⁵ are absent or represent halo. Within this subset of compounds of the invention, all other variables are as originally described with respect to formula I.

Another embodiment of the present invention that is of
30 particular interest is represented by formula I wherein B is CH=CH or 1,2-cyclopropyl, and in particular, where B is CH=CH in the E-isomeric form. Within this subset of compounds of the invention, all other variables are as originally described with respect to formula I.

Another embodiment of the present invention that is of
35 particular interest is represented by formula I wherein Z is NHSO₂R¹⁹. Within this subset of compounds of the invention, all other variables are as originally described with respect to formula I.

5 Another embodiment of the present invention that is of particular interest is represented by formula I wherein Z is $\text{NHSO}_2\text{R}^{19}$ and R^{19} represents a member selected from the group consisting of: lower alkyl and $\text{HET}(\text{Ra})_3$. Within this aspect of the invention, HET is selected from the group consisting of: phenyl, thienyl, naphthyl,
10 furanyl, thiazolyl, imidazolyl and indolyl.

Another embodiment of the present invention that is of particular interest is represented by formula I wherein Z is $\text{NHSO}_2\text{R}^{19}$ and R^{19} represents benzene or thiophene, substituted with $\text{R}^1\text{R}^2\text{R}^3$.

15 Another embodiment of the present invention that is of particular interest is represented by formula I wherein Z represents OH. Within this subset, all other variables are as originally defined.

A subset of compounds that is of particular interest is defined with respect to formula I wherein:

20 HET represents a member selected from the group consisting of: phenyl, naphthalene, biphenyl, pyridine, quinoline, isoquinoline, furan, benzofuran, thiophene, benzothiophene, oxazole, thiazole, imidazole, benzothiazole, 1,2,5-thiadiazole, thienopyridine, indole, tetrazole, imidazole, benzoxazole and pyrrole;

25 A represents a one or two atom moiety and is selected from the group consisting of: S, S(O), SO_2 , CH_2 , $-\text{C}(\text{O})-$, $-\text{OCH}_2-$, $-\text{CHOH}-$, $-\text{C}(\text{OH})(\text{CH}_3)-$ and $-\text{CH}_2\text{O}-$;

X represents phenyl optionally substituted with R^{14} and R^{15} ;
B is $\text{CH}=\text{CH}$;


30 Z is $\text{NHSO}_2\text{R}^{19}$ and

R^{19} represents a member selected from the group consisting of: lower alkyl and $\text{HET}(\text{Ra})_3$.

Examples of compounds of the present invention are shown in Tables I and II below.

35

Table I



Ia

(Compounds 1-323 and 347-454)

5

R ¹ R ² R ³ -Het	A	X	B	R ¹⁹	Cpd
1-naphthyl	CH ₂	1,2-Ph	CH=CH	Ph(F) ₅	1
2-naphthyl	S(O) ₂	1,2-Ph	CH=CH	Ph(F) ₅	2
3-methylindol -1-yl	CH ₂	1,2-Ph	CH=CH	2-thienyl	3
2-naphthyl	CH ₂	1,2-Ph	CH=CH	2-thienyl	4
2-naphthyl	S(O) ₂	1,2-Ph	CH=CH	phenyl	5
3-methylindol -1-yl	S(O) ₂	1,2-Ph	CH=CH	2-thienyl	6
2-naphthyl	S(O) ₂	1,2-Ph	CH=CH	3,5-di-(CF ₃) phenyl	7
3,4-dichloro phenyl	CH ₂	1,2-Ph	CH=CH	2-thienyl	8
2-naphthyl	S(O) ₂	1,2-Ph	CH=CH	2-thienyl	9
2,4-dichloro phenyl	CH ₂	1,2-Ph	CH=CH	2-thienyl	10
1-naphthyl	S(O) ₂	1,2-Ph	CH=CH	Ph(F) ₅	11
1-naphthyl	S(O) ₂	1,2-Ph	CH=CH	3,5-di-(CF ₃) phenyl	12
2-naphthyl	S(O) ₂	1,2-Ph	1,2-c-propyl	2-thienyl	13
3,4-chloro fluoro phenyl	CH ₂	1,2-Ph	CH=CH	2-thienyl	14
1-naphthyl	CH ₂	1,2-Ph	CH=CH	2-thienyl	15
3,4-dichloro phenyl	S(O) ₂	1,2-Ph	CH=CH	2-thienyl	16
4-methylthio phenyl	CH ₂	1,2-Ph	CH=CH	2-thienyl	17
4-chlorophenyl	CH ₂	1,2-Ph	CH=CH	2-thienyl	18
2-naphthyl	S	1,2-Ph	CH=CH	2-thienyl	19
2-naphthyl	O-CH ₂	1,2-Ph	CH=CH	2-thienyl	20
2-naphthyl	S(O)	1,2-Ph	CH=CH	2-thienyl	21
1-naphthyl	S(O) ₂	1,2-Ph	CH=CH	phenyl	22
2-benzofuranyl	CH ₂	1,2-Ph	CH=CH	2-thienyl	23

R ¹ R ² R ³ -Het	A	X	B	R ¹⁸	Cpd
3,5-dichloro phenyl	CH ₂	1,2-Ph	CH=CH	2-thienyl	24
1-naphthyl	S(O) ₂	1,2-Ph	CH=CH	3,5-di-(CF ₃) phenyl	25
1-naphthyl	S(O) ₂	1,2-Ph	CH=CH	2-thienyl	26
3-(1,2-(methylene dioxy)benzene)	CH ₂	1,2-Ph	CH=CH	2-thienyl	27
2-naphthyl	O	1,2-Ph	CH=CH	2-thienyl	28
RS-2-phenyl	CH ₂	1,2-Ph	CH ₂ -O	2-thienyl	29
RS-2-phenyl	CH ₂	1,2-Ph	CH ₂ -CH ₂	2-thienyl	30
2-naphthyl	S(O) ₂	1,2-Ph	CH ₂ -O	2-thienyl	31
3-((2-(Qn)vinyl)) phenyl	CH ₂	1,2-Ph	CH ₂ -O	2-thienyl	32
2-(6-benzyloxy) naphthyl	CH ₂	1,2-Ph	CH=CH	2-thienyl	33
3-((2-(Qn)vinyl)) phenyl	SO	1,2-Ph	CH ₂ -O	2-thienyl	34
3-((2-(Qn)vinyl)) phenyl	-CHOH-	1,2-Ph	CH ₂ -O	2-thienyl	35
3-((2-(Qn)vinyl)) phenyl	S(O) ₂	1,2-Ph	CH ₂ -O	phenyl	36
3-((2-(Qn)vinyl)) phenyl	O-CH ₂	1,2-Ph	CH ₂ -O	2-thienyl	37
3-tolyl-D-3-phenyl	O-CH ₂	1,2-Ph	CH ₂ -O	2-thienyl	38
3-((2-(Qn)vinyl)) phenyl	CH(OH)-CH ₃ -	1,2-Ph	CH ₂ -O	phenyl	39
3-((2-(Qn)vinyl)) phenyl	S	1,2-Ph	CH ₂ -O	2-thienyl	40
3-((2-(Qn)vinyl)) phenyl	O	1,2-Ph	CH ₂ -O	phenyl	41
3-((2-(Qn)vinyl)) phenyl	C=O	1,2-Ph	CH ₂ -O	2-thienyl	42
3-((2-(Qn)vinyl)) phenyl	O	1,2-Ph	C(CH ₃) ₂ -O	2-thienyl	43
3-((2-(Qn)vinyl)) phenyl	O	1,2-Ph	CH ₂ -O	2-thienyl	44
2-naphthyl	CH ₂	1,2-Ph	1,2-c-propyl	2-thienyl	45
2-(6-benzyloxy) naphthyl	CH ₂	1,2-Ph	CH=CH	2-methoxy-5-bromophenyl	46
2-naphthyl	CH ₂	1,2-Ph	1,2-c-propyl	3,4-dichloro phenyl	47
2-naphthyl	CH ₂	1,2-Ph	1,2-c-propyl	4-fluoro phenyl	48

R ¹ R ² R ³ -Het	A	X	B	R ¹⁹	Cpd
2-naphthyl	CH ₂	1,2-Ph	1,2-c-propyl	4-chloro phenyl	49
2-naphthyl	CH ₂	1,2-Ph	1,2-c-propyl	4-propyl phenyl	50
2-naphthyl	CH ₂	1,2-Ph	1,2-c-propyl	2,5-dichloro thienyl	51
2-naphthyl	CH ₂	1,2-Ph	1,2-c-propyl	styryl	52
2-naphthyl	CH ₂	1,2-Ph	1,2-c-propyl	3-chloro-4- fluorophenyl	53
2-naphthyl	CH ₂	1,2-Ph	1,2-c-propyl	4-methoxy phenyl	54
2-naphthyl	CH ₂	1,2-Ph	1,2-c-propyl	3-bromo phenyl	55
2-naphthyl	CH ₂	1,2-Ph	1,2-c-propyl	2,5-dimethyl phenyl	56
2-naphthyl	CH ₂	1,2-Ph	1,2-c-propyl	2-nitro-4-chloro phenyl	57
2-naphthyl	CH ₂	1,2-Ph	1,2-c-propyl	2-carbomethoxy phenyl	58
2-naphthyl	CH ₂	1,2-Ph	1,2-c-propyl	2,4-difluoro phenyl	59
2-naphthyl	CH ₂	1,2-Ph	1,2-c-propyl	4-butyl-phenyl	60
2-naphthyl	CH ₂	1,2-Ph	1,2-c-propyl	butyl	61
2-naphthyl	CH ₂	1,2-Ph	1,2-c-propyl	2,5-dimethoxy phenyl	62
2-naphthyl	CH ₂	1,2-Ph	1,2-c-propyl	3-trifluoro methylphenyl	63
2-naphthyl	CH ₂	1,2-Ph	1,2-c-propyl	3,5-difluoro phenyl	64
2-naphthyl	CH ₂	1,2-Ph	1,2-c-propyl	3,5-dichloro phenyl	65
2-naphthyl	CH ₂	1,2-Ph	1,2-c-propyl	4-((1-hydroxy-1- methyl)ethyl) phenyl	66
2-naphthyl	CH ₂	1,2-Ph	1,2-c-propyl	4-(hydroxy methyl)phenyl	67
2-naphthyl	CH ₂	1,2-Ph	1,2-c-propyl	3-(hydroxy methyl)phenyl	68
2-naphthyl	CH ₂	1,2-Ph	1,2-c-propyl	4-(methyl sulfonyl)phenyl	69
2-naphthyl	CH ₂	1,2-Ph	1,2-c-propyl	3-(methyl sulfonyl)phenyl	70
2-naphthyl	CH ₂	1,2-Ph	1,2-c-propyl	4-(propyl sulfonyl)phenyl	71

R ¹ R ² R ³ -Het	A	X	B	R ¹⁰	Cpd
2-naphthyl	CH ₂	1,2-Ph	1,2-c-propyl	4-((bis-trifluoromethyl)-hydroxymethyl)phenyl	72
2-naphthyl	CH ₂	1,2-Ph	1,2-c-propyl	4-(benzyloxy)phenyl	73
2-naphthyl	CH ₂	1,2-Ph	1,2-c-propyl	4-((1-methoxy-1-methyl)ethyl)phenyl	74
2-naphthyl	CH ₂	1,2-Ph	1,2-c-propyl	4-dimethylaminophenyl	75
2-naphthyl	CH ₂	1,2-Ph	1,2-c-propyl	cyclohexyl	76
2-naphthyl	CH ₂	1,2-Ph	1,2-c-propyl	cyclopentyl	77
2-naphthyl	CH ₂	1,2-Ph	1,2-c-propyl	4-morpholinyl	78
2-naphthyl	CH ₂	1,2-Ph	1,2-c-propyl	2-naphthyl	79
2-naphthyl	CH ₂	1,2-Ph	1,2-c-propyl	2-thiazolyl	80
2-naphthyl	CH ₂	1,2-Ph	1,2-c-propyl	1-imidazolyl	81
2-naphthyl	CH ₂	1,2-Ph	1,2-c-propyl	2-furanyl	82
2-naphthyl	CH ₂	1,2-Ph	1,2-c-propyl	3-(2-chloro)-furanyl	83
2-naphthyl	CH ₂	1,2-Ph	1,2-c-propyl	2-pyridinyl	84
2-naphthyl	CH ₂	1,2-Ph	1,2-c-propyl	2-(4-chloro)pyridinyl	85
2-naphthyl	CH ₂	1,2-Ph	1,2-c-propyl	3-indolyl	86
2-naphthyl	CH ₂	1,2-Ph	1,2-c-propyl	4-nitrophenyl	87
2-naphthyl	CH ₂	1,2-Ph	1,2-c-propyl	4-cyanophenyl	88
2-naphthyl	S(O) ₂	1,2-Ph	1,2-c-propyl	4-((1-hydroxy-1-methyl)ethyl)phenyl	89
2-naphthyl	S(O) ₂	1,2-Ph	1,2-c-propyl	4-(hydroxymethyl)phenyl	90
2-naphthyl	S(O) ₂	1,2-Ph	1,2-c-propyl	3-(hydroxymethyl)phenyl	91
2-naphthyl	S(O) ₂	1,2-Ph	1,2-c-propyl	2,5-dimethylphenyl	92
2-naphthyl	S(O) ₂	1,2-Ph	1,2-c-propyl	2-carbomethoxyphenyl	93
2-naphthyl	S(O) ₂	1,2-Ph	1,2-c-propyl	2,4-difluorophenyl	94
2-naphthyl	S(O) ₂	1,2-Ph	1,2-c-propyl	4-(methylsulfonyl)phenyl	95
2-naphthyl	S(O) ₂	1,2-Ph	1,2-c-propyl	3-(methylsulfonyl)phenyl	96
2-naphthyl	S(O) ₂	1,2-Ph	1,2-c-propyl	4-(propylsulfonyl)phenyl	97

R ¹ R ² R ³ -Het	A	X	B	R ¹⁹	Cpd
2-naphthyl	S(O) ₂	1,2-Ph	1,2-c-propyl	4-butyl-phenyl	98
2-naphthyl	S(O) ₂	1,2-Ph	1,2-c-propyl	3,5-di-(CF ₃) phenyl	99
2-naphthyl	S(O) ₂	1,2-Ph	1,2-c-propyl	4-((bis-trifluoro methyl)-hydroxy methyl)phenyl	100
2-naphthyl	S(O) ₂	1,2-Ph	1,2-c-propyl	3-bromophenyl	101
2-naphthyl	S(O) ₂	1,2-Ph	1,2-c-propyl	4-(benzyloxy) phenyl	102
2-naphthyl	S(O) ₂	1,2-Ph	1,2-c-propyl	2-nitro-4-chloro phenyl	103
2-naphthyl	S(O) ₂	1,2-Ph	1,2-c-propyl	4-isopropyl phenyl	104
2-naphthyl	S(O) ₂	1,2-Ph	1,2-c-propyl	4-((1-methoxy-1- methyl) ethyl)phenyl	105
2-naphthyl	S(O) ₂	1,2-Ph	1,2-c-propyl	4-methoxy phenyl	106
2-naphthyl	S(O) ₂	1,2-Ph	1,2-c-propyl	4-dimethyl aminophenyl	107
2-naphthyl	S(O) ₂	1,2-Ph	1,2-c-propyl	3,4-dichloro phenyl	108
2-naphthyl	S(O) ₂	1,2-Ph	1,2-c-propyl	3,4-difluoro phenyl	109
2-naphthyl	S(O) ₂	1,2-Ph	1,2-c-propyl	4-fluorophenyl	110
2-naphthyl	S(O) ₂	1,2-Ph	1,2-c-propyl	cyclohexyl	111
2-naphthyl	S(O) ₂	1,2-Ph	1,2-c-propyl	cyclopentyl	112
2-naphthyl	S(O) ₂	1,2-Ph	1,2-c-propyl	4-morpholinyl	113
2-naphthyl	S(O) ₂	1,2-Ph	1,2-c-propyl	butyl	114
2-naphthyl	S(O) ₂	1,2-Ph	1,2-c-propyl	4-chlorophenyl	115
2-naphthyl	S(O) ₂	1,2-Ph	1,2-c-propyl	4-propylphenyl	116
2-naphthyl	S(O) ₂	1,2-Ph	1,2-c-propyl	2-naphthyl	117
2-naphthyl	S(O) ₂	1,2-Ph	1,2-c-propyl	2-thiazolyl	118
2-naphthyl	S(O) ₂	1,2-Ph	1,2-c-propyl	1-imidazolyl	119
2-naphthyl	S(O) ₂	1,2-Ph	1,2-c-propyl	2,5-dimethoxy phenyl	120
2-naphthyl	S(O) ₂	1,2-Ph	1,2-c-propyl	3-trifluoro methylphenyl	121
2-naphthyl	S(O) ₂	1,2-Ph	1,2-c-propyl	2,5-dichloro-3- thienyl	122
2-naphthyl	S(O) ₂	1,2-Ph	1,2-c-propyl	2-furanyl	123
2-naphthyl	S(O) ₂	1,2-Ph	1,2-c-propyl	3-(2-chloro)- furanyl	124
2-naphthyl	S(O) ₂	1,2-Ph	1,2-c-propyl	2-pyridinyl	125

R ¹ R ² R ³ -Het	A	X	B	R ¹⁹	Cpd
2-naphthyl	S(O) ₂	1,2-Ph	1,2-c-propyl	2-styryl	126
2-naphthyl	S(O) ₂	1,2-Ph	1,2-c-propyl	3,5-difluoro-phenyl	127
2-naphthyl	S(O) ₂	1,2-Ph	1,2-c-propyl	3,5-dichloro-phenyl	128
2-naphthyl	S(O) ₂	1,2-Ph	1,2-c-propyl	2-(4-chloro)pyridinyl	129
2-naphthyl	S(O) ₂	1,2-Ph	1,2-c-propyl	3-indolyl	130
2-naphthyl	S(O) ₂	1,2-Ph	1,2-c-propyl	4-nitrophenyl	131
2-naphthyl	S(O) ₂	1,2-Ph	1,2-c-propyl	4-cyanophenyl	132
2-naphthyl	S(O) ₂	1,2-Ph	1,2-c-propyl	3-chloro-4-fluorophenyl	133
3-methylindol-1-yl	CH ₂	1,2-Ph	1,2-c-propyl	3,5-di-(CF ₃)-phenyl	134
3-methylindol-1-yl	CH ₂	1,2-Ph	1,2-c-propyl	4-isopropyl phenyl	135
3-methylindol-1-yl	CH ₂	1,2-Ph	1,2-c-propyl	3,4-dichloro phenyl	136
3-methylindol-1-yl	CH ₂	1,2-Ph	1,2-c-propyl	3,4-difluoro phenyl	137
3-methylindol-1-yl	CH ₂	1,2-Ph	1,2-c-propyl	4-fluorophenyl	138
3-methylindol-1-yl	CH ₂	1,2-Ph	1,2-c-propyl	4-chlorophenyl	139
3-methylindol-1-yl	CH ₂	1,2-Ph	1,2-c-propyl	4-propylphenyl	140
3-methylindol-1-yl	CH ₂	1,2-Ph	1,2-c-propyl	2,5-dichloro-3-thienyl	141
3-methylindol-1-yl	CH ₂	1,2-Ph	1,2-c-propyl	2-styryl	142
3-methylindol-1-yl	CH ₂	1,2-Ph	1,2-c-propyl	3-chloro-4-fluoro phenyl	143
3-methylindol-1-yl	CH ₂	1,2-Ph	1,2-c-propyl	4-methoxy phenyl	144
3-methylindol-1-yl	CH ₂	1,2-Ph	1,2-c-propyl	3-bromophenyl	145
3-methylindol-1-yl	CH ₂	1,2-Ph	1,2-c-propyl	2,5-dimethyl phenyl	146
3-methylindol-1-yl	CH ₂	1,2-Ph	1,2-c-propyl	2-nitro-4-chloro phenyl	147
3-methylindol-1-yl	CH ₂	1,2-Ph	1,2-c-propyl	2-carbomethoxy phenyl	148
3-methylindol-1-yl	CH ₂	1,2-Ph	1,2-c-propyl	2,4-difluoro phenyl	149

R¹R²R³-Het	A	X	B	R¹⁹	Cpd
3-methylindol -1-yl	CH ₂	1,2-Ph	1,2-c-propyl	4-butylphenyl	150
3-methylindol -1-yl	CH ₂	1,2-Ph	1,2-c-propyl	n-butyl	151
3-methylindol -1-yl	CH ₂	1,2-Ph	1,2-c-propyl	2,5-dimethoxy phenyl	152
3-methylindol -1-yl	CH ₂	1,2-Ph	1,2-c-propyl	3-trifluoro methylphenyl	153
3-methylindol -1-yl	CH ₂	1,2-Ph	1,2-c-propyl	3,5-difluoro phenyl	154
3-methylindol -1-yl	CH ₂	1,2-Ph	1,2-c-propyl	3,5-dichloro phenyl	155
3-methylindol -1-yl	CH ₂	1,2-Ph	1,2-c-propyl	4-((1-hydroxy-1- methyl)ethyl) phenyl	156
3-methylindol -1-yl	CH ₂	1,2-Ph	1,2-c-propyl	4-(hydroxy methyl)phenyl	157
3-methylindol -1-yl	CH ₂	1,2-Ph	1,2-c-propyl	3-(hydroxy methyl)phenyl	158
3-methylindol -1-yl	CH ₂	1,2-Ph	1,2-c-propyl	4-(methyl sulfonyl)phenyl	159
3-methylindol -1-yl	CH ₂	1,2-Ph	1,2-c-propyl	3-(methyl sulfonyl)phenyl	160
3-methylindol -1-yl	CH ₂	1,2-Ph	1,2-c-propyl	4-(propyl sulfonyl)phenyl	161
3-methylindol -1-yl	CH ₂	1,2-Ph	1,2-c-propyl	4-((bis-trifluoro methyl)hydroxy methyl)phenyl	162
3-methylindol -1-yl	CH ₂	1,2-Ph	1,2-c-propyl	4-(benzyloxy) phenyl	163
3-methylindol -1-yl	CH ₂	1,2-Ph	1,2-c-propyl	4-((1-methoxy-1- methyl) ethyl)phenyl	164
3-methylindol -1-yl	CH ₂	1,2-Ph	1,2-c-propyl	4-dimethyl aminophenyl	165
3-methylindol -1-yl	CH ₂	1,2-Ph	1,2-c-propyl	cyclohexyl	166
3-methylindol -1-yl	CH ₂	1,2-Ph	1,2-c-propyl	cyclopentyl	167
3-methylindol -1-yl	CH ₂	1,2-Ph	1,2-c-propyl	4-morpholinyl	168
3-methylindol -1-yl	CH ₂	1,2-Ph	1,2-c-propyl	2-naphthyl	169

R¹R²R³-Het	A	X	B	R^{1b}	Cpd
3-methylindol -1-yl	CH ₂	1,2-Ph	1,2-c-propyl	2-thiazolyl	170
3-methylindol -1-yl	CH ₂	1,2-Ph	1,2-c-propyl	1-imidazolyl	171
3-methylindol -1-yl	CH ₂	1,2-Ph	1,2-c-propyl	2-furanyl	172
3-methylindol -1-yl	CH ₂	1,2-Ph	1,2-c-propyl	3-(2-chloro)- furanyl	173
3-methylindol -1-yl	CH ₂	1,2-Ph	1,2-c-propyl	2-pyridinyl	174
3-methylindol -1-yl	CH ₂	1,2-Ph	1,2-c-propyl	2-(4-chloro) pyridinyl	175
3-methylindol -1-yl	CH ₂	1,2-Ph	1,2-c-propyl	3-indolyl	176
3-methylindol -1-yl	CH ₂	1,2-Ph	1,2-c-propyl	4-nitrophenyl	177
3-methylindol -1-yl	CH ₂	1,2-Ph	1,2-c-propyl	4-cyanophenyl	178
3-methylindol -1-yl	SO ₂	1,2-Ph	1,2-c-propyl	3,5-di-(CF ₃) phenyl	179
3-methylindol -1-yl	SO ₂	1,2-Ph	1,2-c-propyl	4-isopropyl phenyl	180
3-methylindol -1-yl	SO ₂	1,2-Ph	1,2-c-propyl	3,4-dichloro phenyl	181
3-methylindol -1-yl	SO ₂	1,2-Ph	1,2-c-propyl	3,4-difluoro phenyl	182
3-methylindol -1-yl	SO ₂	1,2-Ph	1,2-c-propyl	4-fluorophenyl	183
3-methylindol -1-yl	SO ₂	1,2-Ph	1,2-c-propyl	4-chlorophenyl	184
3-methylindol -1-yl	SO ₂	1,2-Ph	1,2-c-propyl	4-propylphenyl	185
3-methylindol -1-yl	SO ₂	1,2-Ph	1,2-c-propyl	2,5-dichloro-3- thienyl	186
3-methylindol -1-yl	SO ₂	1,2-Ph	1,2-c-propyl	2-styryl	187
3-methylindol -1-yl	SO ₂	1,2-Ph	1,2-c-propyl	3-chloro-4- fluorophenyl	188
3-methylindol -1-yl	SO ₂	1,2-Ph	1,2-c-propyl	4-methoxy phenyl	189
3-methylindol -1-yl	SO ₂	1,2-Ph	1,2-c-propyl	3-bromo phenyl	190
3-methylindol -1-yl	SO ₂	1,2-Ph	1,2-c-propyl	2,5-dimethyl phenyl	191

R ¹ R ² R ³ -Het	A	X	B	R ¹⁰	Cpd
3-methylindol-1-yl	SO ₂	1,2-Ph	1,2-c-propyl	2-nitro-4-chloro phenyl	192
3-methylindol-1-yl	SO ₂	1,2-Ph	1,2-c-propyl	2-carbomethoxy phenyl	193
3-methylindol-1-yl	SO ₂	1,2-Ph	1,2-c-propyl	2,4-difluoro phenyl	194
3-methylindol-1-yl	SO ₂	1,2-Ph	1,2-c-propyl	4-butylphenyl	195
3-methylindol-1-yl	SO ₂	1,2-Ph	1,2-c-propyl	n-butyl	196
3-methylindol-1-yl	SO ₂	1,2-Ph	1,2-c-propyl	2,5-dimethoxy phenyl	197
3-methylindol-1-yl	SO ₂	1,2-Ph	1,2-c-propyl	3-trifluoromethyl phenyl	198
3-methylindol-1-yl	SO ₂	1,2-Ph	1,2-c-propyl	3,5-difluoro phenyl	199
1-(3-methyl)indolyl	SO ₂	1,2-Ph	1,2-c-propyl	3,5-dichloro phenyl	200
3-methylindol-1-yl	SO ₂	1,2-Ph	1,2-c-propyl	4-((1-hydroxy-1-methyl)ethyl) phenyl	201
3-methylindol-1-yl	SO ₂	1,2-Ph	1,2-c-propyl	4-(hydroxy methyl)phenyl	202
3-methylindol-1-yl	SO ₂	1,2-Ph	1,2-c-propyl	3-(hydroxy methyl)phenyl	203
3-methylindol-1-yl	SO ₂	1,2-Ph	1,2-c-propyl	4-(methyl sulfonyl)phenyl	204
3-methylindol-1-yl	SO ₂	1,2-Ph	1,2-c-propyl	3-(methyl sulfonyl)phenyl	205
3-methylindol-1-yl	SO ₂	1,2-Ph	1,2-c-propyl	4-(propyl sulfonyl)phenyl	206
3-methylindol-1-yl	SO ₂	1,2-Ph	1,2-c-propyl	4-((bis-trifluoro methyl)hydroxy methyl)phenyl	207
3-methylindol-1-yl	SO ₂	1,2-Ph	1,2-c-propyl	4-(benzyloxy) phenyl	208
3-methylindol-1-yl	SO ₂	1,2-Ph	1,2-c-propyl	4-((1-methoxy-1-methyl)ethyl)-phenyl	209
3-methylindol-1-yl	SO ₂	1,2-Ph	1,2-c-propyl	4-dimethyl aminophenyl	210
3-methylindol-1-yl	SO ₂	1,2-Ph	1,2-c-propyl	cyclohexyl	211

R¹R²R³.Het	A	X	B	R¹⁹	Cpd
3-methylindol -1-yl	SO ₂	1,2-Ph	1,2-c-propyl	cyclopentyl	212
3-methylindol -1-yl	SO ₂	1,2-Ph	1,2-c-propyl	4-morpholinyl	213
3-methylindol -1-yl	SO ₂	1,2-Ph	1,2-c-propyl	2-naphthyl	214
3-methylindol -1-yl	SO ₂	1,2-Ph	1,2-c-propyl	2-thiazolyl	215
3-methylindol -1-yl	SO ₂	1,2-Ph	1,2-c-propyl	1-imidazolyl	216
3-methylindol -1-yl	SO ₂	1,2-Ph	1,2-c-propyl	2-furanyl	217
3-methylindol -1-yl	SO ₂	1,2-Ph	1,2-c-propyl	3-(2-chloro)- furanyl	218
3-methylindol -1-yl	SO ₂	1,2-Ph	1,2-c-propyl	2-pyridinyl	219
3-methylindol -1-yl	SO ₂	1,2-Ph	1,2-c-propyl	2-(4-chloro) pyridinyl	220
3-methylindol -1-yl	SO ₂	1,2-Ph	1,2-c-propyl	3-indolyl	221
3-methylindol -1-yl	SO ₂	1,2-Ph	1,2-c-propyl	4-nitrophenyl	222
3-methylindol -1-yl	SO ₂	1,2-Ph	1,2-c-propyl	4-cyanophenyl	223
2-naphthyl	CH ₂	1,2-Ph	CH=CH	3,5-di-(CF ₃) phenyl	224
2-naphthyl	CH ₂	1,2-Ph	CH=CH	4-isopropyl phenyl	225
2-naphthyl	CH ₂	1,2-Ph	CH=CH	2,3-dichloro phenyl	226
2-naphthyl	CH ₂	1,2-Ph	CH=CH	3,4-difluoro phenyl	227
2-naphthyl	CH ₂	1,2-Ph	CH=CH	4-chlorophenyl	228
2-naphthyl	CH ₂	1,2-Ph	CH=CH	4-fluorophenyl	229
2-naphthyl	CH ₂	1,2-Ph	CH=CH	2,5-dichloro-3- thienyl	230
2-naphthyl	CH ₂	1,2-Ph	CH=CH	3-chloro-4-fluoro phenyl	231
2-naphthyl	CH ₂	1,2-Ph	CH=CH	4-methoxy phenyl	232
2-naphthyl	CH ₂	1,2-Ph	CH=CH	butyl	233
2-naphthyl	CH ₂	1,2-Ph	CH=CH	3-trifluoro methylphenyl	234

R ¹ R ² R ³ -Het	A	X	B	R ¹⁹	Cpd
2-naphthyl	CH ₂	1,2-Ph	CH=CH	4-((1-hydroxy-1-methyl)ethyl)phenyl	235
2-naphthyl	CH ₂	1,2-Ph	CH=CH	4-(methylsulfonyl)phenyl	236
2-naphthyl	CH ₂	1,2-Ph	CH=CH	4-(benzyloxy)phenyl	237
2-naphthyl	CH ₂	1,2-Ph	CH=CH	cyclohexyl	238
2-naphthyl	CH ₂	1,2-Ph	CH=CH	4-morpholinyl	239
2-naphthyl	CH ₂	1,2-Ph	CH=CH	2-thiazolyl	240
2-naphthyl	CH ₂	1,2-Ph	CH=CH	2-furanyl	241
2-naphthyl	CH ₂	1,2-Ph	CH=CH	2-pyridinyl	242
2-naphthyl	CH ₂	1,2-Ph	CH=CH	4-cyanophenyl	243
2-naphthyl	SO ₂	1,2-Ph	CH=CH	3,5-di-(CF ₃)phenyl	244
2-naphthyl	SO ₂	1,2-Ph	CH=CH	4-isopropylphenyl	245
2-naphthyl	SO ₂	1,2-Ph	CH=CH	2,3-dichlorophenyl	246
2-naphthyl	SO ₂	1,2-Ph	CH=CH	3,4-difluorophenyl	247
2-naphthyl	SO ₂	1,2-Ph	CH=CH	4-chlorophenyl	248
2-naphthyl	SO ₂	1,2-Ph	CH=CH	4-fluorophenyl	249
2-naphthyl	SO ₂	1,2-Ph	CH=CH	2,5-dichloro-3-thienyl	250
2-naphthyl	SO ₂	1,2-Ph	CH=CH	3-chloro-4-fluorophenyl	251
2-naphthyl	SO ₂	1,2-Ph	CH=CH	4-methoxyphenyl	252
2-naphthyl	SO ₂	1,2-Ph	CH=CH	butyl	253
2-naphthyl	SO ₂	1,2-Ph	CH=CH	3-trifluoromethylphenyl	254
2-naphthyl	SO ₂	1,2-Ph	CH=CH	4-((1-hydroxy-1-methyl)ethyl)phenyl	255
2-naphthyl	SO ₂	1,2-Ph	CH=CH	4-(methylsulfonyl)phenyl	256
2-naphthyl	SO ₂	1,2-Ph	CH=CH	4-(benzyloxy)phenyl	257
2-naphthyl	SO ₂	1,2-Ph	CH=CH	cyclohexyl	258
2-naphthyl	SO ₂	1,2-Ph	CH=CH	4-morpholinyl	259
2-naphthyl	SO ₂	1,2-Ph	CH=CH	2-thiazolyl	260
2-naphthyl	SO ₂	1,2-Ph	CH=CH	2-furanyl	261
2-naphthyl	SO ₂	1,2-Ph	CH=CH	2-pyridinyl	262

R¹R²R³-Het	A	X	B	R¹⁹	Cpd
2-naphthyl	SO ₂	1,2-Ph	CH=CH	4-cyanophenyl	263
2-naphthyl	CH ₂ -O	1,2-Ph	CH=CH	3,5-di-(CF ₃) phenyl	264
2-naphthyl	CH ₂ -O	1,2-Ph	CH=CH	4-isopropyl phenyl	265
2-naphthyl	CH ₂ -O	1,2-Ph	CH=CH	2,3-dichloro phenyl	266
2-naphthyl	CH ₂ -O	1,2-Ph	CH=CH	3,4-difluoro phenyl	267
2-naphthyl	O-CH ₂	1,2-Ph	CH=CH	3,5-di-(CF ₃) phenyl	268
2-naphthyl	O-CH ₂	1,2-Ph	CH=CH	4-isopropyl phenyl	269
2-naphthyl	O-CH ₂	1,2-Ph	CH=CH	2,3-dichloro phenyl	270
2-naphthyl	O-CH ₂	1,2-Ph	CH=CH	3,4-difluoro phenyl	271
2-naphthyl	S	1,2-Ph	CH=CH	3,5-di-(CF ₃) phenyl	272
2-naphthyl	S	1,2-Ph	CH=CH	4-isopropyl phenyl	273
2-naphthyl	S	1,2-Ph	CH=CH	2,3-dichloro phenyl	274
2-naphthyl	S	1,2-Ph	CH=CH	3,4-difluoro phenyl	275
2-(6-benzyloxy) naphthyl	SO ₂	1,2-Ph	CH=CH	2-thienyl	276
2-(6-benzyloxy) naphthyl	S	1,2-Ph	CH=CH	2-thienyl	277
2-(6-benzyloxy) naphthyl	SO ₂	1,2-Ph	1,2-c-propyl	2-thienyl	278
2-(6-benzyloxy) naphthyl	S	1,2-Ph	1,2-c-propyl	2-thienyl	279
2-(5-benzyloxy) naphthyl	SO ₂	1,2-Ph	CH=CH	2-thienyl	280
2-(5-benzyloxy) naphthyl	S	1,2-Ph	CH=CH	2-thienyl	281
2-(5-benzyloxy) naphthyl	SO ₂	1,2-Ph	1,2-c-propyl	2-thienyl	282
2-(5-benzyloxy) naphthyl	S	1,2-Ph	1,2-c-propyl	2-thienyl	283
2-(6-(4-trifluoro methyl)benzyloxy)) naphthyl	SO ₂	1,2-Ph	CH=CH	2-thienyl	284

R¹R²R³-Het	A	X	B	R^{1b}	Cpd
2-(6-(4-trifluoro methyl)benzyloxy)) naphthyl	CH ₂	1,2-Ph	CH=CH	2-thienyl	285
2-(6-(4-trifluoro methyl)benzyl oxy))naphthyl	CH ₂	1,2-Ph	1,2-c-propyl	2-thienyl	286
2-(6-(4-trifluoro methyl)benzyl oxy))naphthyl	CH ₂	1,2-Ph	1,2-c-propyl	2-thienyl	287
1-(6-benzyloxy) naphthyl	SO ₂	1,2-Ph	CH=CH	2-thienyl	288
1-(6-benzyloxy) naphthyl	CH ₂	1,2-Ph	CH=CH	2-thienyl	289
2-(6-(3,4-difluoro benzyloxy)) naphthyl	SO ₂	1,2-Ph	CH=CH	2-thienyl	290
2-(6-(3,4-difluoro benzyloxy)) naphthyl	CH ₂	1,2-Ph	CH=CH	2-thienyl	291
2-(6-(4-fluoro benzyloxy)) naphthyl	CH ₂	1,2-Ph	1,2-c-propyl	2-thienyl	292
2-(7-benzyloxy) naphthyl	SO ₂	1,2-Ph	CH=CH	2-thienyl	293
2-(6-(3,4-difluoro benzyloxy)) naphthyl	SO ₂	1,2-Ph	CH=CH	3,4-difluoro phenyl	294
2-(6-(3,4-difluoro benzyloxy)) naphthyl	CH ₂	1,2-Ph	CH=CH	3,4-difluoro phenyl	295
2-(6-(4-fluoro benzyloxy)) naphthyl	CH ₂	1,2-Ph	1,2-c-propyl	3,4-difluoro phenyl	296
2-(7-benzyloxy) naphthyl	SO ₂	1,2-Ph	CH=CH	3,5-di-(CF ₃) phenyl	297
2-(6-(3,4-difluoro benzyloxy)) naphthyl	SO ₂	1,2-Ph	CH=CH	3,5-di-(CF ₃) phenyl	298
2-(6-(3,4-difluoro benzyloxy)) naphthyl	CH ₂	1,2-Ph	CH=CH	3,5-di-(CF ₃) phenyl	299
2-(7-benzyloxy) naphthyl	SO ₂	1,2-Ph	1,2-c-propyl	3,4-difluoro phenyl	300
2-naphthyl	CH ₂	1,2-Ph	CH=CH	2-methoxy-5-bromophenyl	301

R¹R²R³-Het	A	X	B	R¹⁹	Cpd
2-naphthyl	CH ₂	4-Cl-1,2-Ph	CH=CH	2-methoxy-5-bromophenyl	302
2-naphthyl	CH ₂	4-Cl-1,2-Ph	CH=CH	2-thienyl	303
2-naphthyl	SO	1,2-Ph	CH=CH	2-methoxy-5-bromophenyl	304
2-naphthyl	SO ₂	1,2-Ph	CH=CH	2-methoxy-5-bromophenyl	305
2-naphthyl	O	1,2-Ph	CH=CH	2-methoxy-5-bromophenyl	306
2-(5-benzyloxy)naphthyl	CH ₂	1,2-Ph	CH=CH	2-methoxy-5-bromophenyl	307
2-(5-benzyloxy)naphthyl	SO ₂	1,2-Ph	CH=CH	2-methoxy-5-bromophenyl	308
2-(5-benzyloxy)naphthyl	S	1,2-Ph	CH=CH	2-methoxy-5-bromophenyl	309
2-naphthyl	CH ₂	1,2-Ph	1,2-c-propyl	2-methoxy-5-bromophenyl	310
1,2-Ph	SO ₂	1,2-Ph	1,2-c-propyl	2-methoxy-5-bromophenyl	311
2-naphthyl	S	1,2-Ph	1,2-c-propyl	2-methoxy-5-bromophenyl	312
2-naphthyl	CH ₂ -O	1,2-Ph	CH=CH	2-methoxy-5-bromophenyl	313
2-naphthyl	S	1,2-Ph	CH=CH	2-methoxy-5-bromophenyl	314
3-methyl indol-1-yl	SO ₂	1,2-Ph	1,2-c-propyl	2-methoxy-5-bromophenyl	315
3-methyl indol-1-yl	S	1,2-Ph	1,2-c-propyl	2-methoxy-5-bromophenyl	316
3-methyl indol-1-yl	CH ₂ -O	1,2-Ph	CH=CH	2-methoxy-5-bromophenyl	317
3-methyl indol-1-yl	S	1,2-Ph	CH=CH	2-methoxy-5-bromophenyl	318
3-methyl indol-1-yl	O-CH ₂	1,2-Ph	1,2-c-propyl	2-methoxy-5-bromophenyl	319
3-methyl indol-1-yl	SO	1,2-Ph	1,2-c-propyl	2-methoxy-5-bromophenyl	320
3-methyl indol-1-yl	CH ₂ -O	4-Cl-1,2-Ph	CH=CH	2-methoxy-5-bromophenyl	321
3-methyl indol-1-yl	S	4-Cl-1,2-Ph	CH=CH	2-methoxy-5-bromophenyl	322
3-methyl indol-1-yl	SO ₂	4-Cl-1,2-Ph	1,2-c-propyl	2-methoxy-5-bromophenyl	323

R¹R²R³-Het	A	X	B	R¹⁰	Cpd
2-(7-fluoro) naphthyl	SO ₂	4-Cl-1,2-Ph	CH=CH	2-thienyl	347
2-(7-fluoro) naphthyl	O	4-Cl-1,2-Ph	CH=CH	2-thienyl	348
2-(7-fluoro) naphthyl	S	4-Cl-1,2-Ph	CH=CH	2-thienyl	349
2-(7-fluoro) naphthyl	CH ₂	4-Cl-1,2-Ph	CH=CH	2-thienyl	350
2-(7-fluoro) naphthyl	CH ₂	6-Cl-1,2-Ph	CH=CH	2-thienyl	351
2-(7-fluoro) naphthyl	CH ₂	4-Cl-1,2-Ph	1,2-c-Pr	2-thienyl	352
2-(7-fluoro) naphthyl	CH ₂	3-Cl-1,2-Ph	CH=CH	2-thienyl	353
2-(7-fluoro) naphthyl	SO ₂	4-Cl-1,2-Ph	CH=CH	2-methoxy-5- bromophenyl	354
2-(7-fluoro) naphthyl	O	4-Cl-1,2-Ph	CH=CH	2-methoxy-5- bromophenyl	355
2-(7-fluoro) naphthyl	S	4-Cl-1,2-Ph	CH=CH	2-methoxy-5- bromophenyl	356
2-naphthyl	CH ₂	4,5-Cl ₂ - 1,2-Ph	CH=CH	2-methoxy-5- bromophenyl	357
2-(7-fluoro) naphthyl	CH ₂	6-Cl-1,2-Ph	CH=CH	2-methoxy-5- bromophenyl	358
2-(7-fluoro) naphthyl	CH ₂	4-Cl-1,2-Ph	1,2-c-Pr	2-methoxy-5- bromophenyl	359
2-(7-fluoro) naphthyl	CH ₂	3-Cl-1,2-Ph	CH=CH	2-methoxy-5- bromophenyl	360
2-(7-fluoro) naphthyl	SO ₂	4-Cl-1,2-Ph	CH=CH	2-trifluoro methoxy-5- chlorophenyl	361
2-(7-fluoro) naphthyl	O	4-Cl-1,2-Ph	CH=CH	2-trifluoro methoxy-5- chlorophenyl	362
2-(7-fluoro) naphthyl	S	4-Cl-1,2-Ph	CH=CH	2-trifluoro methoxy-5- chlorophenyl	363
2-(7-fluoro) naphthyl	CH ₂	4-Cl-1,2-Ph	CH=CH	2-trifluoro methoxy-5- chlorophenyl	364
2-(7-fluoro) naphthyl	CH ₂	6-Cl-1,2-Ph	CH=CH	2-trifluoro methoxy-5- chlorophenyl	365

R¹R²R³-Het	A	X	B	R¹⁹	Cpd
2-(7-fluoro) naphthyl	CH ₂	4-Cl-1,2-Ph	1,2-c-Pr	2-trifluoro methoxy-5- chlorophenyl	366
2-(7-fluoro) naphthyl	CH ₂	3-Cl-1,2-Ph	CH=CH	2-trifluoro methoxy-5- chlorophenyl	367
2-(7-fluoro) naphthyl	SO ₂	4-Cl-1,2-Ph	CH=CH	2-thienyl	368
2-(7-fluoro) naphthyl	O	4-Cl-1,2-Ph	CH=CH	2-thienyl	369
2-(7-fluoro) naphthyl	S	4-Cl-1,2-Ph	CH=CH	2-thienyl	370
2-(7-fluoro) naphthyl	CH ₂	4-Cl-1,2-Ph	CH=CH	2-thienyl	371
2-(7-fluoro) naphthyl	CH ₂	6-Cl-1,2-Ph	CH=CH	2-thienyl	372
2-(7-fluoro) naphthyl	CH ₂	4-Cl-1,2-Ph	1,2-c-Pr	2-thienyl	373
2-(7-fluoro) naphthyl	CH ₂	3-Cl-1,2-Ph	CH=CH	2-thienyl	374
2-(7-fluoro) naphthyl	SO ₂	4-Cl-1,2-Ph	CH=CH	2-methoxy-5- bromophenyl	375
2-(6-fluoro) naphthyl	O	4-Cl-1,2-Ph	CH=CH	2-methoxy-5- bromophenyl	376
2-(6-fluoro) naphthyl	S	4-Cl-1,2-Ph	CH=CH	2-methoxy-5- bromophenyl	377
2-(6-fluoro) naphthyl	CH ₂	4-Cl-1,2-Ph	CH=CH	2-methoxy-5- bromophenyl	378
2-(6-fluoro) naphthyl	CH ₂	6-Cl-1,2-Ph	CH=CH	2-methoxy-5- bromophenyl	379
2-(6-fluoro) naphthyl	CH ₂	4-Cl-1,2-Ph	1,2-c-Pr	2-methoxy-5- bromophenyl	380
2-(6-fluoro) naphthyl	CH ₂	3-Cl-1,2-Ph	CH=CH	2-methoxy-5- bromophenyl	381
2-(7-chloro) naphthyl	SO ₂	4-Cl-1,2-Ph	CH=CH	2-thienyl	382
2-(7-chloro) naphthyl	O	4-Cl-1,2-Ph	CH=CH	2-thienyl	383
2-(7-chloro) naphthyl	S	4-Cl-1,2-Ph	CH=CH	2-thienyl	384
2-(7-chloro) naphthyl	CH ₂	4-Cl-1,2-Ph	CH=CH	2-thienyl	385
2-(7-chloro) naphthyl	CH ₂	6-Cl-1,2-Ph	CH=CH	2-thienyl	386

R ¹ R ² R ³ -Het	A	X	B	R ¹⁹	Cpd
2-(7-chloro) naphthyl	CH ₂	4-Cl-1,2-Ph	1,2-c-Pr	2-thienyl	387
2-(7-chloro) naphthyl	CH ₂	3-Cl-1,2-Ph	CH=CH	2-thienyl	388
2-(6,7-difluoro) naphthyl	SO ₂	4-Cl-1,2-Ph	CH=CH	2-thienyl	389
2-(6,7-difluoro) naphthyl	O	4-Cl-1,2-Ph	CH=CH	2-thienyl	390
2-(6,7-difluoro) naphthyl	S	4-Cl-1,2-Ph	CH=CH	2-thienyl	391
2-(6,7-difluoro) naphthyl	CH ₂	4-Cl-1,2-Ph	CH=CH	2-thienyl	392
2-(6,7-difluoro) naphthyl	CH ₂	6-Cl-1,2-Ph	CH=CH	2-thienyl	393
2-(6,7-difluoro) naphthyl	CH ₂	4-Cl-1,2-Ph	1,2-c-Pr	2-thienyl	394
2-(6,7-difluoro) naphthyl	CH ₂	3-Cl-1,2-Ph	CH=CH	2-thienyl	395
2-(6,7-difluoro) naphthyl	SO ₂	4-Cl-1,2-Ph	CH=CH	2-methoxy-5- bromophenyl	396
2-(6,7-difluoro) naphthyl	O	4-Cl-1,2-Ph	CH=CH	2-methoxy-5- bromophenyl	397
2-(6,7-difluoro) naphthyl	S	4-Cl-1,2-Ph	CH=CH	2-methoxy-5- bromophenyl	398
2-(6,7-difluoro) naphthyl	CH ₂	4-Cl-1,2-Ph	CH=CH	2-methoxy-5- bromophenyl	399
2-(6,7-difluoro) naphthyl	CH ₂	6-Cl-1,2-Ph	CH=CH	2-methoxy-5- bromophenyl	400
2-(6,7-difluoro) naphthyl	CH ₂	4-Cl-1,2-Ph	1,2-c-Pr	2-methoxy-5- bromophenyl	401
2-(6,7-difluoro) naphthyl	CH ₂	3-Cl-1,2-Ph	CH=CH	2-methoxy-5- bromophenyl	402
2-(5,7-difluoro) naphthyl	CH ₂	4-Cl-1,2-Ph	CH=CH	2-methoxy-5- bromophenyl	403
2-(5,7-difluoro) naphthyl	S	4-Cl-1,2-Ph	CH=CH	2-methoxy-5- bromophenyl	404
2-(5,7-difluoro) naphthyl	O	4-Cl-1,2-Ph	CH=CH	2-methoxy-5- bromophenyl	405
2-(5,7-difluoro) naphthyl	SO ₂	4-Cl-1,2-Ph	CH=CH	2-methoxy-5- bromophenyl	406
2-(6-fluoro) quinolinyl	SO ₂	4-Cl-1,2-Ph	CH=CH	2-methoxy-5- bromophenyl	407
2-(6-fluoro) quinolinyl	S	4-Cl-1,2-Ph	CH=CH	2-methoxy-5- bromophenyl	408


R¹R²R³-Het	A	X	B	R^{1b}	Cpd
2-(6-fluoro)-quinolinyl	CH ₂	4-Cl-1,2-Ph	CH=CH	2-methoxy-5-bromophenyl	409
2-(6-fluoro)-quinolinyl	CH ₂	1,2-Ph	CH=CH	2-methoxy-5-bromophenyl	410
2-(6-fluoro)-quinolinyl	O	4-Cl-1,2-Ph	CH=CH	2-methoxy-5-bromophenyl	411
2-(6-fluoro)-quinolinyl	CH ₂	4-Cl-1,2-Ph	1,2-c-Pr	2-methoxy-5-bromophenyl	412
2-(5,7-difluoro)-quinolinyl	SO ₂	4-Cl-1,2-Ph	CH=CH	2-methoxy-5-bromophenyl	413
2-(5,7-difluoro)-quinolinyl	S	4-Cl-1,2-Ph	CH=CH	2-methoxy-5-bromophenyl	414
2-(5,7-difluoro)-quinolinyl	CH ₂	4-Cl-1,2-Ph	CH=CH	2-methoxy-5-bromophenyl	415
2-(5,7-difluoro)-quinolinyl	CH ₂	1,2-Ph	CH=CH	2-methoxy-5-bromophenyl	416
2-(5,7-difluoro)-quinolinyl	O	4-Cl-1,2-Ph	CH=CH	2-methoxy-5-bromophenyl	417
2-(5,7-difluoro)-quinolinyl	CH ₂	4-Cl-1,2-Ph	1,2-c-Pr	2-methoxy-5-bromophenyl	418
3,4-dichloro phenyl	SO ₂	4-Cl-1,2-Ph	CH=CH	2-methoxy-5-bromophenyl	419
3,4-dichloro phenyl	S	4-Cl-1,2-Ph	CH=CH	2-methoxy-5-bromophenyl	420
3,4-dichloro phenyl	CH ₂	4-Cl-1,2-Ph	CH=CH	2-methoxy-5-bromophenyl	421
3,4-dichloro phenyl	CH ₂	1,2-Ph	CH=CH	2-methoxy-5-bromophenyl	422
3,4-dichloro phenyl	O	4-Cl-1,2-Ph	CH=CH	2-methoxy-5-bromophenyl	423
3,4-dichloro phenyl	CH ₂	4-Cl-1,2-Ph	1,2-c-Pr	2-methoxy-5-bromophenyl	424
3,4-dichloro phenyl	CH ₂	5-Cl-1,2-Ph	CH=CH	2-methoxy-5-bromophenyl	425
4-chloro phenyl	SO ₂	4-Cl-1,2-Ph	CH=CH	2-methoxy-5-bromophenyl	426
4-chloro phenyl	S	4-Cl-1,2-Ph	CH=CH	2-methoxy-5-bromophenyl	427
4-chloro phenyl	CH ₂	4-Cl-1,2-Ph	CH=CH	2-methoxy-5-bromophenyl	428
4-chloro phenyl	CH ₂	1,2-Ph	CH=CH	2-methoxy-5-bromophenyl	429
4-chloro phenyl	O	4-Cl-1,2-Ph	CH=CH	2-methoxy-5-bromophenyl	430

R ¹ R ² R ³ -Het	A	X	B	R ¹⁹	Cpd
4-chloro phenyl	CH ₂	4-Cl-1,2-Ph	1,2-c-Pr	2-methoxy-5-bromophenyl	431
4-chloro phenyl	CH ₂	4-Cl-1,2-Ph	CH=CH	2-methoxy-5-bromophenyl	432
3,4-dichloro phenyl	SO ₂	4-Cl-1,2-Ph	CH=CH	2-thienyl	433
3,4-dichloro phenyl	S	4-Cl-1,2-Ph	CH=CH	2-thienyl	434
3,4-dichloro phenyl	CH ₂	4-Cl-1,2-Ph	CH=CH	2-thienyl	435
3,4-dichloro phenyl	CH ₂	1,2-Ph	CH=CH	2-thienyl	436
3,4-dichloro phenyl	O	4-Cl-1,2-Ph	CH=CH	2-thienyl	437
3,4-dichloro phenyl	CH ₂	4-Cl-1,2-Ph	CH=CH	2-thienyl	438
3,4-dichloro phenyl	CH ₂	5-Cl-1,2-Ph	CH=CH	2-thienyl	439
4-chloro phenyl	SO ₂	4-Cl-1,2-Ph	CH=CH	2-thienyl	440
4-chloro phenyl	S	4-Cl-1,2-Ph	CH=CH	2-thienyl	441
4-chloro phenyl	CH ₂	4-Cl-1,2-Ph	CH=CH	2-thienyl	442
4-chloro phenyl	CH ₂	1,2-Ph	CH=CH	2-thienyl	443
1-(5-chloro) indolyl	CH ₂	3,2-Pyr	CH=CH	2,4-(Me) ₂ -thiazol-5-yl	444
1-(5-chloro) indolyl	CH ₂	3,2-Pyr	CH=CH	2-thienyl	445
1-(6-(4-chloro) phenyl)indolyl	CH ₂	4-F-1,2-Ph	CH=CH	3-chloro-4-fluorophenyl	446
2-(6-difluoro methoxy) naphthyl	CH ₂	4-Cl-1,2-Ph	CH=CH	2-methoxy-5-bromophenyl	447
2-naphthyl	CH ₂	4-MeO-1,2-Ph	CH=CH	2-methoxy-5-bromophenyl	448
2-naphthyl	CH ₂	5-Cl-1,2-Ph	CH=CH	2-methoxy-5-bromophenyl	449
2-(6-chloro naphthyl)	CH ₂	4-Cl-1,2-Ph	CH=CH	2-methoxy-5-bromophenyl	450
1-(5-phenyl methoxy) indolyl	CH ₂	4-F-1,2-Ph	CH=CH	2-methoxy-5-bromophenyl	451

R ¹ R ² R ³ -Het	A	X	B	R ¹⁹	Cpd
2-(benzo[b]thiophenyl)	CH ₂	4-F-1,2-Ph	CH=CH	2-methoxy-5-bromophenyl	452
5-(1-benzyl)indolyl	CH ₂	4-F-1,2-Ph	CH=CH	2-methoxy-5-bromophenyl	453
1-(6-(4-chloro)phenyl)indolyl	CH ₂	4-F-1,2-Ph	CH=CH	2-methoxy-5-bromophenyl	454

5

Table II



I-b

(Compounds 324-346 and 455-542)

R ¹ R ² R ³ -Het	A	X	B	Cpd
2-naphthyl	S(O) ₂	1,2-phenyl	CH=CH	324
2-naphthyl	S	1,2-phenyl	CH=CH	325
4-methylthiophenyl	CH ₂	1,2-phenyl	CH=CH	326
3-methylindol-1-yl	CH ₂	1,2-phenyl	CH=CH	327
3-chloro-4-fluorophenyl	CH ₂	1,2-phenyl	CH=CH	328
4-chlorophenyl	CH ₂	1,2-phenyl	CH=CH	329
2-naphthyl	CH ₂	1,2-phenyl	CH=CH	330
2-naphthyl	S(O) ₂	1,2-phenyl	1,2-c-propyl	331
2-naphthyl	S(O) ₂	1,2-phenyl	CH ₂ -CH ₂	332
2-naphthyl	S	1,2-phenyl	CH=CH	333
3,4-dichlorophenyl	S(O) ₂	1,2-phenyl	CH ₂ -CH ₂	334
3,4-dichlorophenyl	CH ₂	1,2-phenyl	CH=CH	335
2-(6-benzyloxy)naphthyl	CH ₂	1,2-phenyl	CH=CH	336
2-(6-benzyloxy)naphthyl	CH ₂	1,2-phenyl	1,2-c-propyl	337
2-(6-benzyloxy)naphthyl	SO ₂	1,2-phenyl	1,2-c-propyl	338
2-(6-benzyloxy)naphthyl	CH ₂ -O	1,2-phenyl	1,2-c-propyl	339
2-(6-benzyloxy)naphthyl	O-CH ₂	1,2-phenyl	1,2-c-propyl	340
2-(6-benzyloxy)naphthyl	SO ₂	1,2-phenyl	CH=CH	341
2-(6-benzyloxy)naphthyl	CH ₂ -O	1,2-phenyl	CH=CH	342

R1R2R3-Het	A	X	B	Cpd
2-(6-benzyloxy)naphthyl	O-CH ₂	1,2-phenyl	CH=CH	343
2-(6-benzyloxy)naphthyl	S	1,2-phenyl	CH=CH	344
2-(7-benzyloxy)naphthyl	SO ₂	1,2-phenyl	CH=CH	345
2-(6-(4-trifluoromethyl)benzyloxy)naphthyl	CH ₂	1,2-phenyl	CH=CH	346
2-(6-fluoro)naphthyl	SO ₂	4-Cl-1,2-Ph	CH=CH	455
2-(6-fluoro)naphthyl	S	4-Cl-1,2-Ph	CH=CH	456
2-(6-fluoro)naphthyl	CH ₂	4-Cl-1,2-Ph	CH=CH	457
2-(6-fluoro)naphthyl	CH ₂	1,2-Ph	CH=CH	458
2-(6-fluoro)naphthyl	O	4-Cl-1,2-Ph	CH=CH	459
2-(6-fluoro)naphthyl	CH ₂	4-Cl-1,2-Ph	1,2-c-Pr	460
2-(7-fluoro)naphthyl	SO ₂	4-Cl-1,2-Ph	CH=CH	461
2-(7-fluoro)naphthyl	S	4-Cl-1,2-Ph	CH=CH	462
2-(7-fluoro)naphthyl	CH ₂	4-Cl-1,2-Ph	CH=CH	463
2-(7-fluoro)naphthyl	CH ₂	1,2-Ph	CH=CH	464
2-(7-fluoro)naphthyl	O	4-Cl-1,2-Ph	CH=CH	465
2-(7-fluoro)naphthyl	CH ₂	4-Cl-1,2-Ph	1,2-c-Pr	466
2-(6-chloro)naphthyl	SO ₂	4-Cl-1,2-Ph	CH=CH	467
2-(6-chloro)naphthyl	S	4-Cl-1,2-Ph	CH=CH	468
2-(6-chloro)naphthyl	CH ₂	4-Cl-1,2-Ph	CH=CH	469
2-(6-chloro)naphthyl	CH ₂	1,2-Ph	CH=CH	470
2-(6-chloro)naphthyl	O	4-Cl-1,2-Ph	CH=CH	471
2-(6-chloro)naphthyl	CH ₂	4-Cl-1,2-Ph	1,2-c-Pr	472
2-(7-chloro)naphthyl	SO ₂	4-Cl-1,2-Ph	CH=CH	473
2-(7-chloro)naphthyl	S	4-Cl-1,2-Ph	CH=CH	474
2-(7-chloro)naphthyl	CH ₂	4-Cl-1,2-Ph	CH=CH	475
2-(7-chloro)naphthyl	CH ₂	4-Cl-1,2-Ph	CH=CH	476
2-(7-chloro)naphthyl	CH ₂	4-Cl-1,2-Ph	CH=CH	477
2-(7-chloro)naphthyl	CH ₂	4-Cl-1,2-Ph	CH=CH	478
2-(6,7-difluoro)naphthyl	SO ₂	4-Cl-1,2-Ph	CH=CH	479
2-(6,7-difluoro)naphthyl	S	4-Cl-1,2-Ph	CH=CH	480
2-(6,7-difluoro)naphthyl	CH ₂	4-Cl-1,2-Ph	CH=CH	481
2-(6,7-difluoro)naphthyl	CH ₂	4-Cl-1,2-Ph	CH=CH	482
2-(6,7-difluoro)naphthyl	CH ₂	4-Cl-1,2-Ph	CH=CH	483
2-(6,7-difluoro)naphthyl	CH ₂	4-Cl-1,2-Ph	1,2-c-Pr	484
2-(6,7-difluoro)naphthyl	CH ₂	4-Cl-1,2-Ph	CH=CH	485
2-(6,7-difluoro)naphthyl	CH ₂	4-Cl-1,2-Ph	CH=CH	486
2-(6,7-difluoro)naphthyl	CH ₂	4-Cl-1,2-Ph	CH=CH	487
2-(6,7-difluoro)naphthyl	CH ₂	1,2-Ph	CH=CH	488
2-(6,7-difluoro)naphthyl	CH ₂	4-Cl-1,2-Ph	CH=CH	489
2-(6,7-difluoro)naphthyl	CH ₂	4-Cl-1,2-Ph	1,2-c-Pr	490
3-methyl-5-fluoro indol-1-yl	SO ₂	4-Cl-1,2-Ph	CH=CH	491

R ¹ R ² R ³ -Het	A	X	B	Cpd
3-methyl-5-fluoro indol-1-yl	S	4-Cl-1,2-Ph	CH=CH	492
3-methyl-5-fluoro indol-1-yl	CH ₂	4-Cl-1,2-Ph	CH=CH	493
3-methyl-5-fluoro indol-1-yl	CH ₂	1,2-Ph	CH=CH	494
3-methyl-5-fluoro indol-1-yl	CH ₂	4-Cl-1,2-Ph	CH=CH	495
3-methyl-5-fluoro indol-1-yl	CH ₂	4-Cl-1,2-Ph	CH=CH	496
2-(6-fluoro)quinolinyl	SO ₂	4-Cl-1,2-Ph	CH=CH	497
2-(6-fluoro)quinolinyl	S	4-Cl-1,2-Ph	CH=CH	498
2-(6-fluoro)quinolinyl	CH ₂	4-Cl-1,2-Ph	CH=CH	499
2-(6-fluoro)quinolinyl	CH ₂	4-Cl-1,2-Ph	CH=CH	500
2-(6-fluoro)quinolinyl	O	4-Cl-1,2-Ph	CH=CH	501
2-(6-fluoro)quinolinyl	CH ₂	4-Cl-1,2-Ph	CH=CH	502
2-(6-difluoromethoxy)- naphthyl	SO ₂	4-Cl-1,2-Ph	CH=CH	503
2-(6-difluoromethoxy)- naphthyl	SO ₂	4-Cl-1,2-Ph	CH=CH	504
2-(6-difluoromethoxy)- naphthyl	SO ₂	4-Cl-1,2-Ph	CH=CH	505
2-(6-difluoromethoxy)- naphthyl	SO ₂	4-Cl-1,2-Ph	CH=CH	506
2-(6-difluoromethoxy)- naphthyl	SO ₂	4-Cl-1,2-Ph	CH=CH	507
2-(6-difluoromethoxy)- naphthyl	SO ₂	4-Cl-1,2-Ph	CH=CH	508
2-(7-difluoromethoxy)- naphthyl	SO ₂	4-Cl-1,2-Ph	CH=CH	509
2-(7-difluoromethoxy)- naphthyl	S	4-Cl-1,2-Ph	CH=CH	510
2-(7-difluoromethoxy)- naphthyl	CH ₂	4-Cl-1,2-Ph	CH=CH	511
2-(7-difluoromethoxy)- naphthyl	CH ₂	4-Cl-1,2-Ph	CH=CH	512
2-(7-difluoromethoxy)- aphthyl	O	4-Cl-1,2-Ph	CH=CH	513
2-(7-difluoromethoxy)- naphthyl	CH ₂	4-Cl-1,2-Ph	CH=CH	514
2-(6-methoxy)naphthyl	SO ₂	4-Cl-1,2-Ph	CH=CH	515
2-(6-methoxy)naphthyl	S	4-Cl-1,2-Ph	CH=CH	516
2-(6-methoxy)naphthyl	CH ₂	4-Cl-1,2-Ph	CH=CH	517
2-(6-methoxy)naphthyl	CH ₂	4-Cl-1,2-Ph	CH=CH	518

R ¹ R ² R ³ -Het	A	X	B	Cpd
2-(6-methoxy)naphthyl	O	4-Cl-1,2-Ph	CH=CH	519
2-(6-methoxy)naphthyl	CH ₂	4-Cl-1,2-Ph	CH=CH	520
2-(6-fluoro)naphthyl	CH ₂	4-Cl-1,2-Ph	CH=CH	521
2-(6-fluoro)naphthyl	CH ₂	4-Cl-1,2-Ph	CH=CH	522
2-(6-fluoro)naphthyl	CH ₂	4-Cl-1,2-Ph	CH=CH	523
2-(6-fluoro)naphthyl	CH ₂	4-Cl-1,2-Ph	CH=CH	524
2-(6-fluoro)naphthyl	CH ₂	4-Cl-1,2-Ph	CH=CH	525
2-(6-fluoro)naphthyl	CH ₂	4-Cl-1,2-Ph	CH=CH	526
2-(7-fluoro)naphthyl	CH ₂	4-Cl-1,2-Ph	CH=CH	527
2-(7-fluoro)naphthyl	CH ₂	4-Cl-1,2-Ph	CH=CH	528
2-(7-fluoro)naphthyl	CH ₂	4-Cl-1,2-Ph	CH=CH	529
2-(7-fluoro)naphthyl	CH ₂	4-Cl-1,2-Ph	CH=CH	530
2-(7-fluoro)naphthyl	CH ₂	4-Cl-1,2-Ph	CH=CH	531
2-(7-fluoro)naphthyl	CH ₂	4-Cl-1,2-Ph	CH=CH	532
2-naphthyl	CH ₂	4,5-Cl ₂ -1,2-Ph	CH=CH	533
2-naphthyl	CH ₂	4-Cl-1,2-Ph	CH=CH	534
3,4-dichlorophenyl	CH ₂	4-Cl-1,2-Ph	CH=CH	535
2-naphthyl	CH ₂	4-Cl-1,2-Ph	CH=CH	536
4-chlorophenyl	CH ₂	4-Cl-1,2-Ph	CH=CH	537
1-(5-phenylmethoxy) indolyl	CH ₂	4-F-1,2-Ph	CH=CH	538
2-(benzo[b]thiophenyl)	CH ₂	4-F-1,2-Ph	CH=CH	539
5-(1-benzyl)indolyl	CH ₂	4-F-1,2-Ph	CH=CH	540
1-(6-(4-chloro)phenyl) indolyl	CH ₂	4-F-1,2-Ph	CH=CH	541
1-(5-chloro)indolyl	CH ₂	3,2-Pyr	CH=CH	542

5

Some of the compounds described herein contain one or more asymmetric centers and may thus give rise to diastereomers and optical isomers. The present invention is meant to comprehend such possible diastereomers as well as their racemic and resolved, enantiomerically pure forms and pharmaceutically acceptable salts thereof.

10

Some of the compounds described herein contain olefinic double bonds, and unless specified otherwise, are meant to include both E and Z geometric isomers.

15

The pharmaceutical compositions of the present invention comprise a compound of Formula I as an active ingredient or a pharmaceutically acceptable salt, thereof, and may also contain a

5 pharmaceutically acceptable carrier and optionally other therapeutic ingredients. The term "pharmaceutically acceptable salts" refers to salts prepared from pharmaceutically acceptable non-toxic bases including inorganic bases and organic bases. Salts derived from inorganic bases include aluminum, ammonium, calcium, copper, 10 ferric, ferrous, lithium, magnesium, manganic salts, manganous, potassium, sodium, zinc, and the like. Particularly preferred are the ammonium, calcium, magnesium, potassium, and sodium salts. Salts derived from pharmaceutically acceptable organic non-toxic bases include salts of primary, secondary, and tertiary amines, substituted 15 amines including naturally occurring substituted amines, cyclic amines, and basic ion exchange resins, such as arginine, betaine, caffeine, choline, N,N'-dibenzylethylenediamine, diethylamine, 2-diethylaminoethanol, 2-dimethylaminoethanol, ethanolamine, ethylenediamine, N-ethyl-morpholine, N-ethylpiperidine, glucamine, 20 glucosamine, histidine, hydrabamine, isopropylamine, lysine, methylglucamine, morpholine, piperazine, piperidine, polyamine resins, procaine, purines, theobromine, triethylamine, trimethylamine, tripropylamine, tromethamine, and the like.

When the compound of the present invention is basic, salts 25 may be prepared from pharmaceutically acceptable non-toxic acids, including inorganic and organic acids. Such acids include acetic, benzenesulfonic, benzoic, camphorsulfonic, citric, ethanesulfonic, fumaric, gluconic, glutamic, hydrobromic, hydrochloric, isethionic, lactic, maleic, malic, mandelic, methanesulfonic, mucic, nitric, 30 pamoic, pantothenic, phosphoric, succinic, sulfuric, tartaric, p-toluenesulfonic acid, and the like. Particularly preferred are citric, hydrobromic, hydrochloric, maleic, phosphoric, sulfuric, and tartaric acids.

It will be understood that in the discussion of methods of 35 treatment which follows, references to the compounds of Formula I are meant to also include the pharmaceutically acceptable salts.

The magnitude of prophylactic or therapeutic dose of a compound of Formula I will, of course, vary with the nature and the

5 severity of the condition to be treated and with the particular compound
of Formula I and its route of administration. It will also vary according
to a variety of factors including the age, weight, general health, sex, diet,
time of administration, rate of excretion, drug combination and
response of the individual patient. In general, the daily dose from about
10 0.001 mg to about 100 mg per kg body weight of a mammal, preferably
0.01 mg to about 10 mg per kg. On the other hand, it may be necessary to
use dosages outside these limits in some cases.

The amount of active ingredient that may be combined with
the carrier materials to produce a single dosage form will vary
15 depending upon the host treated and the particular mode of
administration. For example, a formulation intended for oral
administration to humans may contain from about 0.5 mg to about 5 g of
active agent compounded with an appropriate and convenient amount of
carrier material which may vary from about 5 to about 95 percent of the
20 total composition. Dosage unit forms will generally contain from about 1
mg to about 2 g of an active ingredient, typically 25 mg, 50 mg, 100 mg,
200 mg, 300 mg, 400 mg, 500 mg, 600 mg, 800 mg, or 1000 mg.

For the treatment of any of the prostanoid mediated diseases
compound I may be administered orally, topically, parenterally, by
25 inhalation spray or rectally in dosage unit formulations containing
conventional non-toxic pharmaceutically acceptable carriers, adjuvants
and vehicles. The term parenteral as used herein includes
subcutaneous, intravenous, intramuscular, intrasternal injection or
infusion techniques. In addition to the treatment of warm-blooded
30 animals such as mice, rats, horses, cattle, sheep, dogs, cats, etc., the
compound of the invention is effective in the treatment of humans.

The pharmaceutical compositions containing the active
ingredient may be in a form suitable for oral use, for example, as tablets,
troches, lozenges, solutions, aqueous or oily suspensions, dispersible
35 powders or granules, emulsions, hard or soft capsules, syrups or
elixirs. Compositions intended for oral use may be prepared according
to any method known to the art for the manufacture of pharmaceutical
compositions and such compositions may contain one or more agents

- 5 selected from the group consisting of sweetening agents, flavouring agents, colouring agents and preserving agents in order to provide pharmaceutically elegant and palatable preparations. Tablets contain the active ingredient in admixture with non-toxic pharmaceutically acceptable excipients which are suitable for the manufacture of tablets.
- 10 These excipients may be for example, inert diluents, such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, for example, corn starch, or alginic acid; binding agents, for example starch, gelatin or acacia, and lubricating agents, for example, magnesium stearate,
- 15 stearic acid or talc. The tablets may be uncoated or they may be coated by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period. For example, a time delay material such as glyceryl monostearate or glyceryl distearate may be employed. They may also be
- 20 coated by the technique described in the U.S. Patent 4,256,108; 4,166,452; and 4,265,874 to form osmotic therapeutic tablets for control release.

Formulations for oral use may also be presented as hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or

25 kaolin, or as soft gelatin capsules wherein the active ingredients is mixed with water-miscible solvents such as propylene glycol, PEGs and ethanol, or an oil medium, for example peanut oil, liquid paraffin, or olive oil.

Aqueous suspensions contain the active material in

30 admixture with excipients suitable for the manufacture of aqueous suspensions. Such excipients are suspending agents, for example sodium carboxymethylcellulose, methylcellulose, hydroxypropyl methylcellulose, sodium alginate, polyvinylpyrrolidone, gum tragacanth and gum acacia; dispersing or wetting agents may be a naturally-

35 occurring phosphatide, for example lecithin, or condensation products of an alkylene oxide with fatty acids, for example polyoxyethylene stearate, or condensation products of ethylene oxide with long chain aliphatic alcohols, for example heptadecaethyleneoxycetanol, or

5 condensation products of ethylene oxide with partial esters derived from
fatty acids and a hexitol such as polyoxyethylene sorbitol monooleate, or
condensation products of ethylene oxide with partial esters derived from
fatty acids and hexitol anhydrides, for example polyethylene sorbitan
monooleate. The aqueous suspensions may also contain one or more
10 preservatives, for example ethyl, or n-propyl, p-hydroxybenzoate, one or
more colouring agents, one or more flavouring agents, and one or more
sweetening agents, such as sucrose, saccharin or aspartame.

Oily suspensions may be formulated by suspending the
active ingredient in a vegetable oil, for example arachis oil, olive oil,
15 sesame oil or coconut oil, or in mineral oil such as liquid paraffin. The
oily suspensions may contain a thickening agent, for example beeswax,
hard paraffin or cetyl alcohol. Sweetening agents such as those set forth
above, and flavouring agents may be added to provide a palatable oral
preparation. These compositions may be preserved by the addition of an
20 anti-oxidant such as ascorbic acid.

Dispersible powders and granules suitable for preparation
of an aqueous suspension by the addition of water provide the active
ingredient in admixture with a dispersing or wetting agent, suspending
agent and one or more preservatives. Suitable dispersing or wetting
25 agents and suspending agents are exemplified by those already
mentioned above. Additional excipients, for example sweetening,
flavouring and colouring agents, may also be present.

The pharmaceutical compositions of the invention may also
be in the form of an oil-in-water emulsion. The oily phase may be a
30 vegetable oil, for example olive oil or arachis oil, or a mineral oil, for
example liquid paraffin or mixtures of these. Suitable emulsifying
agents may be naturally-occurring phosphatides, for example soy bean,
lecithin, and esters or partial esters derived from fatty acids and hexitol
anhydrides, for example sorbitan monooleate, and condensation
35 products of the said partial esters with ethylene oxide, for example
polyoxyethylene sorbitan monooleate. The emulsions may also contain
sweetening and flavouring agents.

5 Syrups and elixirs may be formulated with sweetening
agents, for example glycerol, propylene glycol, sorbitol or sucrose. Such
formulations may also contain a demulcent, a preservative and
flavouring and colouring agents. The pharmaceutical compositions
may be in the form of a sterile injectable aqueous or oleagenous
10 suspension. This suspension may be formulated according to the known
art using those suitable dispersing or wetting agents and suspending
agents which have been mentioned above. The sterile injectable
preparation may also be a sterile injectable solution or suspension in a
non-toxic parenterally-acceptable diluent or solvent, for example as a
15 solution in 1,3-butane diol. Among the acceptable vehicles and solvents
that may be employed are water, Ringer's solution and isotonic sodium
chloride solution. Cosolvents such as ethanol, propylene glycol or
polyethylene glycols may also be used. In addition, sterile, fixed oils are
conventionally employed as a solvent or suspending medium. For this
20 purpose any bland fixed oil may be employed including synthetic mono-
or diglycerides. In addition, fatty acids such as oleic acid find use in the
preparation of injectables.

 Compound I may also be administered in the form of
suppositories for rectal administration of the drug. These compositions
25 can be prepared by mixing the drug with a suitable non-irritating
excipient which is solid at ambient temperatures but liquid at the rectal
temperature and will therefore melt in the rectum to release the drug.
Such materials are cocoa butter and polyethylene glycols.

 For topical use, creams, ointments, gels, solutions or
30 suspensions, etc., containing the compound of Formula I are employed.
(For purposes of this application, topical application shall include mouth
washes and gargles.) Topical formulations may generally be comprised
of a pharmaceutical carrier, cosolvent, emulsifier, penetration
enhancer, preservative system, and emollient.

35 The ability of the compounds of Formula I to interact with
prostaglandin receptors makes them useful for treating, preventing or
reversing undesirable symptoms caused by prostaglandins in a
mammalian, especially human subject. This mimicking or antagonism

5 of the actions of prostaglandins indicates that the compounds and
pharmaceutical compositions thereof are useful to treat, prevent or
ameliorate prostaglandin mediated diseases and conditions in
mammals and especially in humans: Pain, fever and inflammation of a
variety of conditions including rheumatic fever, symptoms associated
10 with influenza or other viral infections, common cold, low back and neck
pain, skeletal pain, post-partum pain, dysmenorrhea, headache,
migraine, toothache, sprains and strains, myositis, neuralgia,
synovitis, arthritis, including rheumatoid arthritis, degenerative joint
diseases (osteoarthritis), gout and ankylosing spondylitis, bursitis,
15 burns including radiation and corrosive chemical injuries, sunburns,
pain following surgical and dental procedures as well as immune and
autoimmune diseases. In addition, such a compound may inhibit
cellular neoplastic transformations and metastatic tumor growth and
hence can be used in the treatment of cancer. Compound I may also be
20 of use in the treatment and/or prevention prostaglandin-mediated
proliferation disorders such as may occur in diabetic retinopathy and
tumor angiogenesis. Compound I will also inhibit prostanoid-induced
smooth muscle contraction by antagonizing contractile prostanoids or
mimicking relaxing prostanoids and hence may be use in the treatment
25 of dysmenorrhea, premature labor, asthma and eosinophil related
disorders. It will also be of use in the treatment of Alzheimer's disease,
the treatment of glaucoma, for the prevention of bone loss (treatment of
osteoporosis) and for the promotion of bone formation (treatment of
fractures) and other bone diseases such as Paget's disease.

30 By virtue of its prostanoid or prostanoid antagonist activity,
compound I will prove useful as an alternative to NSAID'S particularly
where such non-steroidal anti-inflammatory drugs may be
contraindicated such as in patients with peptic ulcers, gastritis,
regional enteritis, ulcerative colitis, diverticulitis or with a recurrent
35 history of gastrointestinal lesions; GI bleeding, coagulation disorders
including anemia such as hypoprothrombinemia, haemophilia or other
bleeding problems; kidney disease; thrombosis, occlusive vascular
diseases; those prior to surgery or taking anti-coagulants. Compound I

- 5 will also be useful as a cytoprotective agent for patients under chemotherapy.

Compound of Formula I, will be useful as a partial or complete substitute for conventional antiinflammatory or analgesic compounds in preparations wherein they are presently co-administered
10 with other agents or ingredients. Thus in further aspects, the invention encompasses pharmaceutical compositions for treating prostaglandin E_2 mediated diseases as defined above comprising a non-toxic therapeutically effective amount of the compound of Formula I as defined above and one or more ingredients such as another pain reliever
15 including acetaminophen or phenacetin; a COX-2 selective NSAID; a conventional NSAID; a potentiator including caffeine; an H_2 -antagonist, aluminum or magnesium hydroxide, simethicone, a decongestant including phenylephrine, phenylpropanolamine, pseudophedrine, oxymetazoline, ephinephrine, naphazoline, xylometazoline,
20 propylhexedrine, or levo-desoxyephedrine; an antiitussive including codeine, hydrocodone, caramiphen, carbetapentane, or dexamethorphan; another prostaglandin ligand including misoprostol, enprostil, rioprostil, ornoprostol or rosaprostol; a diuretic; a sedating or non-sedating antihistamine. In addition, the invention
25 encompasses a method of treating prostaglandin E_2 mediated diseases comprising: administration to a patient in need of such treatment a non-toxic therapeutically effective amount of the compound of Formula I, optionally co-administered with one or more of such ingredients as listed immediately above.

- 30 Compounds of the present invention can be prepared according to the following methods. Temperatures are in degrees Celsius.

Boronic acids and esters can be prepared from the corresponding halide according to literature procedure and reference
35 cited therein (Charette, A.B.; Giroux, A. J. Org. Chem. 1996, 61, 8718; Ishiyama, T.; Murata, M.; Miyaura, N. J. Org. Chem. 1995, 60, 7508; Miyaura, N.; Suzuki, A. Chem. Rev, 1995, 95, 2457; Murata, M.; Watanabe, S.; Masuda, Y. J. Org. Chem. 1997, 62, 6458; Watanabe, T.

- 5 Miyaura, N.; Suzuki, A. Synlett, 1992, 207; Maddaford, S.; Keay, B.A. J. Org. Chem. 1994, 59, 6501; Cristofoli, W.A.; Keay, B.A. Tetrahedron Lett. 1991, 32, 5881; Passafaro, M.S.; Keay, B.A. . Tetrahedron Lett. 1996, 37, 429; Serafin, B.; Makosza, M. Tetrahedron, 1963, 19, 821). In some cases, the triflate, the tin or the zinc derivatives may be used instead of the
- 10 boronic acid.

Method A

- Cinnamic ester 1 is treated with a brominating agent such as NBS in a refluxing inert solvent such as CCl_4 , with the use of an
- 15 initiator like benzoyl peroxide or light. The resulting benzylic bromide is reacted in a Suzuki coupling reaction with the appropriate boronic acid or ester, a catalyst such as tetrakis(triphenylphosphine) palladium and cesium fluoride or Na_2CO_3 or a base in an inert refluxing solvent such as DME at 80-90° C. The new cinnamic ester 3 is hydrolyzed with aqueous
- 20 sodium hydroxide to afford the acid 4 that is converted to the cinnamic sulfonamide 5 with a coupling reagent such as DCC or DCI in CH_2Cl_2 at r.t.

5 Method B

Cinnamic ester **2** is treated with an aryl or heteroaryl mercaptan, alcohol or amine, and with a base such as a hydride or an amine in benzene or THF at 0-23° C. The resulting cinnamic ester **6** is converted to **7** according to Method A.

- 10 If W= sulfur, it is oxidized to the sulfoxide or sulfone **8** with hydrogen peroxide, m-CPBA or other peracetic acid. The cinnamic ester **8** is converted to **9** according to Method A.

Method C

- 15 The aldehyde **11** is prepared by an addition-elimination of a mercapto, hydroxy or amino aryl or heteroaryl with a base such as K_2CO_3 in refluxing $CHCl_3$. If needed a higher boiling point solvent can be used. This type of reaction can also be performed with CuO in DMF. An Emmons-Horner type reaction (or Wittig) in toluene at r.t. followed
20 by Method A (or oxidation as described in Method B) results in the cinnamic sulfonamide **13**.

Method D

- Acetal **14** that came from an acetalization from a suitably
25 substituted bromo benzaldehyde is converted to the Grignard reagent with magnesium in an etheral solvent at reflux and quenched with an aryl or heteroaryl ketone. The alcohol **16** is reacted with an halide and a base (or protected as the *o*-nitrobenzyl, and removed at the end of the sequence) to furnish the compound **17**. Deprotection of the acetal under
30 standard conditions followed by Method C gives **18**.

Method E

- Alcohol **16** is converted to an acetate with acetyl chloride (or acetic anhydride and an amine base) and coupled with a Grignard
35 reagent and a copper salt at low temperature. The alcohol **16** could also be converted to the bromide and treated in a similar way to yield **20**. Alternatively the tetramethyl acetal (R= methyl) version of alcohol **16** can be treated with $TiCl_4/Me_2Zn$ (or R^7_2Zn) at -30 °C. Compound **20** is then

5 converted to the cinnamic sulfonamide **21** according to Method D. Also, **22** can be treated with $\text{Al}(\text{R}^7)_3$ in toluene at 80 °C for 24h and **23** converted to the aldehyde with n-BuLi/DMF followed by an Emmons-Horner reaction and Method A to yield compound **21**.

10 Method F

A suitably substituted bromo toluene **24** is treated with n-Buli at low temperature and quenched with an aryl or heteroaryl aldehyde. The resulting alcohol is oxidized to the ketone with PDC, PCC, MnO_2 or other typical oxidizing agent. The carbonyl is treated with SF_4 ,
15 $\text{MoF}_6\text{-BF}_3$ (or converted to a thioacetal and treated with nitrosonium $\text{BF}_4\text{-pyridinium}\cdot\text{HF}$) to yield the difluoride. Benzylic bromination with NBS followed by oxidation with N-methylmorpholine N-oxide at 100 °C in dioxane for 4 h, yielded compound **25** that is converted to cinnamic sulfonamide **26** with Method C.

20

Method G

The appropriately substituted methyl bromo(or triflate) benzoate **27** is converted to compound **28** by a Suzuki coupling reaction followed by hydrogenation. A Stille coupling reaction could also be used.
25 Benzylic bromination or benzylic oxidation followed by treatment with a brominating agent such as CBr_4 /triphenylphosphine gives compound **29** which can be treated with a boronic acid, or a tin compound (Stille) to furnish compound **30**. Reduction of the ester with DIBAL, oxidation with MnO_2 and Method C gives compound **31**.

30

Method H

Compound **29** (one $\text{R}^7 = \text{H}$) is treated with triphenyl phosphine to give the salt and, with a base such as LDA, is converted to compound **32** with the aryl or heteroaryl ketone. The halide **29** can also
35 be converted the Grignard reagent and added to the ketone. Dehydration under acidic conditions results in compound **32**. Reduction of the double bond under standard conditions, followed by Methods G and C gives compound **33**. From compound **32**, cyclopropanation with

- 5 diazomethane and palladium (0) followed by Methods G, C and A gives compound **34**.

5 Method I

The (heterocyclic) vinylic bromide **35** is reacted in a Suzuki coupling reaction with an aryl or hetero aryl boronic acid and converted to a new borane by 9-BBN addition followed by a second Suzuki reaction with compound **14**. Compound **37** thus formed is reduced by
10 hydrogenolysis (H_2 /metal or diimide) and deprotection followed by Method C gives cinnamic sulfonamide **39**.

Method J

Ketone **40** which comes from oxidation of the corresponding
15 alcohol is reacted with a phosphonium salt or phosphono ester with a base such as LDA to give the cinnamic ester **41**. Method A yields **42** and reduction of the double bond by the previously mentioned method gives the acyl sulfonamide **43**.

20 Method K

Cinnamic ester **3** is reduced to **44** by the previously mentioned method. α Alkylation with a base such as LDA followed by an alkylating agent results in **45** after conversion to the acyl sulfonamide.

25 Method L

Cinnamic ester **3** is reduced to **46** with DIBAL and the double bond converted to a cyclopropane by a Simmons-Smith reaction, or similar reactions recently described in the literature. Compound **47** is then oxidized and the cinnamic sulfonamide **48** is prepared according to
30 Method A.

Method M

Ester **49** which can come from the homologation of the appropriately substituted methyl ortho-toluate, is treated with a base and
35 with an alkylating agent to furnish compound **50**. Benzylic bromination and Suzuki coupling gives an intermediate ester. Homologation according to *J. Amer. Chem. Soc.*; **1985**, 1429; *J. Org. Chem.* **1992**, 7194,

- 5 followed by alkylation with a base such as LDA and an alkylating agent furnishes acylsulfonamide **51** by Method A.

Compound **50** can also be converted to the benzylic bromide and to compound **52** by Method A.

10 Method N

- Suitably substituted compound **53** is treated with a boronic acid to give compound **54** which is reduced with LDA to the alcohol **55**. Treatment with phosgene followed with the appropriate sulfonamide gives compound **56**. This can also be prepared by mixing phosgene and
15 the sulfonamide at 140°C to generate the isocyanate.

Compound **54** is treated with a Grignard reagent to give the corresponding alcohol and as previously described, converted to compound **57**.

20 Method O

Ester **58** is treated with Lawesson's reagent, DAST and light to give the benzylic alcohol **59**. The procedure according to Method N yields compound **60**.

25 Method P

Compound **59** is brominated as described earlier (or iodinated) and reacted in a S_N2 type reaction with an ester and a base such as LDA to furnish ester **61**. Method A gives the acylsulfonamide
30 **62**.

30

Method Q

- Compound **55** is treated with NH₃/Ph₃P/DEAD (or treated with CBr₄/Ph₃P and the bromide converted to the amine **63** with ammonia). Treatment with phosgene followed by sulfonamide yields **64**,
35 treatment of which with a base and an alkyl or benzylic halide gives compounds **65**.

Method R

5 Aldehyde **10** is treated with a silylated source of hydroxyl or
thiol at 80-130 °C, and the silyl group removed by fluoride treatment.
Compound **66** is then treated with an aryl or heteroaryl methylene
bromide with a base such as a tertiary amine in CHCl₃ or benzene to
yield aldehyde **67**. Emmons-Horner (or Wittig reaction) with LDA
10 results in compound **68** via Method A.

Method S


 In the case of an amine an alternative to method R can be
used. A suitably substituted nitro aldehyde **69** is converted to compound
15 **70** as described earlier and the nitro group reduced with standard
methods. Mono-alkylation followed by displacement with an aryl or
heteroaryl methylene bromide and processing by Method A yields
cinnamic sulfonamide **71**.

20 Method T


 A suitably substituted bromo toluene **24** is converted to the
anion in an etheral solvent at low temperature and trapped with an
aldehyde of an aryl or heteroaryl. The resulting alcohol is oxidized with
MnO₂, Jones' reagent, PDC, PCC or any other oxidant. Benzylic
25 bromination followed by oxidation with N-methyl morpholine N-oxide,
yields a ketoaldehyde. Emmons-Horner and Method A gives the
cinnamic sulfonamides **72**.

 Generic structures 4, 5, 7, 9, 13, 18, 21, 26, 31, 33, 34, 39, 42,
30 43, 45, 48, 51, 52, 56, 57, 60, 62, 64, 65, 68, 71 and 72 are representative of
the compounds of the present invention. It is also noted that where the
chemistry allows in the generic schemes, alternate embodiments of -A-,
such as heteroaryl groups, can be substituted for phenyl in the schemes.

Method A




Method B





5

Method C






Method D




5

Method E




5


Method F



Method G




Method H






5

Method I





Method J






5


Method K




Method L





Method M



Method N




Method O






5

Method P





Method Q



$$\begin{array}{c}
 \text{10} \xrightarrow[2\text{- Deprotection}]{1\text{-Ph}_3\text{SiSH or Ph}_3\text{SiOH}} \text{66} \\
 \text{66} \xrightarrow{\text{Base}} \text{67} \\
 \text{67} \xrightarrow[\text{LDA}]{\text{Emmons-Horner [Ox] when W= Sulfur}} \text{68} \\
 \text{68} \xrightarrow{\text{Method A}} \text{68}
 \end{array}$$

Method S





5

ASSAYS FOR DETERMINING BIOLOGICAL ACTIVITY

Biological activity and thus utility for the compounds of formula I as modulators of prostaglandin mediated diseases can be demonstrated in accordance with the following assays which demonstrate prostanoid antagonist or agonist activity *in vitro* and *in vivo* and their selectivity. The prostaglandin receptors investigated were DP, EP₁, EP₂, EP₃, EP₄, FP, IP and TP.

Stable expression of prostanoid receptors in the human embryonic kidney (HEK) 293(ebna) cell line

5 Prostanoid receptor cDNAs corresponding to full length coding sequences were subcloned into the appropriate sites of mammalian expression vectors and transfected into HEK 293(ebna) cells. HEK 293(ebna) cells expressing the individual cDNAs were grown under selection and individual colonies were isolated after 2-3 weeks of
10 growth using the cloning ring method and subsequently expanded into clonal cell lines.

Prostanoid receptor binding assays

HEK 293(ebna) cells are maintained in culture, harvested
15 and membranes are prepared by differential centrifugation, following lysis of the cells in the presence of protease inhibitors, for use in receptor binding assays. Prostanoid receptor binding assays are performed in 10 mM MES/KOH (pH 6.0) (EPs, FP and TP) or 10 mM HEPES/KOH (pH 7.4) (DP and IP), containing 1 mM EDTA, 10 mM divalent cation and the
20 appropriate radioligand. The reaction is initiated by addition of membrane protein. Ligands are added in dimethylsulfoxide which is kept constant at 1 % (v/v) in all incubations. Non-specific binding is determined in the presence of 1 μ M of the corresponding non-radioactive prostanoid. Incubations are conducted for 60 min at room temperature
25 or 30 °C and terminated by rapid filtration. Specific binding is calculated by subtracting non specific binding from total binding. The residual specific binding at each ligand concentration is calculated and expressed as a function of ligand concentration in order to construct sigmoidal concentration-response curves for determination of ligand
30 affinity.

Prostanoid receptor agonist and antagonist assays

Whole cell second messenger assays measuring stimulation (EP₂, EP₄, DP and IP in HEK 293(ebna) cells) or inhibition
35 (EP₃ in human erythroleukemia (HEL) cells) of intracellular cAMP accumulation or mobilization of intracellular calcium (EP₁, FP and TP in HEK 293(ebna) cells stably transfected with apo-aequorin) are performed to determine whether receptor ligands are agonists or

- 5 antagonists. For cAMP assays, cells are harvested and resuspended in HBSS containing 25 mM HEPES, pH 7.4. Incubations contain 100 μ M RO-20174 (phosphodiesterase type IV inhibitor, available from Biomol) and, in the case of the EP₃ inhibition assay only, 15 μ M forskolin to stimulate cAMP production. Samples are incubated at 37°C for 10 min,
- 10 the reaction is terminated and cAMP levels are then measured. For calcium mobilization assays, cells are charged with the co-factors reduced glutathione and coelenterazine, harvested and resuspended in Ham's F12 medium. Calcium mobilization is measured by monitoring luminescence provoked by calcium binding to the intracellular
- 15 photoprotein aequorin. Ligands are added in dimethylsulfoxide which is kept constant at 1 % (v/v) in all incubations. For agonists, second messenger responses are expressed as a function of ligand concentration and both EC₅₀ values and the maximum response as compared to a prostanoid standard are calculated. For antagonists, the
- 20 ability of a ligand to inhibit an agonist response is determined by Schild analysis and both K_b and slope values are calculated.

Rat Paw Edema Assay

- The method is the same as described in Chan *et al* (J. Pharmacol. Exp. Ther. 274: 1531-1537, 1995).
- 25

LPS-Induced Pyrexia in Conscious Rats

- The method is the same as described in Chan *et al* (J. Pharmacol. Exp. Ther. 274: 1531-1537, 1995).
- 30

LPS-Induced Pyrexia in Conscious Squirrel Monkeys

- The method is the same as described in Chan *et al* (Eur. J. Pharmacol. 327: 221- 225, 1997).
- 35

Acute Inflammatory Hyperalgesia Induced by Carrageenan in Rats

- The method is the same as described in Boyce *et al* (Neuropharmacology 33: 1609-1611, 1994).

5 Adjuvant-Induced Arthritis in Rats

Female Lewis rats (body weight ~146-170 g) were weighed, ear marked, and assigned to groups (a negative control group in which arthritis was not induced, a vehicle control group, a positive control group administered indomethacin at a total daily dose of 1 mg/kg and four groups administered with a test compound at total daily doses of 0.10-3.0 mg/kg) such that the body weights were equivalent within each group. Six groups of 10 rats each were injected into a hind paw with 0.5 mg of *Mycobacterium butyricum* in 0.1 mL of light mineral oil (adjuvant), and a negative control group of 10 rats was not injected with adjuvant. Body weights, contralateral paw volumes (determined by mercury displacement plethysmography) and lateral radiographs (obtained under Ketamine and Xylazine anesthesia) were determined before (day -1) and 21 days following adjuvant injection, and primary paw volumes were determined before (day -1) and on days 4 and 21 following adjuvant injection. The rats were anesthetized with an intramuscular injection of 0.03 - 0.1 mL of a combination of Ketamine (87 mg/kg) and Xylazine (13 mg/kg) for radiographs and injection of adjuvant. The radiographs were made of both hind paws on day 0 and day 21 using the Faxitron (45 kVp, 30 seconds) and Kodak X-OMAT TL film, and were developed in an automatic processor. Radiographs were evaluated for changes in the soft and hard tissues by an investigator who was blinded to experimental treatment. The following radiographic changes were graded numerically according to severity: increased soft issue volume (0-4), narrowing or widening of joint spaces (0-5) subchondral erosion (0-3), periosteal reaction (0-4), osteolysis (0-4) subluxation (0-3), and degenerative joint changes (0-3). Specific criteria were used to establish the numerical grade of severity for each radiographic change. The maximum possible score per foot was 26. A test compound at total daily doses of 0.1, 0.3, 1, and 3 mg/kg/day, indomethacin at a total daily dose of 1 mg/kg/day, or vehicle (0.5% methocel in sterile water) were administered per os b.i.d. beginning post injection of adjuvant and continuing for 21 days. The compounds were

- 5 prepared weekly, refrigerated in the dark until used, and vortex mixed immediately prior to administration.

The invention is illustrated in connection with the following non-limiting Examples. All the end products of the formula I were analyzed by NMR, TLC and mass spectrometry.

- 10 Intermediates were analyzed by NMR and TLC.

Most compounds were purified by flash chromatography on silica gel. Recrystallization and/or swish (suspension in a solvent followed by filtration of the solid) with a solvent such as ether:hexane 1:1.

- 15 The course of reactions was followed by thin layer chromatography (TLC) and reaction times are given for illustration only.

Temperatures are in degrees Celsius.

The compounds of the examples are numbered in accordance with the compounds that appear in Tables I and II.

20

EXAMPLE 1

N-((E)-3-{2-[4-(METHYLTHIO)BENZYL]PHENYL}-2-PROPENOYL)-2-
THIOPHENESULFONAMIDE (17)

- 25 Step 1: Methyl (E)-3-(2-methylphenyl)-2-propenoate

- To 2-methylcinnamic acid (100g; 617 mmol) in 1.2 L of DMF was added DBU (112.6 g; 740 mmol) and 15 min later methyl iodide (131.3 g; 925 mmol) and left overnight. The solution was diluted in ether and washed with HCl (10%), H₂O and brine. The solvent was removed to
30 give 106.8 g of the title compound.

¹H NMR (CDCl₃) δ 2.4 (3H, s), 3.8 (3H, s), 6.35 (1H, d), 7.15 (1H, t), 7.22 (1H, t), 7.5 (1H, d) and 7.95 (1H, d).

- The ethyl ester can be prepared as well in the same way or from the 2-methyl benzaldehyde (5.00 g; 41.6 mmol) and triethyl
35 phosphonoacetate (9.9 mL; 50.0 mmol) in 150 mL of toluene at 0 °C, to which was added portionwise NaH (63.0 mmol). After 2 h of stirring the mixture was quenched with NH₄OAc (25%) and extracted with EtOAc. The solvent was removed to give 7.1 g of the ethyl cinnamate.

5 Step 2: Ethyl (E)-3-[2-(bromomethyl)phenyl]-2-propenoate

To the previous ethyl cinnamate (20.0 g; 105 mmol) and NBS (19.64 g; 110.3 mmol) in refluxing CCl₄ was added benzoyl peroxide (1.27 g) and the mixture was stirred for 12 h. The solution was cooled to r.t. and filtered. The solvent was removed and the crude oil purified by
10 silica gel chromatography (5% EtOAc in hexane) to yield 14.18 g of the title compound.

¹H NMR (CDCl₃) δ 1.30 (3H, t), 4.25 (2H, q), 4.60 (2H, s), 6.45 (1H, d), 7.30 (3H, m), 7.57 (1H, m) and 8.05 (1H, d).

5 Step 3: Ethyl (E)-3-[2-[4-(methylthio)benzyl]phenyl]-2-propenoate

A mixture of the previous benzyl bromide (0.50 g; 1.86 mmol), 4-(methylthio)benzeneboronic acid (0.63 g; 3.7 mmol) CsF (1.13 g) and (Ph₃P)₄Pd (0.11 g) in 10 mL of DME was heated to reflux for 10 h. The mixture was cooled to r.t. and quenched with NH₄OAc (25%) and
10 extracted with EtOAc. The organic phases were combined, dried and the solvent removed. Purification by silica gel chromatography (10% EtOAc in hexane) yielded 0.35 g of the title compound.

¹H NMR (CDCl₃) δ 1.27 (3H, t), 2.41 (3H, s), 4.08 (2H, s), 4.21 (2H, q), 6.30 (1H, d), 7.00 (1H, d), 7.1-7.4 (6H, m), 7.55 (1H, d) and 7.97 (1H,
15 d).

Step 4: (E)-3-[2-[4-Methylthio)benzyl]phenyl]-2-propenoic acid

Hydrolysis of the previous ester (0.34 g; 1.1 mmol) was run in THF/MeOH (6 mL/3 mL) with 2 equivalent of a 2N NaOH solution for 4
20 h. The solution was diluted with EtOAc and quenched with HCl (10%). The organic phase was dried over Na₂SO₄ and the solvent removed. Purification was done by a swish in hexane to yield 0.21 g of the title compound.

¹H NMR (CDCl₃) δ 2.42 (3H, s), 4.09 (2H, s), 6.31 (1H, d), 7.00-
25 7.35 (7H, m), 7.50 (1H, d) and 8.07 (1H, d).

Step 5: N-((E)-3-[2-[4-(methylthio)benzyl]phenyl]-2-propenoyl)-2-thiophenesulfonamide (17)

2-Thiophenesulfonamide was prepared from the
30 corresponding sulfonyl chloride with 2.2 equivalent of NH₄OH in THF at 0 °C. The solution was brought to r.t. and left 2 h. It was then quenched with NaHCO₃ and extracted with EtOAc. The organic phase was dried over Na₂SO₄ and the solvent removed. The crude product was crystallized in toluene/EtOAc.

35 To the previous acid (100 mg; 0.35 mmol), 2-thiophenesulfonamide (60 mg; 0.37 mmol), DMAP (86 mg; 0.7 mmol) in 2 mL of CH₂Cl₂ was added DCI (134 mg; 0.7 mmol) and the mixture was stirred overnight. The solution was diluted with EtOAc and quenched

5 with HCl (10%). The organic phase was dried over Na₂SO₄ and the solvent removed. Purification by silica gel chromatography (5% MeOH in CH₂Cl₂) yielded 87 mg of the title compound.

¹H NMR (CDCl₃) δ 2.40 (3H, s), 4.01 (2H, s), 6.33 (1H, d), 6.9-7.3 (8H, m), 7.49 (1H, d), 7.61 (1H, s), 7.89 (1H, s) and 8.03 (1H, d). The
10 product was converted to the sodium salt with 1 equivalent of NaOH and freeze dried.

Elemental analysis calcd. for C₂₁H₁₈NNaO₃S₃·1/2H₂O: C, 54.77; H, 4.13; N, 3.04; S, 20.88; Found: C, 54.55; H, 4.01; N, 3.06; S, 20.58.

15

EXAMPLE 2

N-((E)-3-{2-[(3-METHYL-1H-1-INDOLYL)METHYL]PHENYL}-2-PROPENOYL)-2-THIOPHENESULFONAMIDE (3)

Step 1: Ethyl (E)-3-{2-[(3-methyl-1H-1-indolyl)methyl]phenyl}-2-propenoate
20

To benzylic bromide (400 mg, 1.49 mmol) of step 2 in example 1 and skatole (200mg, 1.51 mmol) in 6 mL of DMF was added portionwise 1.6 equivalent of NaH. The reaction mixture was left for 6 h and quenched with NH₄OAc (25%) and diluted with EtOAc. The organic
25 phase was dried over Na₂SO₄, filtered and the solvent removed. Purification by silica gel chromatography (10% EtOAc in hexane) yielded 260mg of the title compound.

¹H NMR (CDCl₃) δ 1.2 (3H, t), 2.3 (3H, s), 4.25 (2H, q), 5.4 (2H, s), 6.35 (1H, d), 6.65 (1H, d), 6.8 (1H, s), 7.1-7.3 (5H, m), 7.56 (2H, d) and
30 7.97 (1H, d).

Step 2: (E)-3-{2-[(3-methyl-1H-1-indolyl)methyl]phenyl}-2-propenoic acid

The hydrolysis of the previous ester (260 mg) was done according to Step 4 of example 1 to yield 212 mg of the title compound.

35 HRMS calcd. for C₁₉H₁₇NO₃ + H⁺ = 292.1337; Found: 292.1337.

Step 3: N2-((E)-3-{2-[(3-methyl-1H-1-indolyl)methyl]phenyl}-2-propenoyl)-2-thiophenesulfonamide (3)

5 The coupling reaction of the previous acid (196 mg; 0.67 mmol) was done according to step 5 of example 1 to yield 134 mg of the title compound.

^1H NMR (acetone- d_6) δ 2.39 (3H, s), 5.57 (2H, s), 6.65 (2H, m), 7.03 (3H, m), 7.27 (4H, m), 7.5 (1H, d), 7.63 (1H, d), 7.87 (1H, d), 7.95 (1H, s) and 8.14 (1H, d).

10 HRMS calcd. for $\text{C}_{23}\text{H}_{20}\text{N}_2\text{O}_3\text{S}_2 + \text{H}^+ = 437.0994$; Found: 437.0992.

EXAMPLE 3

15 N-[(E)-3-[2-(2-NAPHTHYLMETHYL)PHENYL]-2-PROPENOYL]-2-
THIOPHENESULFONAMIDE (4)

Step 1: Ethyl (E)-3-[2-(2-naphthylmethyl)phenyl]-2-propenoate

20 The benzyl bromide (500 mg) of example 1, step 2 was treated with 2-naphthylboronic acid according to the same procedure previously described to yield 360 mg of the title compound.

^1H NMR (CDCl_3) δ 1.30 (3H, t), 4.27 (2H, q), 4.33 (2H, s), 6.48 (1H, d), 7.2-7.4 (4H, m), 7.45 (2H, m), 7.55 (1H, s), 7.62 (1H, d), 7.8 (3H, m) and 8.15 (1H, d).

25

Step 2: (E)-3-[2-(2-naphthylmethyl)phenyl]-2-propenoic acid

 The hydrolysis of the previous ester (300 mg) was done according to Step 4 of example 1 to yield 202 mg of the title compound.

30 ^1H NMR (CDCl_3) δ 4.29 (2H, s), 6.32 (1H, d), 7.2-7.4 (6H, m), 7.5 (1H, s), 7.62 (1H, d), 7.73 (3H, m) and 8.19 (1H, d).

Step 3: N-[(E)-3-[2-(2-naphthylmethyl)phenyl]-2-propenoyl]-2-thiophenesulfonamide (4)

35 The coupling reaction of the previous acid (100 mg; 0.35 mmol) was done according to step 5 of example 1 to yield 60 mg of the title compound.

^1H NMR (CDCl_3) δ 4.24 (2H, s), 6.31 (1H, d), 7.02 (1H, m), 7.15-7.8 (12H, m), 7.84 (1H, m) and 8.08 (1H, d).

5 The acid was converted to the sodium salt with 1 equivalent of NaOH.

Elemental analysis calcd. for $C_{24}H_{18}NNaO_3S_2 \cdot H_2O$: C, 60.87; H, 4.22; N, 2.96; S, 13.54; Found: C, 60.36; H, 4.25; N, 3.29; S, 12.53.

5

EXAMPLE 4

N-[(E)-3-[2-(3,4-DICHLOROBENZYL)PHENYL]-2-PROPENOYL]-2-
THIOPHENESULFONAMIDE (8)Step 1: Ethyl (E)-3-[2-(3,4-dichlorobenzyl)phenyl]-2-propenoate

10

The benzyl bromide (500 mg) of example 1, step 2 was treated with 3,4-dichlorobenzenboronic acid according to the same procedure described in step 3 of example 1 to yield 410 mg of the title compound.

¹H NMR (CDCl₃) δ 1.30 (3H, t), 4.03 (2H, s), 4.23 (2H, q), 6.28 (1H, d), 6.90 (1H, dd), 7.1-7.4 (5H, m), 7.57 (1H, d) and 7.89 (1H, d).

15

Step 2: (E)-3-[2-(3,4-dichlorobenzyl)phenyl]-2-propenoic acid

The hydrolysis of the previous ester (400 mg) was done according to Step 4 of example 1 to yield 296 mg of the title compound.

20

¹H NMR (CDCl₃) δ 4.07 (2H, s), 6.31 (1H, d), 6.93 (1H, dd), 7.1-7.4 (5H, m), 7.50 (1H, d) and 7.99 (1H, d).

Step 3: N-[(E)-3-[2-(3,4-dichlorobenzyl)phenyl]-2-propenoyl]-2-thiophenesulfonamide (8)

25

The coupling reaction of the previous acid (170 mg; 0.55 mmol) was done according to step 5 of example 1 to yield 110 mg of the title compound.

¹H NMR (CDCl₃) δ 4.07 (2H, s), 6.33 (1H, d), 6.85 (1H, d), 7.07 (3H, m), 7.24 (2H, m), 7.32 (1H, t), 7.53 (1H, d), 7.63 (1H, d), 7.88 (1H, d) and 7.97 (1H, d).

30

The acid was converted to the sodium salt with 1 equivalent of NaOH.

Elemental analysis calcd. for C₂₀H₁₄Cl₂NNaO₃S₂·1/2H₂O: C, 49.7; H, 3.1; N, 2.9; S, 13.27; Found: : C, 49.46; H, 2.9; N, 2.86; S, 13.73;

35

5

EXAMPLE 5

N-((E)-3-{2-[(2-NAPHTHYLOXY)METHYL]PHENYL}-2-PROPENOYL)-2-
THIOPHENESULFONAMIDE (20)

Step 1: Ethyl (E)-3-{2-[naphthyloxy)methyl]phenyl}-2-propenoate

10 The benzyl bromide (250 mg, 0.93 mmol) of step 2 in example
1 and 2-naphthol (147 mg) in 5 mL of DMF were treated with cesium
carbonate (394 mg) at 40 °C for 12 h. The mixture was diluted with
EtOAc and washed with water and brine. The organic phase was dried
15 over Na₂SO₄, filtered and the solvent removed. Purification by silica gel
chromatography (10% EtOAc in hexane) yielded 245 mg of the title
compound.

¹H NMR (CDCl₃) δ 1.2 (3H, t), 4.22 (2H, q), 5.28 (2H, s), 6.41
(1H, d), 7.22 (2H, m), 7.3-7.5 (4H, m), 7.55 (1H, m), 7.64 (1H, m), 7.75 (3H,
m) and 8.05 (1H, d).

20

Step 2: (E)-3-{2-[naphthyloxy)methyl]phenyl}-2-propenoic acid

Hydrolysis of the previous ester (245 mg, 0.74 mmol) was
done according to step 4 of example 1 to yield 185 mg of the title
compound.

25

¹H NMR (CDCl₃) δ 5.27 (2H, s), 6.45 (1H, d), 7.15-7.25 (2H, m),
7.32 (1H, t), 7.42 (3H, m), 7.55 (1H, d), 7.67 (1H, d), 7.77 (3H, m) and 8.11
(1H, d).

30

Step 3: N-((E)-3-{2-[(2-naphthyloxy)methyl]phenyl}-2-propenoyl)-2-
thiophenesulfonamide (20)

The coupling reaction of the previous acid (150 mg; 0.49
mmol) was done according to step 5 of example 1 to yield 77 mg of the title
compound.

35 ¹H NMR (CDCl₃) δ 5.2 (2H, s), 6.39 (1H, d), 7.02 (1H, s), 7.1-
7.2 (2H, m), 7.3-7.4 (4H, m), 7.53 (3H, m), 7.71 (3H, m), 7.83 (1H, s) and
8.07 (1H, d).

The product was converted to the sodium salt with 1
equivalent of NaOH.

5 Elemental analysis calcd. for $C_{24}H_{28}NNaO_4S_2 \cdot 3/2H_2O$: C, 57.82; H, 4.21; N, 2.81; Found: : C, 58.31; H, 3.96; N, 2.91.

EXAMPLE 6

10 N-[(E)-3-[2-(2-NAPHTHYLSULFINYL)PHENYL]-2-PROPENOYL]-2-
 THIOPHENESULFONAMIDE (21)

Step 1: 2-(2-naphthylthio)benzaldehyde

 A mixture of 2-thionaphthol (5.29 g; 33 mmol), 2-fluorobenzaldehyde (3.73 g; 33 mmol) and potassium carbonate (4.57 g; 33
15 mmol) in 28 mL of iso-propanol was heated to reflux for 12 h. The mixture was cooled to r.t., diluted with water and filtered. The solution was diluted with EtOAc and washed with water, brine and dry over $MgSO_4$. The crude product (7.9 g) was used as is for the next step.

1H NMR ($CDCl_3$) δ 7.07 (1H, d), 7.32 (2H, m), 7.42 (1H, d), 7.51
20 (2H, m), 7.78 (1H, m), 7.83 (2H, d), 7.88 (1H, s), 7.95 (1H, s) and 10.39 (1H, s).

Step 2: Ethyl (E)-3-[2-(2-naphthylthio)phenyl]-2-propenoate

 The previous aldehyde (7.72 g; 29.2 mmol) was converted to
25 the ethyl ester according to step 1 of example 1 to furnish 6.36 g of the title compound.

1H NMR ($CDCl_3$) δ 1.24 (3H, t), 4.21 (2H, q), 6.36 (1H, d), 7.28 (4H, m), 7.42 (2H, m), 7.61 (1H, d), 7.72 (4H, m) and 8.28 (1H, d).

30 Step 3: Ethyl (E)-3-[2-(2-naphthylsulfinyl)phenyl]-2-propenoate

 The previous ester (3.00 g; 8.97 mmol) in 45 mL of dichloromethane was treated with 1.1 equivalent of mCPBA at 0 °C for 1 h. The mixture was quenched with sodium thiosulfite and extracted with EtOAc. The organic phase was dry over Na_2SO_4 and the crude
35 purified by silica gel chromatography (30% EtOAc in hexane) to yield 2.35 g of the title compound.

1H NMR ($CDCl_3$) δ 1.34 (3H, t), 4.27 (2H, q), 6.26 (1H, d), 7.42 (2H, m), 7.53 (4H, m), 7.77 (2H, m), 7.88 (2H, m), 8.07 (2H, d), 8.22 (1H, s) and 8.28 (2H, m).

5

Step 4: Ethyl (E)-3-[2-(2-naphthylsulfinyl)phenyl]-2-propenoic acid

The previous ester (1.20 g; 3.43mmol) was hydrolyzed according to the procedure of step 4 of example 1 to yield 1.08 g of the title compound.

10

¹H NMR (methanol-d₆) δ 6.23 (1H, d), 7.33 (1H, dd), 7.45 (3H, m), 7.53 (1H, t), 7.62 (1H, d), 7.8 (3H, m), 7.98 (1H, d), 8.05 (1H, d) and 8.27 (1H, s).

15

Step 5: 2-[(E)-3-[2-(2-naphthylsulfinyl)phenyl]-2-propenoyl]-2-thiophenesulfonamide (21)

The coupling reaction of the previous acid (500 mg; 1.55 mmol) was done according to step 5 of example 1 to yield 416 mg of the title compound.

20

¹H NMR (methanol-d₆) δ 6.19 (1H, d), 7.1 (1H, m), 7.22 (1H, dd), 7.45 (3H, m), 7.55 (2H, m), 7.67 (1H, d), 7.72-7.85 (4H, m), 7.99 (1H, d), 8.1 (1H, d) and 8.17 (1H, s).

25

The sodium salt was prepared with 1N NaOH. Elemental analysis calcd. for C₂₃H₁₆NNaO₄S₃·1/2H₂O: C, 55.36; H, 3.40; N, 2.81; S, 19.27; Found: : C, 55.00; H, 3.62; N, 2.81; S, 18.18.

EXAMPLE 7

N-[(E)-3-[2-(2-NAPHTHYLOXY)PHENYL]-2-PROPENOYL]-2-THIOPHENESULFONAMIDE (28)

30

Step 1: Ethyl (E)-3-[2-(2-naphthyloxy)phenyl]-2-propenoate

35

2-fluoro benzaldehyde (3.0 g; 24.2 mmol), 2-naphthol (24.2 mmol) and potassium carbonate (26.6 mmol) were heated at reflux in dimethyl acetamide for 2 h. The mixture was cooled to r.t., diluted with EtOAc and washed with water and brine. The organic phase was dried over Na₂SO₄, filtered and the solvent removed. Purification by silica gel chromatography (10% EtOAc in hexane) yielded 3.4 g of the title compound.

5 ^1H NMR (CDCl_3) δ 6.93 (1H, d), 7.17-7.23 (1H, m), 7.28 (1H, dd), 7.37 (1H, s), 7.37 (3H, m), 7.7 (1H, d), 7.84 (2H, m), 7.94 (1H, d) and 10.53 (1H, s).

Step 2: Ethyl (E)-3-[2-(2-naphthyloxy)phenyl]-2-propenoate

10 The previous aldehyde (2.00 g; 8.0 mmol) was converted to the title compound according to step 1 of example 1 to yield 2.52 g.

^1H NMR (CDCl_3) δ 1.25 (3H, t), 4.21 (2H, q), 6.55 (1H, d), 6.9 (1H, d), 7.15 (1H, t), 7.25 (3H, m), 7.42 (2H, m), 7.65 (2H, m), 7.83 (2H, t) and 8.02 (1H, d).

15

Step 3: (E)-3-[2-(2-naphthyloxy)phenyl]-2-propenoic acid

The previous ester (2.52 g; 7.9 mmol) was hydrolyzed according to the procedure of step 4 of example 1 to yield 1.57 g of the title compound.

20

^1H NMR (CDCl_3) δ 6.62 (1H, d), 7.03 (1H, d), 7.2-7.5 (6H, m), 7.78 (1H, d) and 7.88-8.03 (4H, m). HRMS calcd. for $\text{C}_{19}\text{H}_{14}\text{O}_3 + \text{H}^+ = 291.1021$; Found: 291.1022.

25 Step 4: N-[(E)-3-[2-(2-naphthyloxy)phenyl]-2-propenoyl]-2-thiophenesulfonamide (28)

The coupling reaction of the previous acid (1.00 g; 3.4 mmol) was done according to step 5 of example 1 to yield 790 mg of the title compound.

30

^1H NMR (CDCl_3) δ 6.91 (1H, d), 6.97 (1H, d), 7.15 (1H, dd), 7.24 (1H, t), 7.29 (1H, dd), 7.37 (1H, d), 7.40-7.55 (3H, m), 7.74-7.83 (2H, m), 7.92 (2H, m) and 7.99 (2H, m).

The sodium salt was prepared with 1N NaOH. HRMS calcd. for $\text{C}_{23}\text{H}_{16}\text{NNaO}_4\text{S}_2 + \text{H}^+ = 458.0497$; Found: 458.0497.

35

EXAMPLE 8

THIOPHENE-2-SULFONYL CARBAMIC ACID [2-(2-NAPHTHYLSULFONYL)PHENYL]METHYL ESTER (31)

Step 1: [2-(2-naphthylthio)phenyl]methanol

5 To 2-(2-naphthylthio) benzaldehyde (7.24 g; 27.4 mmol from Example 6, step 1) in 70 mL of methanol and 30 mL of THF at 0 °C was added NaBH₄ (54.8 mmol) portionwise. After 1h at 0 °C, the solution was brought to r.t. and quenched with water. After dilution with EtOAc, the solution was washed with water and brine. The organic phase was dry
10 over Na₂SO₄, filtered and the crude purified by silica gel chromatography to yield 6.71 g of the title compound.

¹H NMR (acetone-d₆) δ 4.29 (1H, t), 4.7 (2H, d), 7.29 (2H, m), 7.35-7.52 (4H, m), 7.71 (2H, m), 7.77 (1H, m) and 7.83 (2H, m).

15 Step 2: [2-(2-Naphthylsulfonyl)phenyl]methanol

To the previous sulfide (500 mg; 1.88 mmol) in 8 mL of dichloromethane at 0 °C was added m-CPBA (5.64 mmol) and let stirred for 2 h. The mixture was diluted with EtOAc and washed with NaOH (1N) and brine. The organic phase was dry over Na₂SO₄, filtered and the
20 crude purified by silica gel chromatography (40% EtOAc in hexane) to yield 390 mg of the title compound.

¹H NMR (acetone-d₆) δ 4.37 (1H, t), 4.9 (2H, d), 7.57 (1H, dt), 7.65-7.80 (4H, m), 7.82 (1H, d), 8.0-8.1 (2H, m), 8.2 (2H, m) and 8.63 (1H, s).

25

Step 3: 2-Thiophenesulfonyl isocyanate

A mixture of 2-thiophenesulfonylamide (1.5 g) and oxalyl chloride (6 mL) in 10 mL of 1,2-dichloroethane was refluxed for 14h. The solvent was removed under vacuum and the crude used as is for the
30 next step.

Step 4:

To the alcohol of step 2 (250 mg; 0.84 mmol) in ether at 0 °C was added the previous isocyanate (2 equivalent) and let stirred 1h at 0
35 °C. The solution was quenched with water and extracted with EtOAc. The organic phase dry over Na₂SO₄, filtered and the crude purified by silica gel chromatography (5% CH₃OH in CH₂Cl₂) to yield 300 mg of the title compound.

5 ¹H NMR (CDCl₃) δ 5.55 (2H, s), 7.08 (1H, m), 7.55-7.72 (6H, m), 7.82 (2H, m), 8.0 (1H, d), 8.07 (1H, d), 8.2 (2H, m) and 8.66 (1H, s).

 The sodium salt was prepared with 1N NaOH.

 Elemental analysis calcd. for C₂₂H₁₆NNaO₆S₃·2H₂O: C, 48.44; H, 3.67; N, 2.57; S, 17.63;

10 Found: : C, 48.86; H, 3.13; N, 2.63; S, 16.46.

5

EXAMPLE 9

N-({2-[2-(2-NAPHTHYLMETHYL)PHENYL]CYCLOPROPYL}
CARBONYL-2-THIOPHENESULFONAMIDE (45)

Step 1: Ethyl 2-[2-(2-naphthylmethyl)phenyl]-1-cyclopropanecarboxylate

10

The ethyl ester (300 mg; 0.95 mmol) of step 1 in example 3 and Pd(OAc)₂ (10 mg) were treated with diazomethane at 0° C for 1h. The solvent was removed and the crude oil purified by silica gel chromatography (5% EtOAc in hexane) to yield 300 mg of the title compound.

15

¹H NMR (CDCl₃) δ 1.1 (3H, t), 1.27 (1H, m), 1.45 (1H, m), 1.7 (1H, m), 2.53 (1H, m), 3.98 (2H, m), 4.29 (2H, s), 7.0 (1H, m), 7.18 (3H, m), 7.27 (1H, m), 7.39 (2H, m), 7.48 (1H, s) and 7.75 (3H, m).

Step 2: 2-[2-(2-naphthylmethyl)phenyl]-1-cyclopropanecarboxylic acid

20

The previous ester (300 mg; 0.91 mmol) was hydrolyzed according to the procedure of step 4 of example 1 to yield 230 mg of the title compound.

25

¹H NMR (CDCl₃) δ 1.45 (1H, m), 1.6 (1H, m), 1.8 (1H, m), 2.67 (1H, m), 4.33 (2H, s), 7.1 (1H, m), 7.24 (4H, m), 7.41 (2H, m), 7.58 (1H, s) and 7.78 (3H, m).

Step 3: N-({2-[2-(2-naphthylmethyl)phenyl]cyclopropyl}carbonyl-2-thiophenesulfonamide (45)

30

The coupling reaction of the previous acid (230 mg; 0.76 mmol) was done according to step 5 of example 1 to yield 100 mg of the title compound.

35

¹H NMR (CDCl₃) δ 1.32 (1H, m), 1.48 (1H, m), 1.63 (1H, m), 2.6 (1H, m), 4.13 (2H, s), 6.97 (2H, m), 7.12 (4H, m), 7.38 (3H, m), 7.52 (1H, d), 7.65 (2H, m) and 7.79 (2H, m). The sodium salt was prepared with 1N NaOH. Elemental analysis calcd. for C₂₅H₂₀NNaO₃S₂·1/2H₂O: C, 62.75; H, 4.39; N, 2.93; S, 13.4; Found: : C, 62.25; H, 4.24; N, 3.02; S, 12.15.

5

EXAMPLE 10

N-((E)-3-(2-(6-BENZYLOXY-2-NAPHTHYL)METHYL)PHENYL)-2-PROPENOYL)-5-BROMO-2-METHOXYBENZENESULFONAMIDE (46)

(E)-3-(2-(6-benzyloxy-2-naphthyl)methyl)phenyl)-2-propenoic acid

10

Step 1: [(6-bromo-2-naphthyl)oxy](phenyl)methane

To a mixture of 6-bromo-2-naphthol (1.99 g, 8.9 mmol) and benzyl bromide (1.2 ml, 1.1 equiv.) in DMF (18 ml) at 0°C was added a suspension of NaH 80% in oil (324 mg, 1.2 equiv.) and the mixture was stirred at 0°C for an hour and at r.t. for another hour. After addition of half saturated NH₄Cl, the product was extracted in i-PrOAc, washed with 1 N HCl, dried over Na₂SO₄ and concentrated to yield 2.84 g of an oil.

Step 2: 6-benzyloxy-2-naphthaleneboronic acid

To a solution of the previous bromide (940 mg, 3.00 mmol) in THF (15 ml) at -78°C was added n-BuLi 1.6 M in hexanes (2.2 ml, 1.2 equiv.) and the mixture was stirred at -78°C for 15 min. Tri-isopropyl borate (0.97 ml, 1.4 equiv.) was added and the reaction mixture was warmed to r.t. After addition of 2 N HCl, the product was extracted in EtOAc, dried over Na₂SO₄ and concentrated to yield a solid. This solid was washed with ether:hexane 1:1 to yield 679 mg of pure material.

¹H NMR (Acetone-d₆:DMSO-d₆) δ 5.27 (2H, s), 7.22 (1H, dd), 7.33 (1H, dd), 7.40 (3H, m), 7.54 (2H, d), 7.63 (2H, s), 7.72 (1H, d), 7.83 (1H, d), 7.90 (1H, d), 8.36 (1H, s).

30 Step 3: Ethyl (E)-3-(2-[(6-benzyloxy)-2-naphthyl]methyl)phenyl)-2-propenoate

A mixture of the previous boronic acid (1.05 g, 3.8 mmol), Pd(Ph₃P)₄ (185 mg), the benzylic bromide of step 2 in example 1 (1.07 g, 4.0 mmol), 2 M aq. Na₂CO₃ (4 ml) and toluene (8 ml) was degazed and stirred at 100°C under nitrogen for 4 h. After addition of half saturated NH₄Cl, the product was extracted in EtOAc, dried over Na₂SO₄ and concentrated. Purification by flash chromatography with EtOAc:toluene:hexane 2.5:75:25 yielded 1.17 g of the title compound as an oil.

5

Step 4: (E)-3-(2-([6-(benzyloxy)-2-naphthyl)methyl]phenyl)-2-propenoic acid

The previous ester was hydrolyzed according to the procedure of step 4 of example 1 to yield the title compound.

10

Step 5: 5-Bromo-2-methoxybenzenesulfonamide

To 5-bromo-2-methoxybenzenesulfonyl chloride (45g; 157.6 mmol, from Lancaster Chemical) at 0°C in THF, was added concentrated NH₄OH (42.5 mL) and the reaction mixture was brought to r.t. for 2 h. The reaction mixture was diluted with EtOAc, extracted with NaHCO₃ (2X), brine, and the organic phase was dried over MgSO₄. The solvent was removed to give the title compound.

15

Step 6: N-((E)-3-(2-(6-benzyloxy-2-naphthyl)methyl)phenyl)-2-propenoyl)-5-bromo-2-methoxybenzenesulfonamide (46)

20

To the acid from step 5 (190 mg, 0.482 mmol) in CH₂Cl₂ was added DMF (10 µL) and oxalyl chloride (60 µL) at 0°C and the mixture was warmed to r.t. for an hour and concentrated to dryness. The resulting acid chloride was redissolved in CH₂Cl₂:THF 1:1 (10 mL) and 5-bromo-2-methoxybenzenesulfonamide (154 mg, 1.2 equiv., from step 6) and Et₃N (135 µL, 2 equiv.) were added at 0°C. The mixture was then warmed to r.t. for an hour, 0.5 N HCl was added and the product was extracted in i-PrOAc, dried over Na₂SO₄ and purified by flash chromatography with EtOAc:toluene:acetic acid 20:80:1 to yield 93 mg of a white solid.

25

30

¹H NMR (CDCl₃) δ

MS (APCI, neg.) 643.3, 641.8, 640.0 (M-1), 393.2.

EXAMPLE 11

N-((E)-3-[2-NAPHTHYLMETHYL]PHENYL)-2-PROPENOYL)-5-BROMO-2-METHOXY-1-BENZENESULFONAMIDE (301)

35

Step 1: N-((E)-3-[2-naphthylmethyl]phenyl)-2-propenoyl)-5-bromo-2-methoxy-1-benzenesulfonamide (301)

5 The carboxylic acid (400 mg; 1.22 mmol) of example 3 step 2 was coupled with 5-bromo-2-methoxy-1-benzenesulfonyl chloride according to the procedure of step 5 in example 1 to yield 284 mg of the title compound.

¹H NMR (acetone-d₆-DMSO-d₆) δ 3.85 (3H, s), 4.31 (2H, s),
10 6.65 (1H, d), 7.15 (1H, d), 7.3 (1H, m), 7.35-7.50 (4H, m), 7.55-7.65 (2H, m),
 7.7-7.9 (5H, m) and 8.01 (1H, d).

 The acid was converted to the sodium salt with 1 equivalent of NaOH. Elemental analysis calcd. for C₂₇H₂₁BrNNaO₄S.1/2H₂O: C, 57.15; H, 3.88; N, 2.47; Found: : C, 56.88; H, 3.73; N, 2.52.

15

EXAMPLE 12

N-[(E)-3-[5-CHLORO-2-(2-NAPHTHYLMETHYL)PHENYL]-2-PROPENOYL]-2-THIOPHENESULFONAMIDE (303)

20 Step 1: 5-chloro-2-methylbenzaldehyde

 To a solution of 2-bromo-4-chlorotoluene (20.0 g; 97.3 mmol) in 300 mL of THF at -78 °C was added dropwise a 2.5 M solution of n-BuLi (102.2 mmol). After 30 min of stirring at that temperature, 1-formylpiperidine (11.4 mL) in 10 mL of THF was added and the solution
25 left for 1 h. It was brought to 0 °C , quenched with NH₄OAc (25%) and diluted with EtOAc. The organic phase was dried over Na₂SO₄, filtered and the solvent removed to yield 13.3 g of the title compound.

¹H NMR (CDCl₃) δ 2.6 (3H, s), 7.15 (1H, d), 7.4 (1H, d), 7.75 (1H, s) and 10.2 (1H, s).

30

Step 2: Ethyl (E)-3-(5-chloro-2-methylphenyl)-2-propenoate

 The previous aldehyde (13.3 g; 86.0 mmol) was converted to the ethyl cinnamate according to step 1 of example 1 to yield 16.67 g.

¹H NMR (CDCl₃) δ 1.2 (3H, t), 2.26 (3H, s), 4.15 (2H, q), 6.21
35 (1H, d), 6.99 (1H, d), 7.13 (2H, m), 7.39 (1H, s) and 7.73 (1H, d).

Step 3: Ethyl (E)-3-[2-(bromomethyl)-5-chlorophenyl]-2-propenoate

5 The previous ester (16.66 g; 74.1 mmol) was converted to the benzylic bromide according to step 2 of example 1 to yield 9.0 g of the title compound.

^1H NMR (CDCl_3) δ 1,2 (3H, t), 4.25 (2H, q), 4.5 (2H, s), 6.4 (1H, d), 7.28 (2H, s), 7.55 (1H, s) and 7.95 (1H, d).

10

Step 4: Ethyl (E)-3-[5-chloro-2-(2-naphthylmethyl)phenyl]-2-propenoate

The previous benzylic bromide was coupled in a Suzuki type reaction with 2-naphthylboronic acid according to step 3 of example 1 to yield 1.14 g of the title compound.

15 ^1H NMR (CDCl_3) δ 1.15 (3H, t), 4.09 (2H, q), 4.12 (2H, s), 6.2 (1H, d), 7.03 (1H, d), 7.15 (2H, m), 7.3 (2H, m), 7.37 (1H, s), 7.45 (1H, s), 7.65 (3H, m) and 7.87 (1H, d).

Step 5: (E)-3-[5-chloro-2-(2-naphthylmethyl)phenyl]-2-propenoic acid

20 The hydrolysis of the previous ester (1.14 g) was done according to Step 4 of example 1 to yield 0.99 g of the title compound.

^1H NMR (CDCl_3) δ 4.23 (2H, s), 6.31 (1H, d), 7.12 (1H, d), 7.22 (1H, m), 7.3 (1H, m), 7.42 (2H, m), 7.48 (1H, s), 7.59 (1H, s), 7.75 (3H, m) and 8.05 (1H, d).

25

Step 6: N-[(E)-3-[5-chloro-2-(2-naphthylmethyl)phenyl]-2-propenoyl]-2-thiophenesulfonamide (303)

The coupling reaction of the previous acid (400 mg; 1.22 mmol) was done according to step 5 of example 1 to yield 272 mg of the
30 title compound.

^1H NMR (acetone- d_6) δ 4.25 (2H, s), 6.58 (1H, d), 7.0 (1H, t), 7.23 (2H, m), 7.33 (1H, m), 7.39 (2H, m), 7.5-7.6 (2H, m), 7.55 (5H, m) 7.86 (1H, m) and 8.04 (1H, d).

35 The product was converted to the sodium salt with 1 equivalent of NaOH. Elemental analysis calcd. for $\text{C}_{24}\text{H}_{17}\text{ClNNaO}_3\text{S}_2 \cdot 1/2\text{H}_2\text{O}$: C, 57.76; H, 3.64; N, 2.81; S, 12.84; Found: : C, 57.78; H, 3.62; N, 2.86; S, 12.85.

5

EXAMPLE 13

(E)-3-(4-CHLORO-2-[6-FLUORO-2-NAPHTHYL)METHYL]PHENYL)-2-
PROPENOIC ACID SODIUM SALT (457)

Step 1: Ethyl (E)-3-(5-chloro-2-methylphenyl)-2-propenoate

10 To 2-bromo-4-chloro toluene (20.0g; 97.3 mmol) in 300 mL of THF at -78 °C was added n-BuLi 2.5 M (40.8 mL) dropwise. After 20 min. 1-formylpiperidine (11.4 mL; 103.0 mmol) in 10 mL of THF was added dropwise. After 30 min the reaction mixture was brought to 0°C and quenched with HCl (10%) and diluted with EtOAc. The organic
15 phase was collected, dry and the solvent evaporated to yield 13.3g (89%) of 5-chloro-2-methylbenzaldehyde. This crude aldehyde was mixed with 1.1 equivalent of triethyl phosphonoacetate in THF. Sodium hydride 80% (1.3 equivalent) was added portionwise and 1 h later the reaction was quenched with 25% NH₄Cl. The reaction mixture was diluted with
20 EtOAc and the organic phase collected, dried and the solvent removed. The crude oil was purified on a short pad of silica gel using 5% EtOAc in hexane to afford 16.67 g of the title compound.

Alternatively, this procedure can be done in one reaction vessel. At the end of the first step, the flask is brought to rt and
25 the phosphonoacetate in THF is added.

¹H NMR (CDCl₃) δ 1.21 (3H, t), 2.27 (3H, s), 4.15 (2H, q), 6.22 (1H, d), 6.95-7.15 (3H, m), 7.40 (1H, s) and 7.75 (1H, d).

Step 2: Ethyl(E)-3-[2-(bromomethyl)-5-chlorophenyl]-2-propenoate

30 The bromination was done according to step 2 of example 1 to provide the title compound in 45% yield.

¹H NMR (CDCl₃) δ 1.32 (3H, t), 4.27 (2H, q), 4.52 (2H, s), 6.43 (1H, d), 7.30 (2H, s), 7.55 (1H, s) and 7.93 (2H, d).

35 Step 3: 6-Fluoro-2-naphthol

A solution of 2-(4-fluorophenyl)acetyl chloride (5.0g; 29 mmol) in CH₂Cl₂ was added to AlCl₃ (7.73g; 58 mmol) in CH₂Cl₂ at -20 °C over 30 min. Trimethylsilyl acetylene (9.96g; 101.43 mmol) was added also over 30 min and stirred at -10 °C for 1h. The mixture was poured in

5 ice and extracted with EtOAc. The organic phase was washed with water, NaHCO₃ and brine. After purification by gel silica chromatography (10% EtOAc in hexane) 2.43 g (36%) of 3-(trimethylsilyl)-6-chloro-2-naphthol was collected. The desilylation was done with TFA in CH₂Cl₂ at rt overnight. Purification by gel silica chromatography (10%
10 EtOAc in hexane) afforded the title compound in 69% yield.
¹H NMR (CDCl₃) δ 7.10-7.20 (3H, m), 7.37 (1H, dd) and 7.65 (2H, m).

15 Step 4: Ethyl (E)-3-[4-chloro-2-[(6-fluoro-2-naphthyl)methyl]phenyl]-2-propenoate

The naphthol of Step 3 was converted to the triflate with triflic anhydride/pyridine in CH₂Cl₂ at 0 °C. This was coupled with the organozinc of the benzyl bromide of step 2 in example 13, with dppf and Pd(dba)₂. This yielded the title compound in 47% yield after purification
20 by silica gel chromatography (10% EtOAc in hexane).
¹H NMR (CDCl₃) δ 1.25 (3H, t), 4.20 (2H, q), 6.30 (1H, d), 7.10-7.27 (4H, m), 7.38 (1H, dd), 7.48 (1H, s), 7.57 (1H, dd), 7.66 (2H, m) and 7.95 (1H, d).

25 Step 5: (E)-3-[4-Chloro-2-[(6-fluoro-2-naphthyl)methyl]phenyl]-2-propenoic acid, sodium salt

The hydrolysis of the ester of Step 4 (1.03g; 2.7 mmol) was done according to step 4 of example 1 to yield 800mg (87%) of the title compound. The sodium salt was prepared with 1N NaOH.
30 ¹H NMR (CDCl₃) δ 4.21 (2H, s), 6.30 (1H, d), 7.10-7.40 (4H, m), 7.38 (1H, dd), 7.45 (1H, s), 7.58 (1H, d), 7.68 (2H, m) and 8.05 (1H, d).
LRMS for M-1= 339.

EXAMPLE 14

35 5-BROMO-N((E)-3-[5-CHLORO-2-[(6-FLUORO-2-NAPHTHYL-2)METHYL]PHENYL]-2-PROPENOYL)-2-METHOXYBENZENESULFONAMIDE SODIUM SALT (378)

5 Step 1: 5-Bromo -N-((E)-3-{5-chloro-2-[(6-fluoro-2-naphthyl)methyl]phenyl}-2-propenoyl)-2-methoxybenzenesulfonamide

The coupling reaction of the acid of Example 1 Step 5 with 5-bromo-2-methoxybenzenesulfonamide (500 mg; 1.47 mmol) was done according to step 5 of example 1 to yield 662 mg (77%) of the title

10 compound. The sodium salt was prepared with 1N NaOH.

¹H NMR (DMSO-d₆) δ 3.78 (3H, s), 4.22 (2H, s), 6.53 (1H, d), 7.17 (1H, d), 7.27 (1H, d), 7.35 (2H, m), 7.47 (1H, dd), 7.51 (1H, s), 7.58 (1H, d), 7.64 (1H, dd) and 7.75-7.90 (5H, m).

LRMS for M-1= 588.

15

EXAMPLE 15

(E)-3-{5-CHLORO-2-[(6-CHLORO-2-NAPHTHYL)METHYL]PHENYL}-2-
PROPENOIC ACID SODIUM SALT (469)

20 Step 1: 6-Chloro-2-naphthol

The title compound was prepared from 2-(4-fluorophenyl)acetyl chloride according to step 3 of example 13.

¹H NMR (CDCl₃) δ 7.10 (2H, m), 7.34 (1H, dd), 7.55-7.67 (2H, m) and 7.72 (1H, s).

25

Step 2: Ethyl (E)-3-{5-chloro-2-[(6-chloro-2-naphthyl)methyl]phenyl}-2-propenoate

The title compound was prepared according to step 4 of example 13 in 30% yield.

30 ¹H NMR (CDCl₃) δ 1.23 (3H, t), 4.20 (4H, m), 6.29 (1H, d), 7.10 (1H, d), 7.22 (2H, m), 7.33 (1H, dd), 7.42 (1H, s), 7.53 (1H, d), 7.61 (2H, d), 7.70 (1H, s) and 7.91 (1H, d).

Step 3: (E)-3-{5-Chloro-2-[(6-chloro-2-naphthyl)methyl]phenyl}-2-propenoic acid, sodium salt

35

The hydrolysis of the ester of Step 2 (620 mg; 1.6 mmol) was done according to step 4 of example 1 to yield 500mg (87%) of the title compound.

5 ^1H NMR (CDCl_3) δ 4.22 (2H, s), 6.30 (1H, d), 7.15 (1H, d),
7.20-7.39 (3H, m), 7.43 (1H, s), 7.56 (1H, s), 7.62 (2H, t), 7.75 (1H, s) and
8.02 (1H, d).

Elemental analysis calcd for $\text{C}_{20}\text{H}_{13}\text{Cl}_2\text{NaO}_2 \cdot \text{H}_2\text{O}$: C, 60.48;
H, 3.78; Found C, 60.68, H, 3.63.

10

5

EXAMPLE 16

5-BROMO-N((E)-3-{5-CHLORO-2-[(6-CHLORO-2-NAPHTHYL-
2)METHYL]PHENYL}-2-PROPENOYL)-2-
METHOXYBENZENESULFONAMIDE, SODIUM SALT (450)

10 Step 1: 5-Bromo -N-((E)-3-{5-chloro-2-[(6-chloro-2-
naphthyl)methyl]phenyl}-2-propenoyl)-2-methoxybenzenesulfonamide

The coupling reaction of the acid of Example 15 Step 3 (500 mg; 1.4 mmol) was done according to step 5 of example 1 with 5-bromo-2-methoxybenzenesulfonamide to yield 662 mg (74%) of the title compound.

15 The sodium salt was prepared with 1N NaOH.

¹H NMR (DMSO-d₆) δ 3.78 (3H, s), 4.22 (2H, s), 6.53 (1H, d), 7.20 (1H, d), 7.30-7.40 (2H, m), 7.45 (2H, m), 7.55 (1H, s), 7.59 (1H, s), 7.79 (3H, m), 7.85-7.92 (2H, m) and 7.98 (1H, d).

Elemental analysis calcd for C₂₇H₁₉BrCl₂NNaO₄S .2H₂O :

20 C, 49.01; H, 3.33; N, 2.14; Found C, 48.89, H, 3.47; N, 2.11.

EXAMPLE 17

(E)-3-(5-CHLORO-2-[(6-DIFLUOROMETHOXY)-2-
NAPHTHYL]METHYL]PHENYL)-2-PROPENOIC ACID, SODIUM SALT
25 (505)

Step 1: 6-Bromo-2-difluoromethoxynaphthalene

Methyl chlorodifluoroacetate (5.3 mL) was added dropwise to 6-bromonaphthol (10.25 g; 45.9 mmol) and potassium carbonate (7.61g; 30 55.1 mmol) at 90 °C in 160 mL of DMF for 6 h. Purification by gel silica chromatography (3% EtOAc in hexane) gave 4.80 g (38%) of the title compound.

¹H NMR (CDCl₃) δ 6.61 (1H, t), 7.31 (1H, dd), 7.48 (1H, d), 7.56 (1H, dd), 7.67 (1H, d), 7.72 (1H, d) and 8.01 (1H, d).

35

Step 2: Ethyl (E)-3-(5-chloro-2-[(6-difluoromethoxy)-2-
naphthyl]methyl]phenyl)-2-propenoate

5 The corresponding boronic acid of the previous halide was coupled according to step 3 of example 1 of the title compound in 57% yield.

¹H NMR (CDCl₃) δ 1.25 (3H, t), 4.22 (4H, m), 6.28 (1H, d), 6.53 (1H, t), 7.11 (1H, d), 7.25 (2H, m), 7.45 (2H, d), 7.55 (1H, d), 7.72 (2H, t) and 7.92 (1H, d).

Step 3: (E)-3-(5-Chloro-2-[[6-difluoromethoxy]-2-naphthyl]methyl)phenyl)-2-propenoic acid, sodium salt

 The hydrolysis of the ester of Step 2 (1.9 g; 4.7 mmol) was done according to step 4 of example 1 to yield 600mg of the title compound.

¹H NMR of sodium salt (DMSO-d₆) δ 4.20 (2H, s), 6.29 (1H, d), 7.10-7.40 (6H, m), 7.58 (3H, m) and 8.84 (2H, t).

 HRMS calc'd for C₂₁H₁₄O₃F₂ClNa +H= 411.0575; Found: 411.0577.

EXAMPLE 18

5-BROMO-N-[(E)-3-(5-CHLORO-2-[[6-DIFLUOROMETHOXY]-2-NAPHTHYL METHYL)-2-PROPENOYL]-2-METHOXYBENZENESULFONAMIDE, SODIUM SALT (447)

Step 1: 5-Bromo -N-[(E)-3-(5-chloro-2-[[6-difluoromethoxy]-2-naphthyl]methyl)phenyl)-2-propenoyl]-2-methoxybenzenesulfonamide

 The coupling reaction of the acid of Example 17 Step 3 (1.00g; 2.57 mmol) was done according to step 5 of example 1 with 5-bromo-2-methoxybenzenesulfonamide to yield 915 mg (56%) of the title compound. The sodium salt was prepared with 1N NaOH.

¹H NMR of sodium salt DMSO-d₆) δ 3.66 (3H, s), 4.18 (2H, s), 6.36 (1H, d), 6.92 (1H, d), 7.20-7.35 (5H, m), 7.48 (2H, m), 7.55-7.65 (3H, m) and 7.80 (3H, m).

 LRMS for M-1= 634.

5

EXAMPLE 19

(E)-3-[2-(3,4-DICHLOROBENZYL)-5-CHLOROPHENYL]-2-PROPENOIC
ACID, SODIUM SALT (535)

Step 1: Ethyl (E)-3-[2-(3,4-dichlorobenzyl)-5-chlorophenyl]-2-propenoate

10

The benzyl bromide of step 2 of example 13 was treated with 3,4-dichlorobenzenboronic acid according to the procedure described in step 3 of example 1 to yield the title compound in 67% yield.

¹H NMR (CDCl₃) δ 1.30 (3H, t), 4.00 (2H, s), 4.23 (2H, q), 6.30 (1H, d), 6.90 (1H, dd), 7.09 (1H, d), 7.15 (1H, s), 7.28 (1H, m), 7.32 (1H, d),
15 7.55 (1H, d) and 7.79 (1H, d).

Step 2: (E)-3-[2-(3,4-Dichlorobenzyl)-5-chlorophenyl]-2-propenoic acid,
sodium salt

The hydrolysis of the ester of Step 1 (1.00 g; 2.7 mmol) was
20 done according to step 4 of example 1 to yield 907 mg (98%) of the title compound.

¹H NMR (CDCl₃) δ 3.95 (2H, s), 6.30 (1H, d), 6.86 (1H, d),
7.08 (2H, m), 7.32 (2H, m), 7.55 (1H, s) and 7.90 (1H, d).

LRMS for M-1= 339.

25

EXAMPLE 20

5-BROMO-N-[(E)-3-[5-CHLORO-2-(3,4-DICHLOROBENZYL)PHENYL]-2-
PROPENOYL]-2-METHOXYBENZENESULFONAMIDE, SODIUM SALT
30 (421)

Step 1: 5-Bromo-N-[(E)-3-[5-chloro-2-(3,4-dichlorobenzyl)phenyl]-2-
propenoyl]-2-methoxybenzenesulfonamide

The coupling reaction of the acid of Example 19 Step 2 (0.600
35 g; 1.75 mmol) was done according to step 5 of example 1 with 5-bromo-2-methoxybenzenesulfonamide to yield 548 mg (53%) of the title compound.
The sodium salt was prepared with 1N NaOH.

5 ¹H NMR (DMSO-d₆) δ 3.85 (3H, s), 4.10 (2H, s), 6.54 (1H, s),
7.01 (1H, d), 7.22 (1H, d), 7.32 (2H, m), 7.40-7.50 (2H, m), 7.56 (1H, s), 7.67
(1H, d), 7.86 (1H, d), 7.91 (1H, s) and 12.37 (1J, s).

LRMS for M-1= 586.

10

EXAMPLE 21

5-BROMO-N-[(E)-3-[4-CHLORO-2-(2-NAPHTHYLMETHYL)PHENYL]-2-
PROPENOYL]-2-METHOXYBENZENESULFONAMIDE, SODIUM SALT
(449)

15 Step 1: Ethyl (E)-3-[4-chloro-2-[(2-naphthylmethyl)phenyl]-2-propenoate

2-Bromo-5-chloro toluene (20.0 g) was converted to the
corresponding aldehyde and then to the cinnamate according to step 1 of
example 13. This cinnamate was converted to the benzylic bromide
according to step 2 of example 1 and coupled via a Suzuki coupling
20 reaction according to step 3 of example 1 with naphthalene boronic acid
to yield the title compound.

¹H NMR (CDCl₃) δ 1.30 (3H, t), 4.22 (4H, m), 6.29 (1H, d),
7.15-7.27 (3H, m), 7.42 (2H, m), 7.52 (2H, m), 7.75 (3H, m) and 7.99 (1H, d).

25 Step 2: (E)-3-[4-Chloro-2-[(2-naphthylmethyl)phenyl]-2-propenoic acid
(530)

The hydrolysis of the ester of Step 1 (0.56 g; 1.57 mmol) was
done according to step 4 of example 1 to yield 450 mg (88%) of the title
compound.

30 ¹H NMR (CDCl₃) δ 4.24 (2H, s), 6.30 (1H, d), 7.20-7.30 (3H,
m), 7.42 (2H, m), 7.51 (2H, m), 7.75 (3H, m) and 8.09 (1H, d).

LRMS for M-1= 321.

Step 3: 5-Bromo-N-[(E)-3-[4-chloro-2-(2-
35 naphthylmethyl)phenyl]propenoyl]-2-methoxybenzenesulfonamide

The coupling reaction of the acid of Step 2 (0.296 g; 0.89
mmol) was done according to step 5 of example 1 with 5-bromo-2-
methoxybenzenesulfonamide to yield 213 mg (42%) of the title compound.
The sodium salt was prepared with 1N NaOH.

5 ^1H NMR (ACETONE-MEOH- d_6) δ 3.70 (3H, s), 4.20 (2H, s), 6.44 (1H, d), 6.95 (2H, m), 7.25 (3H, m), 7.40 (2H, m), 7.55 (3H, m), 7.75 (3H, m), 7.95 (1H, d) and 8.02 (1H, d).

LRMS for M-1= 568.

5

EXAMPLE 22

(E)-3-[5-METHOXY-2-(2-NAPHTHMETHYL)PHENYL]-2-PROPENOIC
ACID, SODIUM SALT (534)

Step 1: (2-Bromo-4-methoxyphenyl)(2-naphthyl)methanone

10 AlCl_3 (17.48 g; 131.1 mmol) was added portionwise to a mixture of 3-bromocresol (16.04 g; 87.4 mmol) and 2-naphthoyl chloride (25.00 g; 131.1 mmol) in 50 mL of CHCl_3 gave 14.0 g (47%) of the title compound.

15 ^1H NMR (CDCl_3) δ 3.78 (3H, s), 6.92 (1H, dd), 7.19 (1H, d), 7.38 (1H, d), 7.50 (1H, t), 7.59 (1H, t), 7.89 (3H, m), 7.95 (1H, dd) and 8.18 (1H, s).

Step 2: 2-(2-Bromo-4-methoxybenzyl)naphthalene

20 To the methanone of Step 1 (14.0 g) and triethylsilane (15 mL) in 15 mL of CHCl_3 was added TFA and was heated to 50°C overnight. The solution was cooled and quenched with NaOH (2N) to provide the title compound in 82% yield.

25 ^1H NMR (CDCl_3) δ 3.75 (3H, s), 4.20 (2H, s), 6.75 (1H, dd), 7.07 (1H, d), 7.12 (1H, s), 7.30 (1H, d), 7.42 (2H, m), 7.58 (1H, s) and 7.76 (3H, m).

Step 3: Ethyl (E)-3-[5-methoxy-2-(2-naphthylmethyl)phenyl]-2-propenoate

30 The naphthalene of Step 2 was converted to the corresponding aldehyde according to the step 1 of example 13 in 98% yield. This aldehyde was then converted to the cinnamate according to step 1 of example 13 in 90% yield.

35 ^1H NMR (CDCl_3) δ 3.70 (3H, s), 4.11 (4H, m), 6.20 (1H, d), 6.77 (1H, dd), 6.99 (1H, d), 7.03 (1H, d), 7.15 (1H, d), 7.30 (2H, m), 7.39 (1H, s), 7.60-7.70 (3H, m) and 7.90 (1H, s).

Step 4: (E)-3-[5-Methoxy-2-(2-naphthmethyl)phenyl]-2-propenoic acid

5 The hydrolysis of the ester of Step 3 (2.83 g; 8.2 mmol) was done according to step 4 of example 1 to yield 2.16 g (83%) of the title compound. The sodium salt was prepared with 1N NaOH.

1H NMR (CDCl₃) δ 3.70 (3H, s), 4.13 (2H, s), 6.20 (1H, d), 6.80
10 (1H, dd), 7.02 (2H, m), 7.15 (1H, d), 7.29 (2H, m), 7.39 (1H, s), 7.62 (3H, m) and 8.03 (1H, d).

LRMS calcd for M-1= 317.

15

EXAMPLE 23

5-BROMO-2-METHOXY-N-[(E)-3-[5-METHOXY-2-(2-NAPHTHYLMETHYL)PHENYL]-2-PROPENOYL]BENZENESULFONAMIDE SODIUM SALT (448)

20 Step 1: 5-Bromo-2-methoxy-N-[(E)-3-[5-methoxy-2-(2-naphthylmethyl)phenyl]-2-propenoyl]benzenesulfonamide

The coupling reaction of the acid of Example 22 Step 4 (0.600 g; 1.88 mmol) was done according to step 5 of example 1 with 5-bromo-2-methoxybenzenesulfonamide to yield 573 mg (57%) of the title compound.

25 The sodium salt was prepared with 1N NaOH.

1H NMR (CDCl₃) δ 3.72 (3H, s), 3.77 (3H, s), 4.13 (2H, s), 6.40 (1H, d), 6.70 (1H, d), 6.85 (1H, dd), 7.02 (1H, d), 7.10-7.20 (2H, m), 7.37 (3H, m), 7.57 (1H, dd), 7.60-7.80 (3H, m), 7.95 (1H, d), 8.15 (1H, d) and 9.12 (1H, broad s).

30

LRMS calcd for M-1= 564.

EXAMPLE 24

(E)-3-[5-CHLORO-2-(4-CHLOROBENZYL)PHENYL]-2-PROPENOIC
35 ACID SODIUM SALT (537)

Step 1: Ethyl(E)-3-[5-chloro-2-(4-chlorobenzyl)phenyl]-2-propenoate

5 The benzyl bromide of step 2 of example 13 was coupled in a Suzuki coupling reaction with 4-chlorobenzene boronic acid according to the procedure of step 2 example 1 to yield 69% of the title compound.

¹H NMR (CDCl₃) δ 1.30 (3H, t), 4.02 (2H, s), 4.22 (2H, q), 6.29 (1H, d), 6.99 (2H, d), 7.08 (1H, d), 7.20-7.30 (3H, m), 7.52 (1H, s) and 7.83 (1H, d).
10

Step 2: (E)-3-[5-Chloro-2-(4-chlorobenzyl)phenyl]-2-propenoic acid

 The hydrolysis of the ester of Step 1 (1.14 g; 3.4 mmol) was done according to step 4 of example 1 to yield 860 mg (83%) of the title
15 compound. The sodium salt was prepared with 1N NaOH.

¹H NMR (CDCl₃) δ 4.04 (2H, s), 6.30 (1H, d), 7.00 (2H, d), 7.10 (1H, d), 7.23 (2H, d), 7.29 (1H, d), 7.55 (1H, s) and 7.95 (1H, d).

 LRMS calcd for M-1= 305.

20

EXAMPLE 25

(E)-3-{2-[(5-(PHENYLMETHOXY)INDOLYL)METHYL]-5-FLUOROPHENYL}-N-[(5-BROMO-2-METHOXYPHENYL)SULFONYL]-
2-PROPENAMIDE (451)

25

Step 1: Ethyl (E)-3-(5-fluoro-2-methylphenyl)-2-propenoate

 5-Fluoro-2-methylbenzaldehyde (40.58 g; 294 mmol) was converted to the ethyl cinnamate according to step 1 of example 1 to yield 40.81 g. of the title compound.

30 ¹H NMR (acetone-d₆) δ 1.29 (3H, t), 2.40 (3H, s), 4.23 (2H, q), 6.49 (1H, d), 7.07 (1H, td), 7.29 (1H, dd), 7.46 (1H, dd) and 7.87 (1H, dd).

Step 2: Ethyl (E)-3-[2-(bromomethyl)-5-fluorophenyl]-2-propenoate

 The ester of Step 1 (40.80 g; 196 mmol) was converted to the benzylic bromide according to step 2 of example 1 to yield 24.17 g of the
35 title compound.

¹H NMR (acetone-d₆) δ 1.30 (3H, t), 4.24 (2H, q), 4.81 (2H, s), 6.62 (1H, d), 7.18 (1H, td), 7.58 (2H, m) and 8.02 (1H, dd).

5 Step 3: Ethyl (E)-3-{2-[(5-(phenylmethoxy)indolyl)methyl]-5-fluorophenyl}-2-propenoate

The benzylic bromide of Step 2 (3.16 g; 11.0 mmol) was coupled with 5-(phenylmethoxy)indole according to the same procedure described in step 1 of example 2 to yield 2.27 g of the title compound.

10 ^1H NMR (acetone- d_6) δ 1.27 (3H, t), 4.20 (2H, q), 5.11 (2H, s), 5.59 (2H, s), 6.43 (1H, dd), 6.52 (1H, d), 6.80 (1H, dd), 6.86 (1H, dd), 7.08 (1H, td), 7.19 (1H, d), 7.22 (1H, d), 7.31 (2H, m), 7.38 (2H, m), 7.50 (2H, m), 7.55 (1H, dd) and 8.01 (1H, dd).

15 Step 4: (E)-3-{2-[(5-(Phenylmethoxy)indolyl)methyl]-5-fluorophenyl}-2-propenoic acid (493)

The hydrolysis of the ester of Step 3 (2.27 g) was done according to step 4 of example 1 to yield 2.07 g of the title compound.

20 ^1H NMR (acetone- d_6) δ 5.11 (2H, s), 5.62 (2H, s), 6.43 (1H, dd), 6.53 (1H, d), 6.75 (1H, dd), 6.86 (1H, dd), 7.08 (1H, td), , 7.19 (1H, d), 7.25 (1H, d), 7.31 (2H, m), 7.38 (2H, m), 7.50 (2H, m), 7.56 (1H, dd) and 8.04 (1H, dd). Elemental analysis calcd. for $\text{C}_{25}\text{H}_{20}\text{FNO}_3 \cdot 2\text{H}_2\text{O}$: C, 68.64; H, 5.53; N, 3.20; Found: C, 68.16; H, 4.95; N, 3.06.

25 Step 5: (E)-3-{2-[(5-(Phenylmethoxy)indolyl)methyl]-5-fluorophenyl}-N-[(5-bromo-2-methoxyphenyl)sulfonyl]-2-propenamide

The acid of Step 5 (2.06; 5.13 mmol) was coupled with 5-bromo-2-methoxybenzenesulfonamide of example 10, step 5 according to step 5 of example 1 to yield 2.44 g of the title compound.

30 ^1H NMR (acetone- d_6) δ 3.93 (3H, s), 5.10 (2H, s), 5.59 (2H, s), 6.39 (1H, dd), 6.73 (1H, dd), 6.78 (1H, d), 6.81 (1H, dd), 7.09 (1H, td), , 7.18 (1H, d), 7.24 (3H, m), 7.32 (1H, m), 7.39 (3H, m), 7.49 (2H, m), 7.82 (1H, dd), 8.01 (1H, dd) and 8.09 (1H, d). Elemental analysis calcd. for $\text{C}_{32}\text{H}_{26}\text{BrFN}_2\text{O}_5\text{S}_2$: C, 59.17; H, 4.03; N, 4.31; S, 4.94; Found: C, 59.07; H, 4.01; N, 4.34; S, 5.16.

35

EXAMPLE 26

5 (E)-3-[2-(BENZO[B]THIOPHEN-2-YLMETHYL)-5-FLUOROPHENYL]-N-
[(5-BROMO-2-METHOXYPHENYL)SULFONYL]-2-PROPENAMIDE
SODIUM SALT (452)

10 Step 1: Ethyl (E)-3-[2-(benzo[b]thiophen-2-ylmethyl)-5-fluorophenyl]-2-
propenoate

The ester (901 mg, 3.14 mmol) of example 13, step 2 was coupled with benzo[b]thiophene-2-boronic acid (from Lancaster Chemical) in DME according to the same procedure described in step 3 of example 10 to yield 657 mg of the title compound.

15 ¹H NMR (acetone-d₆) δ 1.22 (3H, t), 4.16 (2H, q), 4.43 (2H, s), 6.50 (1H, d), 7.03 (1H, s), 7.15-7.35 (3H, m), 7.47 (1H, dd), 7.56 (1H, dd), 7.69 (1H, dd), 7.78 (1H, dd) and 8.00 (1H, dd).

20 Step 2: (E)-3-[2-(benzo[b]thiophen-2-ylmethyl)-5-fluorophenyl]-2-
propenoic acid (539)

The hydrolysis of the ester of Step 1 (657 mg) was done according to step 4 of example 1 to yield 345 mg of the title compound.

25 ¹H NMR (acetone-d₆) δ 4.45 (2H, s), 6.51 (1H, d), 7.04 (1H, d), 7.2-7.3 (3H, m), 7.49 (1H, dd), 7.57 (1H, dd), 7.70 (1H, d), 7.80 (1H, m) and 8.01 (1H, dd). Elemental analysis calcd. for C₁₈H₁₃FO₂S: C, 69.21; H, 4.19; Found: C, 68.96; H, 4.15.

Step 3: (E)-3-[2-(Benzo[b]thiophen-2-ylmethyl)-5-fluorophenyl]-N-[(5-
bromo-2-methoxyphenyl)sulfonyl]-2-propenamide

30 The previous acid (264 mg; 0.85 mmol) was coupled with 5-bromo-2-methoxybenzenesulfonamide of example 10, step 5 according to step 5 of example 1 to yield 287 mg of the title compound.

35 ¹H NMR (acetone-d₆) δ 3.83 (3H, s), 4.43 (2H, s), 6.77 (1H, d), 7.00 (1H, d), 7.13 (1H, d), 7.2-7.3 (3H, m), 7.41 (1H, dd), 7.49 (1H, dd), 7.65 (1H, dd), 7.78 (2H, m), 7.96 (1H, dd) and 8.05 (1H, d).

The acid was converted to the sodium salt with 1 equivalent of NaOH. Elemental analysis calcd. for C₂₅H₁₈BrFNNaO₄S₂·H₂O: C, 50.01; H, 3.36; N, 2.33; Found: C, 49.84; H, 3.22; N, 2.41.

5

EXAMPLE 27

N-(E)-[(5-BROMO-2-METHOXYPHENYL)SULFONYL]-3-(5-FLUORO-2-
[[1-BENZYLINDOL-5-YL]METHYL]PHENYL)-2-PROPENAMIDE
SODIUM SALT (453)

10 Step 1: Ethyl (E)-3-[5-fluoro-2-(indol-5-ylmethyl)phenyl]-2-propenoate

The ester (1.83 g, 6.37 mmol) of example 13, step 2 was coupled with 5-indolyl boronic acid and NaHCO₃ in DME according to the procedure described in step 3 of example 10 to yield 1.08 g of the title compound.

15 ¹H NMR (acetone-d₆) δ 1.26 (3H, t), 4.17 (2H, q), 4.21 (2H, s), 6.37 (1H, m), 6.44 (1H, d), 6.94 (1H, dd), 7.14 (1H, td), 7.27-7.37 (4H, m), 7.51 (1H, dd), 8.05 (1H, dd) and 10.13 (1H, s).

20 Step 2: Ethyl (E)-3-(5-fluoro-2-[[1-benzylindol-5-yl]methyl]phenyl)-2-propenoate

The indole of Step 1 (621 mg; 1.92 mmol) was coupled with benzyl bromide according to the procedure described in step 1 of example 2 to yield 678 mg of the title compound.

25 ¹H NMR (acetone-d₆) δ 1.26 (3H, t), 4.17 (4H, m), 5.32 (2H, s), 6.43 (2H, m), 6.95 (1H, dd), 7.1-7.4 (11H, m), 7.49 (1H, dd) and 8.08 (1H, dd).

30 Step 3: (E)-3-(5-Fluoro-2-[[1-benzylindol-5-yl]methyl]phenyl)-2-propenoic acid (540)

The hydrolysis of the ester of Step 2 (678 mg) was done according to step 4 of example 1 to yield 276 mg of the title compound.

35 ¹H NMR (acetone-d₆) δ 4.20 (2H, s), 5.38 (2H, s), 6.39 (1H, d), 6.45 (1H, d), 6.95 (1H, d), 7.1-7.3 (10H, m), 7.48 (1H, d) and 8.04 (1H, dd).
Elemental analysis calcd. for C₂₅H₂₀FNO₂: C, 77.91; H, 5.23; N, 3.63;
Found: C, 78.52; H, 5.46; N, 3.66.

Step 4: N-(E)-[(5-Bromo-2-methoxyphenyl)sulfonyl]-3-(5-fluoro-2-[[1-benzylindol-5-yl]methyl]phenyl)-2-propenamide

5 The acid of Step 3 (219 mg; 0.57 mmol) was coupled with 5-bromo-2-methoxybenzenesulfonamide of example 10, step 5 according to step 5 of example 1 to yield 149 mg of the title compound.

¹H NMR (acetone-d₆) δ 3.82 (3H, s), 4.18 (2H, s), 5.38 (2H, s), 6.36 (1H, dd), 6.72 (1H, d), 6.90 (1H, dd), 7.1-7.4 (12H, m), 7.78 (1H, dd),
10 7.98 (1H, dd) and 8.05 (1H, d).

 The acid was converted to the sodium salt with 1 equivalent of NaOH. Elemental analysis calcd. for C₃₂H₂₅BrFN₂NaO₄S.1/2H₂O: C, 57.84; H, 3.94; N, 4.22; Found: C, 57.61; H, 3.86; N, 4.16.

5

EXAMPLE 28

N-(E)-[(2,4-DIMETHYL(1,3-THIAZOL-5-YL))SULFONYL]-3-{3-[(5-CHLOROINDOLYL)METHYL](2-PYRIDYL)}-2-PROPENAMIDE (444)

Step 1: Ethyl (E)-3-(3-methyl-2-pyridyl)-2-propenoate

10 To a solution of 2-bromo-3-methylpyridine (10.36 g; 60.2 mmol) in 120 mL of THF at -100 °C was added dropwise a 1.6 M solution of n-BuLi (65.6 mmol). After 20 min of stirring at that temperature, 1-formylpiperidine (7.65 g) in 10 mL of THF was added and the solution was warmed to r.t.. After 30 min of stirring at r.t., triethyl
15 phosphonoacetate (13.7 mL; 69.1 mmol) was added dropwise below 30 °C. After 1 h of stirring, the mixture was quenched with NH₄OAc (25%) and extracted with EtOAc. The solvent was removed and the crude oil was purified by silica gel chromatography (25% EtOAc in hexane) to yield 10.32 g of the title compound.

20 ¹H NMR (acetone-d₆) δ 1.29 (3H, t), 2.46 (3H, s), 4.22 (2H, q), 6.99 (1H, d), 7.27 (1H, dd), 7.64 (1H, dt), 7.90 (1H, d) and 8.45 (1H, m).

Step 2: Ethyl (E)-3-[3-(bromomethyl)-2-pyridyl]-2-propenoate

The ester of Step 1 (5.93 g; 31.0 mmol) was converted in
25 benzene to the benzylic bromide according to the procedure described in step 2 of example 1 to yield 1.83 g of the title compound.

¹H NMR (acetone-d₆) δ 1.30 (3H, t), 4.25 (2H, q), 4.88 (2H, s), 7.10 (1H, d), 7.41 (1H, dd), 7.91 (1H, dd), 8.03 (1H, d) and 8.60 (1H, dd).

30 Step 3: Ethyl (E)-3-{3-[(5-chloroindolyl)methyl]-2-pyridyl}-2-propenoate

The benzylic bromide of Step 2 (1.33 g; 4.91 mmol) was coupled with 5-chloroindole according to the procedure described in step 1 of example 2 to yield 1.22 g of the title compound.

35 ¹H NMR (acetone-d₆) δ 1.28 (3H, t), 4.22 (2H, q), 5.78 (2H, s), 6.57 (1H, d), 6.94 (1H, d), 7.04 (1H, d), 7.11 (1H, dd), 7.27 (1H, dd), 7.43 (2H, m), 7.63 (1H, d), 7.99 (1H, d) and 8.53 (1H, d).

Step 4: (E)-3-{3-[(5-Chloroindolyl)methyl]-2-pyridyl}-2-propenoic acid (542)

5 The hydrolysis of the ester of Step 3 (283 mg) was done according to step 4 of example 1 to yield 291 mg of the title compound.

¹H NMR (acetone-d₆) δ 5.81 (2H, s), 6.57 (1H, d), 6.88 (1H, d), 7.05 (1H, d), 7.11 (1H, dd), 7.26 (1H, dd), 7.43 (2H, m), 7.63 (1H, d), 8.02 (1H, d) and 8.54 (1H, d). Elemental analysis calcd. for
10 C₁₇H₁₃ClN₂O₂·1/4H₂O: C, 64.36; H, 4.29; N, 8.83; Found: C, 64.63; H, 4.43; N, 8.65.

Step 5: N-(E)-[(2,4-Dimethyl(1,3-thiazol-5-yl))sulfonyl]-3-[3-[(5-chloroindolyl)methyl](2-pyridyl)]-2-propenamide

15 The acid of Step 4 (283 mg; 0.90 mmol) was coupled with 2,4-dimethyl-1,3-thiazole-5-sulfonamide (from Maybridge Chemical) according to step 5 of example 1 to yield 315 mg of the title compound.

¹H NMR (acetone-d₆) δ 2.64 (3H, s), 2.69 (3H, s), 5.81 (2H, s), 6.56 (1H, d), 6.84 (1H, d), 7.09 (1H, dd), 7.26 (1H, dd), 7.31 (1H, d), 7.41 (2H,
20 m), 7.62 (1H, d), 8.05 (1H, d) and 8.51 (1H, d). Elemental analysis calcd. for C₂₂H₁₉ClN₄O₃S₂: C, 54.26; H, 3.93; N, 11.50; S, 13.17; Found: C, 54.69; H, 4.03; N, 11.18; S, 12.89.

EXAMPLE 29

25 N-[(E)-3-[5-CHLORO-2-(2-NAPHTHYLMETHYL)PHENYL]-2-PROPENOYL-2-METHOXYBENZENESULFONAMIDE (302)]

The coupling reaction of the acid (3.00 g; 9.1 mmol) of Step 5 in Example 12 was done with 5-bromo-2-methoxybenzenesulfonamide (2.56g; 9.6 mmol) according to Step 5 of Example 1 to yield 4.13g (79 %) of
30 the title compound. The sodium salt was prepared with 1N NaOH.

¹H NMR (DMSO-d₆) δ 3.76 (3H, s), 4.25 (2H, s), 6.52 (1H, d), 7.15 (1H, d), 7.26 (1H, d), 7.36 (1H, d), 7.41-7.52 (4H, m), 7.58 (1H, s), 7.69 (1H, m), 7.78 (1H, d), 7.82 (3H, m), 7.89 (1H, d) and 12.38 (1H, br s).

35

Elemental analysis:


Calcd. for C₂₇H₂₀BrClNNaO₄S·H₂O: C, 53.08; H, 3.64; N, 2.29;

Found: C, 53.25; H, 3.89; N, 2.91.

- 5 These intermediates were prepared according to the
literature:
5-fluoro-2-methylbenzaldehyde:
 Servis, K. L.; Fang, K.-N. *J. Am. Chem. Soc.* **1968**, 90, 6712-
6717.
- 10 5-indolyl boronic acid:
 Yang, Y.; Martin, A. R. *Heterocycles* **1992**, 34, 1395-1398.

5 WHAT IS CLAIMED IS:

1. A compound represented by formula I:



I

- 10 or a pharmaceutically acceptable salt, hydrate or ester thereof, wherein:

HET represents a 5-12 membered monocyclic or bicyclic aromatic ring system containing 0-3 heteroatoms selected from O, S(O)_n and N(O)_m wherein m is 0 or 1 and n is 0, 1 or 2;

- 15 A is a one or two atom moiety and is selected from the group consisting of: -W-, -C(O)-, -C(R⁷)₂-W-, -W-C(R⁷)₂-, -CR⁷(OR²⁰)-, -C(R⁷)₂-, -C(R⁷)₂-C(OR²⁰)R⁷-, -C(R⁷)₂-C(R⁷)₂- or -CR⁷=CR⁷-, wherein W represents O, S(O)_n or NR¹⁷, with n as previously defined and R¹⁷ as defined below;

- 20 X represents a 5-10 membered monocyclic or bicyclic aryl or heteroaryl group having 1-3 heteroatoms selected from O, S(O)_n and N(O)_m, and optionally substituted with R¹⁴ and R¹⁵, and A and B are attached to the aryl or heteroaryl group ortho relative to each other;

Y represents O, S(O)_n, NR¹⁷, a bond or -CR¹⁸=CR¹⁸-;

B represents -(C(R¹⁸)₂)_p-Y-(C(R¹⁸)₂)_q-

- 25 wherein p and q are independently 0-3, such that when Y represents O, S(O)_n, NR¹⁷ or -CR¹⁸=CR¹⁸-, p + q = 0-6, and when Y represents a bond, p + q is 1-6;

Z is OH or NHSO₂R¹⁹;

- 30 R¹ R² and R³ independently represent H, halogen, lower alkyl, lower alkenyl, lower alkynyl, lower alkenyl-HET(R^a)₄₋₉, - (C(R⁴)₂)_pSR⁵, -(C(R⁴)₂)_pOR⁸, -(C(R⁴)₂)_pN(R⁶)₂, CN, NO₂, -(C(R⁴)₂)_pC(R⁷)₃, -CO₂R⁹, -CON(R⁶)₂ or -(C(R⁴)₂)_pS(O)_nR¹⁰, wherein n and p are as previously defined;

each R⁴ is independently H, F, CF₃ or lower alkyl,

5 or two R^4 groups are taken in conjunction and represent a ring of up to six atoms, optionally containing one heteroatom selected from O, $S(O)_n$ or $N(O)_m$;

each R^5 is independently lower alkyl, lower alkenyl, lower alkynyl, CF_3 , lower alkyl-HET, lower alkenyl-HET or $-(C(R^{18})_2)_pPh(R^{11})_0$ -
 10 2;

each R^6 is independently H, lower alkyl, lower alkenyl, lower alkynyl, CF_3 , Ph, Bn and when two R^6 groups are attached to N they may be taken in conjunction and represents a ring of up to 6 atoms, optionally containing an additional heteroatom selected from O, $S(O)_n$ or
 15 $N(O)_m$;

each R^7 is independently H, F, CF_3 or lower alkyl, and when two R^7 groups are presents, they may be taken in conjunction and represent an aromatic or aliphatic ring of 3 to 6 members containing from 0-2 heteroatoms selected from O, $S(O)_n$ and $N(O)_m$;

20 each R^8 represents H or R^5 ;

each R^9 is independently H, lower alkyl, lower alkenyl, lower alkynyl, Ph or Bn;

each R^{10} is independently lower alkyl, lower alkenyl, lower alkynyl, CF_3 , $Ph(R^{11})_0$ -3, $CH_2Ph(R^{11})_0$ -3 or $N(R^6)_2$;

25 each R^{11} is independently lower alkyl, SR^{20} , OR^{20} , $N(R^6)_2$, $-CO_2R^{12}$, $-CON(R^6)_2$, $-C(O)R^{12}$, CN, CF_3 , NO_2 or halogen;

each R^{12} is independently H, lower alkyl or benzyl;

each R^{13} is independently H, halo, lower alkyl, O-lower alkenyl, S-lower alkyl, $N(R^6)_2$, CO_2R^{12} , CN, CF_3 or NO_2 ;

30 R^{14} and R^{15} are independently lower alkyl, halogen, CF_3 , OR^{16} , $S(O)_nR^{16}$ or $C(R^{16})_2OR^{17}$;

each R^{16} is independently H, lower alkyl, lower alkenyl, Ph, Bn or CF_3 ;


each R^{17} is independently H, lower alkyl or Bn;

35 each R^{18} is independently H, F or lower alkyl, and when two R^{18} groups are present, they may be taken in conjunction and represent a ring of 3 to 6 members comprising carbon atoms and optionally one heteroatom chosen from O, $S(O)_n$ or N;

- 5 each R^{19} is lower alkyl, lower alkenyl, lower alkynyl, CF_3 ,
 HET(R^a)₄₋₉, lower alkyl-HET(R^a)₄₋₉ or lower alkenyl-HET(R^a)₄₋₉;
 each R^{20} is independently H, lower alkyl, lower alkenyl,
 lower alkynyl, CF_3 or $Ph(R^{13})_2$
 and
 10 each R^a is independently selected from the group consisting
 of:
 H, OH, halo, CN, NO₂, amino, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl,
 C₁₋₆ alkoxy, C₂₋₆alkenyloxy, C₂₋₆alkynyloxy, C₁₋₆alkylamino, di-C₁₋₆
 alkylamino, CF_3 , C(O)C₁₋₆alkyl, C(O)C₂₋₆alkenyl, C(O)C₂₋₆alkynyl,
 15 CO₂H, CO₂C₁₋₆alkyl,
 CO₂C₂₋₆alkenyl, and CO₂C₂₋₆alkynyl, said alkyl, alkenyl, alkynyl and
 the alkyl portions of alkylamino and dialkylamino being optionally
 substituted with 1-3 of: hydroxy, halo, aryl, C₁₋₆ alkoxy, C₂₋₆alkenyloxy,
 C₂₋₆alkynyloxy, CF_3 , C(O)C₁₋₆alkyl, C(O)C₂₋₆alkenyl, C(O)C₂₋₆alkynyl,
 20 CO₂H, CO₂C₁₋₆alkyl, CO₂C₂₋₆alkenyl, CO₂C₂₋₆alkynyl, NH₂, NHC₁₋₆
 alkyl and N(C₁₋₆alkyl)₂.

2. A compound represented by formula I:

25



I

or a pharmaceutically acceptable salt, hydrate or ester thereof, wherein:

- HET represents a 5-12 membered monocyclic or bicyclic
 aromatic ring system containing 0-3 heteroatoms selected from O, S(O)_n
 30 and N(O)_m wherein m is 0 or 1 and n is 0, 1 or 2;

- A is a one or two atom moiety and is selected from the group
 consisting of: -W-, -C(O)-, -C(R⁷)₂-W-, -W-C(R⁷)₂-, -CR⁷(OR²⁰)-,
 -C(R⁷)₂-, -C(R⁷)₂-C(OR²⁰)R⁷-, -C(R⁷)₂-C(R⁷)₂- or -CR⁷=CR⁷-, wherein
 W represents O, S(O)_n or NR¹⁷, with n as previously defined and R¹⁷ as
 35 defined below;

- 5 X represents a 5-10 membered monocyclic or bicyclic aryl or heteroaryl group having 1-3 heteroatoms selected from O, S(O)_n and N(O)_m, and optionally substituted with R¹⁴ and R¹⁵, and A and B are attached to the aryl or heteroaryl group ortho relative to each other;
- Y represents O, S(O)_n, NR¹⁷, a bond or -CR¹⁸ = CR¹⁸- ;
- 10 B represents - (C(R¹⁸)₂)_p-Y- (C(R¹⁸)₂)_q-
- wherein p and q are independently 0-3, such that when Y represents O, S(O)_n, NR¹⁷ or -CR¹⁸ = CR¹⁸-, p + q = 0-6, and when Y represents a bond, p + q is 1-6;
- Z is OH or NHSO₂R¹⁹ ;
- 15 R¹ R² and R³ independently represent H, halogen, lower alkyl, lower alkenyl, lower alkynyl, lower alkenyl-HET(R^a)₄₋₉, -(C(R⁴)₂)_pSR⁵, -(C(R⁴)₂)_pOR⁸, -(C(R⁴)₂)_pN(R⁶)₂, CN, NO₂, -(C(R⁴)₂)_pC(R⁷)₃, -CO₂R⁹, -CON(R⁶)₂ or -(C(R⁴)₂)_pS(O)_nR¹⁰, wherein n and p are as previously defined;
- 20 each R⁴ is independently H, F, CF₃ or lower alkyl, or two R⁴ groups are taken in conjunction and represent a ring of up to six atoms, optionally containing one heteroatom selected from O, S(O)_n or N(O)_m;
- each R⁵ is independently lower alkyl, lower alkenyl, lower alkynyl, CF₃, lower alkyl-HET, lower alkenyl-HET or -(C(R¹⁸)₂)_pPh(R¹¹)₀₋₂;
- 25 each R⁶ is independently H, lower alkyl, lower alkenyl, lower alkynyl, CF₃, Ph, Bn and when two R⁶ groups are attached to N they may be taken in conjunction and represents a ring of up to 6 atoms, optionally containing an additional heteroatom selected from O, S(O)_n or N(O)_m;
- 30 each R⁷ is independently H, F, CF₃ or lower alkyl, and when two R⁷ groups are presents, they may be taken in conjunction and represent an aromatic or aliphatic ring of 3 to 6 members containing from 0-2 heteroatoms selected from O, S(O)_n and N(O)_m;
- 35 each R⁸ represents H or R⁵;
- each R⁹ is independently H, lower alkyl, lower alkenyl, lower alkynyl, Ph or Bn;

- 5 each R¹⁰ is independently lower alkyl, lower alkenyl, lower alkynyl, CF₃, Ph(R¹¹)₀₋₃, CH₂Ph(R¹¹)₀₋₃ or N(R⁶)₂ ;
 each R¹¹ is independently lower alkyl, SR²⁰, OR²⁰, N(R⁶)₂,
 -CO₂R¹², -CON(R⁶)₂, -C(O)R¹², CN, CF₃, NO₂ or halogen;
 each R¹² is independently H, lower alkyl or benzyl;
 10 each R¹³ is independently H, halo, lower alkyl, O-lower alkenyl, S-lower alkyl, N(R⁶)₂, CO₂R¹², CN, CF₃ or NO₂ ;
 R¹⁴ and R¹⁵ are independently lower alkyl, halogen, CF₃, OR¹⁶, S(O)_nR¹⁶ or C(R¹⁶)₂OR¹⁷ ;
 each R¹⁶ is independently H, lower alkyl, lower alkenyl, Ph,
 15 Bn, CHF₂ or CF₃;
 each R¹⁷ is independently H, lower alkyl or Bn;
 each R¹⁸ is independently H, F or lower alkyl, and when two R¹⁸ groups are present, they may be taken in conjunction and represent a ring of 3 to 6 members comprising carbon atoms and optionally one
 20 heteroatom chosen from O, S(O)_n or N;
 each R¹⁹ is lower alkyl, lower alkenyl, lower alkynyl, CF₃, HET²(Ra)₄₋₉, lower alkyl-HET²(Ra)₄₋₉ or lower alkenyl-HET²(Ra)₄₋₉, wherein HET² represents a member selected from the group consisting of: phenyl, thienyl, naphthyl, furanyl, thiazolyl, imidazolyl and indolyl;
 25 each R²⁰ is independently H, lower alkyl, lower alkenyl, lower alkynyl, CHF₂, CF₃ or Ph(R¹³)₂
 and
 each Ra is independently selected from the group consisting of:
 30 H, OH, halo, CN, NO₂, amino, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₁₋₆alkoxy, C₂₋₆alkenyloxy, C₂₋₆alkynyloxy, C₁₋₆alkylamino, di-C₁₋₆alkylamino, CF₃, C(O)C₁₋₆alkyl, C(O)C₂₋₆alkenyl, C(O)C₂₋₆alkynyl, CO₂H, CO₂C₁₋₆alkyl, CO₂C₂₋₆alkenyl, and CO₂C₂₋₆alkynyl,
 said alkyl, alkenyl, alkynyl and the alkyl portions of
 35 alkylamino and dialkylamino being optionally substituted with 1-3 of: hydroxy, halo, aryl, C₁₋₆alkoxy, C₂₋₆alkenyloxy, C₂₋₆alkynyloxy, CF₃, C(O)C₁₋₆alkyl, C(O)C₂₋₆alkenyl, C(O)C₂₋₆alkynyl, CO₂H, CO₂C₁₋₆alkyl, CO₂C₂₋₆alkenyl, CO₂C₂₋₆alkynyl, NH₂, NHC₁₋₆alkyl and N(C₁₋₆alkyl)₂.

5

3. A compound in accordance with claim 1 wherein:

HET represents a member selected from the group consisting of: benzene, naphthalene, biphenyl, pyridine, quinoline, isoquinoline, furan, benzofuran, thiophene, benzothiophene, oxazole, thiazole, imidazole, benzothiazole, triazole, 1,2,5-thiadiazole, thienopyridine, indole, tetrazole, imidazole, benzoxazole, 1,3-methylenedioxobenzene and pyrrole.

15

4. A compound in accordance with claim 3 wherein:

HET is selected from the group consisting of: phenyl, biphenyl, naphthyl, indole, thiophene, benzofuran and quinoline.

20

5. A compound in accordance with claim 1 wherein:

A represents a one or two atom moiety and is selected from the group consisting of: S, S(O), SO₂, CH₂, -C(O)-, -OCH₂-, -CHOH-, -C(OH)(CH₃)- and -CH₂O-.

25

6. A compound in accordance with claim 5 wherein:

A is selected from the group consisting of: S, S(O), SO₂, CH₂ and -C(O)-.

30

7. A compound in accordance with claim 1 wherein:

X represents phenyl optionally substituted with R¹⁴ and R¹⁵.

8. A compound in accordance with claim 7 wherein X represents phenyl and R¹⁴ and R¹⁵ are absent or represent halo.

35

9. A compound in accordance with claim 1 wherein:

B represents CH=CH or 1,2-cyclopropyl.

10. A compound in accordance with claim 9 wherein:

B represents CH=CH in the E-isomeric form.

5 11. A compound in accordance with claim 9 wherein:
Z is $\text{NHSO}_2\text{R}^{19}$.

 12. A compound in accordance with claim 11 wherein:
 Z is $\text{NHSO}_2\text{R}^{19}$ and R^{19} represents a member selected from
10 the group consisting of: lower alkyl and $\text{HET}(\text{Ra})_3$.

 13. A compound in accordance with claim 12 wherein:
 R^{19} represents $\text{HET}(\text{Ra})_3$ and HET is selected from the
group consisting of: phenyl, thienyl, naphthyl, furanyl, thiazolyl,
15 imidazolyl and indolyl.

 14. A compound in accordance with claim 12 wherein:
 Z is $\text{NHSO}_2\text{R}^{19}$ and R^{19} represents benzene or thiophene,
substituted with $(\text{Ra})_3$.

20 15. A compound in accordance with claim 1 wherein:
Z represents OH.

 16. A compound in accordance with claim 1 wherein:
25 HET represents a member selected from the group
consisting of: phenyl, naphthalene, biphenyl, pyridine, quinoline,
isoquinoline, furan, benzofuran, thiophene, benzothiophene, oxazole,
thiazole, imidazole, benzothiazole, 1,2,5-thiadiazole, thienopyridine,
indole, tetrazole, imidazole, benzoxazole and pyrrole;

30 A represents a one or two atom moiety and is selected from
the group consisting of: S, S(O), SO_2 , CH_2 , $-\text{C}(\text{O})-$, $-\text{OCH}_2-$, $-\text{CHOH}-$, $-\text{C}(\text{OH})(\text{CH}_3)-$ and $-\text{CH}_2\text{O}-$;

 X represents phenyl optionally substituted with R^{14} and R^{15} ;
 B is $\text{CH}=\text{CH}$;
35 Z is $\text{NHSO}_2\text{R}^{19}$ and
 R^{19} represents a member selected from the group consisting
of: lower alkyl and $\text{HET}(\text{Ra})_3$.

5 17. A compound in accordance with claim 1 wherein:

HET represents a member selected from the group consisting of: phenyl, naphthalene, biphenyl, pyridine, quinoline, isoquinoline, furan, benzofuran, thiophene, benzothiophene, oxazole, thiazole, imidazole, benzothiazole, 1,2,5-thiadiazole, thienopyridine, indole, tetrazole, imidazole, benzoxazole and pyrrole;

A represents a one or two atom moiety and is selected from the group consisting of: S, S(O), SO₂, CH₂, -C(O)-, -OCH₂-, -CHOH-, -C(OH)(CH₃)- and -CH₂-O-;

X represents phenyl optionally substituted with R¹⁴ and R¹⁵;


15 B is CH=CH;

Z is OH.

18. A compound represented in one of the following tables:

20

Table I



Ia

(Compounds 1-323 and 347-454)

R ¹ R ² R ³ -Het	A	X	B	R ¹⁹	Cpd
1-naphthyl	CH ₂	1,2-Ph	CH=CH	Ph(F) ₅	1
2-naphthyl	S(O) ₂	1,2-Ph	CH=CH	Ph(F) ₅	2
3-methylindol-1-yl	CH ₂	1,2-Ph	CH=CH	2-thienyl	3
2-naphthyl	CH ₂	1,2-Ph	CH=CH	2-thienyl	4
2-naphthyl	S(O) ₂	1,2-Ph	CH=CH	phenyl	5
3-methylindol-1-yl	S(O) ₂	1,2-Ph	CH=CH	2-thienyl	6

R¹R²R³-Het	A	X	B	R¹⁰	Cpd
2-naphthyl	S(O) ₂	1,2-Ph	CH=CH	3,5-di-(CF ₃) phenyl	7
3,4-dichloro phenyl	CH ₂	1,2-Ph	CH=CH	2-thienyl	8
2-naphthyl	S(O) ₂	1,2-Ph	CH=CH	2-thienyl	9
2,4-dichloro phenyl	CH ₂	1,2-Ph	CH=CH	2-thienyl	10
1-naphthyl	S(O) ₂	1,2-Ph	CH=CH	Ph(F) ₅	11
1-naphthyl	S(O) ₂	1,2-Ph	CH=CH	3,5-di-(CF ₃) phenyl	12
2-naphthyl	S(O) ₂	1,2-Ph	1,2-c-propyl	2-thienyl	13
3,4-chloro fluoro phenyl	CH ₂	1,2-Ph	CH=CH	2-thienyl	14
1-naphthyl	CH ₂	1,2-Ph	CH=CH	2-thienyl	15
3,4-dichloro phenyl	S(O) ₂	1,2-Ph	CH=CH	2-thienyl	16
4-methylthio phenyl	CH ₂	1,2-Ph	CH=CH	2-thienyl	17
4-chlorophenyl	CH ₂	1,2-Ph	CH=CH	2-thienyl	18
2-naphthyl	S	1,2-Ph	CH=CH	2-thienyl	19
2-naphthyl	O-CH ₂	1,2-Ph	CH=CH	2-thienyl	20
2-naphthyl	S(O)	1,2-Ph	CH=CH	2-thienyl	21
1-naphthyl	S(O) ₂	1,2-Ph	CH=CH	phenyl	22
2-benzofuranyl	CH ₂	1,2-Ph	CH=CH	2-thienyl	23
3,5-dichloro phenyl	CH ₂	1,2-Ph	CH=CH	2-thienyl	24
1-naphthyl	S(O) ₂	1,2-Ph	CH=CH	3,5-di-(CF ₃) phenyl	25
1-naphthyl	S(O) ₂	1,2-Ph	CH=CH	2-thienyl	26
3-(1,2-(methylene dioxy)benzene)	CH ₂	1,2-Ph	CH=CH	2-thienyl	27
2-naphthyl	O	1,2-Ph	CH=CH	2-thienyl	28
Rs-2-phenyl	CH ₂	1,2-Ph	CH ₂ -O	2-thienyl	29
Rs-2-phenyl	CH ₂	1,2-Ph	CH ₂ -CH ₂	2-thienyl	30
2-naphthyl	S(O) ₂	1,2-Ph	CH ₂ -O	2-thienyl	31
3-((2-(Qn)vinyl)) phenyl	CH ₂	1,2-Ph	CH ₂ -O	2-thienyl	32
2-(6-benzyloxy) naphthyl	CH ₂	1,2-Ph	CH=CH	2-thienyl	33
3-((2-(Qn)vinyl)) phenyl	SO	1,2-Ph	CH ₂ -O	2-thienyl	34
3-((2-(Qn)vinyl)) phenyl	-CHOH	1,2-Ph	CH ₂ -O	2-thienyl	35

R¹R²R³-Het	A	X	B	R¹⁹	Cpd
3-((2-(Qn)vinyl)) phenyl	S(O) ₂	1,2-Ph	CH ₂ -O	phenyl	36
3-((2-(Qn)vinyl)) phenyl	O-CH ₂	1,2-Ph	CH ₂ -O	2-thienyl	37
3-tolyl-D-3-phenyl	O-CH ₂	1,2-Ph	CH ₂ -O	2-thienyl	38
3-((2-(Qn)vinyl)) phenyl	CH(OH)- CH ₃ -	1,2-Ph	CH ₂ -O	phenyl	39
3-((2-(Qn)vinyl)) phenyl	S	1,2-Ph	CH ₂ -O	2-thienyl	40
3-((2-(Qn)vinyl)) phenyl	O	1,2-Ph	CH ₂ -O	phenyl	41
3-((2-(Qn)vinyl)) phenyl	C=O	1,2-Ph	CH ₂ -O	2-thienyl	42
3-((2-(Qn)vinyl)) phenyl	O	1,2-Ph	C(CH ₃) ₂ -O	2-thienyl	43
3-((2-(Qn)vinyl)) phenyl	O	1,2-Ph	CH ₂ -O	2-thienyl	44
2-naphthyl	CH ₂	1,2-Ph	1,2-c-propyl	2-thienyl	45
2-(6-benzyloxy) naphthyl	CH ₂	1,2-Ph	CH=CH	2-methoxy-5- bromophenyl	46
2-naphthyl	CH ₂	1,2-Ph	1,2-c-propyl	3,4-dichloro phenyl	47
2-naphthyl	CH ₂	1,2-Ph	1,2-c-propyl	4-fluoro phenyl	48
2-naphthyl	CH ₂	1,2-Ph	1,2-c-propyl	4-chloro phenyl	49
2-naphthyl	CH ₂	1,2-Ph	1,2-c-propyl	4-propyl phenyl	50
2-naphthyl	CH ₂	1,2-Ph	1,2-c-propyl	2,5-dichloro thienyl	51
2-naphthyl	CH ₂	1,2-Ph	1,2-c-propyl	styryl	52
2-naphthyl	CH ₂	1,2-Ph	1,2-c-propyl	3-chloro-4- fluorophenyl	53
2-naphthyl	CH ₂	1,2-Ph	1,2-c-propyl	4-methoxy phenyl	54
2-naphthyl	CH ₂	1,2-Ph	1,2-c-propyl	3-bromo phenyl	55
2-naphthyl	CH ₂	1,2-Ph	1,2-c-propyl	2,5-dimethyl phenyl	56
2-naphthyl	CH ₂	1,2-Ph	1,2-c-propyl	2-nitro-4-chloro phenyl	57
2-naphthyl	CH ₂	1,2-Ph	1,2-c-propyl	2-carbomethoxy phenyl	58

R ¹ R ² R ³ -Het	A	X	B	R ¹⁰	Cpd
2-naphthyl	CH ₂	1,2-Ph	1,2-c-propyl	2,4-difluoro phenyl	59
2-naphthyl	CH ₂	1,2-Ph	1,2-c-propyl	4-butyl-phenyl	60
2-naphthyl	CH ₂	1,2-Ph	1,2-c-propyl	butyl	61
2-naphthyl	CH ₂	1,2-Ph	1,2-c-propyl	2,5-dimethoxy phenyl	62
2-naphthyl	CH ₂	1,2-Ph	1,2-c-propyl	3-trifluoro methylphenyl	63
2-naphthyl	CH ₂	1,2-Ph	1,2-c-propyl	3,5-difluoro phenyl	64
2-naphthyl	CH ₂	1,2-Ph	1,2-c-propyl	3,5-dichloro phenyl	65
2-naphthyl	CH ₂	1,2-Ph	1,2-c-propyl	4-((1-hydroxy-1-methyl)ethyl) phenyl	66
2-naphthyl	CH ₂	1,2-Ph	1,2-c-propyl	4-(hydroxy methyl)phenyl	67
2-naphthyl	CH ₂	1,2-Ph	1,2-c-propyl	3-(hydroxy methyl)phenyl	68
2-naphthyl	CH ₂	1,2-Ph	1,2-c-propyl	4-(methyl sulfonyl)phenyl	69
2-naphthyl	CH ₂	1,2-Ph	1,2-c-propyl	3-(methyl sulfonyl)phenyl	70
2-naphthyl	CH ₂	1,2-Ph	1,2-c-propyl	4-(propyl sulfonyl)phenyl	71
2-naphthyl	CH ₂	1,2-Ph	1,2-c-propyl	4-((bis-trifluoro-methyl)-hydroxy methyl)phenyl	72
2-naphthyl	CH ₂	1,2-Ph	1,2-c-propyl	4-(benzyloxy) phenyl	73
2-naphthyl	CH ₂	1,2-Ph	1,2-c-propyl	4-((1-methoxy-1-methyl) ethyl)phenyl	74
2-naphthyl	CH ₂	1,2-Ph	1,2-c-propyl	4-dimethyl aminophenyl	75
2-naphthyl	CH ₂	1,2-Ph	1,2-c-propyl	cyclohexyl	76
2-naphthyl	CH ₂	1,2-Ph	1,2-c-propyl	cyclopentyl	77
2-naphthyl	CH ₂	1,2-Ph	1,2-c-propyl	4-morpholinYL	78
2-naphthyl	CH ₂	1,2-Ph	1,2-c-propyl	2-naphthyl	79
2-naphthyl	CH ₂	1,2-Ph	1,2-c-propyl	2-thiazolyl	80
2-naphthyl	CH ₂	1,2-Ph	1,2-c-propyl	1-imidazolyl	81
2-naphthyl	CH ₂	1,2-Ph	1,2-c-propyl	2-furanyl	82
2-naphthyl	CH ₂	1,2-Ph	1,2-c-propyl	3-(2-chloro)- furanyl	83

R ¹ R ² R ³ -Het	A	X	B	R ¹⁹	Cpd
2-naphthyl	CH ₂	1,2-Ph	1,2-c-propyl	2-pyridinyl	84
2-naphthyl	CH ₂	1,2-Ph	1,2-c-propyl	2-(4-chloro)pyridinyl	85
2-naphthyl	CH ₂	1,2-Ph	1,2-c-propyl	3-indolyl	86
2-naphthyl	CH ₂	1,2-Ph	1,2-c-propyl	4-nitrophenyl	87
2-naphthyl	CH ₂	1,2-Ph	1,2-c-propyl	4-cyanophenyl	88
2-naphthyl	S(O) ₂	1,2-Ph	1,2-c-propyl	4-((1-hydroxy-1-methyl)ethyl)phenyl	89
2-naphthyl	S(O) ₂	1,2-Ph	1,2-c-propyl	4-(hydroxymethyl)phenyl	90
2-naphthyl	S(O) ₂	1,2-Ph	1,2-c-propyl	3-(hydroxymethyl)phenyl	91
2-naphthyl	S(O) ₂	1,2-Ph	1,2-c-propyl	2,5-dimethylphenyl	92
2-naphthyl	S(O) ₂	1,2-Ph	1,2-c-propyl	2-carbomethoxyphenyl	93
2-naphthyl	S(O) ₂	1,2-Ph	1,2-c-propyl	2,4-difluorophenyl	94
2-naphthyl	S(O) ₂	1,2-Ph	1,2-c-propyl	4-(methylsulfonyl)phenyl	95
2-naphthyl	S(O) ₂	1,2-Ph	1,2-c-propyl	3-(methylsulfonyl)phenyl	96
2-naphthyl	S(O) ₂	1,2-Ph	1,2-c-propyl	4-(propylsulfonyl)phenyl	97
2-naphthyl	S(O) ₂	1,2-Ph	1,2-c-propyl	4-butyl-phenyl	98
2-naphthyl	S(O) ₂	1,2-Ph	1,2-c-propyl	3,5-di-(CF ₃)phenyl	99
2-naphthyl	S(O) ₂	1,2-Ph	1,2-c-propyl	4-((bis-trifluoromethyl)-hydroxymethyl)phenyl	100
2-naphthyl	S(O) ₂	1,2-Ph	1,2-c-propyl	3-bromophenyl	101
2-naphthyl	S(O) ₂	1,2-Ph	1,2-c-propyl	4-(benzyloxy)phenyl	102
2-naphthyl	S(O) ₂	1,2-Ph	1,2-c-propyl	2-nitro-4-chlorophenyl	103
2-naphthyl	S(O) ₂	1,2-Ph	1,2-c-propyl	4-isopropylphenyl	104
2-naphthyl	S(O) ₂	1,2-Ph	1,2-c-propyl	4-((1-methoxy-1-methyl)ethyl)phenyl	105
2-naphthyl	S(O) ₂	1,2-Ph	1,2-c-propyl	4-methoxyphenyl	106

R¹R²R³-Het	A	X	B	R¹⁰	Cpd
2-naphthyl	S(O) ₂	1,2-Ph	1,2-c-propyl	4-dimethyl aminophenyl	107
2-naphthyl	S(O) ₂	1,2-Ph	1,2-c-propyl	3,4-dichloro phenyl	108
2-naphthyl	S(O) ₂	1,2-Ph	1,2-c-propyl	3,4-difluoro phenyl	109
2-naphthyl	S(O) ₂	1,2-Ph	1,2-c-propyl	4-fluorophenyl	110
2-naphthyl	S(O) ₂	1,2-Ph	1,2-c-propyl	cyclohexyl	111
2-naphthyl	S(O) ₂	1,2-Ph	1,2-c-propyl	cyclopentyl	112
2-naphthyl	S(O) ₂	1,2-Ph	1,2-c-propyl	4-morpholinyl	113
2-naphthyl	S(O) ₂	1,2-Ph	1,2-c-propyl	butyl	114
2-naphthyl	S(O) ₂	1,2-Ph	1,2-c-propyl	4-chlorophenyl	115
2-naphthyl	S(O) ₂	1,2-Ph	1,2-c-propyl	4-propylphenyl	116
2-naphthyl	S(O) ₂	1,2-Ph	1,2-c-propyl	2-naphthyl	117
2-naphthyl	S(O) ₂	1,2-Ph	1,2-c-propyl	2-thiazolyl	118
2-naphthyl	S(O) ₂	1,2-Ph	1,2-c-propyl	1-imidazolyl	119
2-naphthyl	S(O) ₂	1,2-Ph	1,2-c-propyl	2,5-dimethoxy phenyl	120
2-naphthyl	S(O) ₂	1,2-Ph	1,2-c-propyl	3-trifluoro methylphenyl	121
2-naphthyl	S(O) ₂	1,2-Ph	1,2-c-propyl	2,5-dichloro-3- thienyl	122
2-naphthyl	S(O) ₂	1,2-Ph	1,2-c-propyl	2-furanyl	123
2-naphthyl	S(O) ₂	1,2-Ph	1,2-c-propyl	3-(2-chloro)- furanyl	124
2-naphthyl	S(O) ₂	1,2-Ph	1,2-c-propyl	2-pyridinyl	125
2-naphthyl	S(O) ₂	1,2-Ph	1,2-c-propyl	2-styryl	126
2-naphthyl	S(O) ₂	1,2-Ph	1,2-c-propyl	3,5-difluoro- phenyl	127
2-naphthyl	S(O) ₂	1,2-Ph	1,2-c-propyl	3,5-dichloro- phenyl	128
2-naphthyl	S(O) ₂	1,2-Ph	1,2-c-propyl	2-(4-chloro) pyridinyl	129
2-naphthyl	S(O) ₂	1,2-Ph	1,2-c-propyl	3-indolyl	130
2-naphthyl	S(O) ₂	1,2-Ph	1,2-c-propyl	4-nitrophenyl	131
2-naphthyl	S(O) ₂	1,2-Ph	1,2-c-propyl	4-cyanophenyl	132
2-naphthyl	S(O) ₂	1,2-Ph	1,2-c-propyl	3-chloro-4- fluorophenyl	133
3-methylindol -1-yl	CH ₂	1,2-Ph	1,2-c-propyl	3,5-di-(CF ₃)- phenyl	134
3-methylindol -1-yl	CH ₂	1,2-Ph	1,2-c-propyl	4-isopropyl phenyl	135
3-methylindol -1-yl	CH ₂	1,2-Ph	1,2-c-propyl	3,4-dichloro phenyl	136

R ¹ R ² R ³ -Het	A	X	B	R ¹⁹	Cpd
3-methylindol-1-yl	CH ₂	1,2-Ph	1,2-c-propyl	3,4-difluorophenyl	137
3-methylindol-1-yl	CH ₂	1,2-Ph	1,2-c-propyl	4-fluorophenyl	138
3-methylindol-1-yl	CH ₂	1,2-Ph	1,2-c-propyl	4-chlorophenyl	139
3-methylindol-1-yl	CH ₂	1,2-Ph	1,2-c-propyl	4-propylphenyl	140
3-methylindol-1-yl	CH ₂	1,2-Ph	1,2-c-propyl	2,5-dichloro-3-thienyl	141
3-methylindol-1-yl	CH ₂	1,2-Ph	1,2-c-propyl	2-styryl	142
3-methylindol-1-yl	CH ₂	1,2-Ph	1,2-c-propyl	3-chloro-4-fluorophenyl	143
3-methylindol-1-yl	CH ₂	1,2-Ph	1,2-c-propyl	4-methoxyphenyl	144
3-methylindol-1-yl	CH ₂	1,2-Ph	1,2-c-propyl	3-bromophenyl	145
3-methylindol-1-yl	CH ₂	1,2-Ph	1,2-c-propyl	2,5-dimethylphenyl	146
3-methylindol-1-yl	CH ₂	1,2-Ph	1,2-c-propyl	2-nitro-4-chlorophenyl	147
3-methylindol-1-yl	CH ₂	1,2-Ph	1,2-c-propyl	2-carbomethoxyphenyl	148
3-methylindol-1-yl	CH ₂	1,2-Ph	1,2-c-propyl	2,4-difluorophenyl	149
3-methylindol-1-yl	CH ₂	1,2-Ph	1,2-c-propyl	4-butylphenyl	150
3-methylindol-1-yl	CH ₂	1,2-Ph	1,2-c-propyl	n-butyl	151
3-methylindol-1-yl	CH ₂	1,2-Ph	1,2-c-propyl	2,5-dimethoxyphenyl	152
3-methylindol-1-yl	CH ₂	1,2-Ph	1,2-c-propyl	3-trifluoromethylphenyl	153
3-methylindol-1-yl	CH ₂	1,2-Ph	1,2-c-propyl	3,5-difluorophenyl	154
3-methylindol-1-yl	CH ₂	1,2-Ph	1,2-c-propyl	3,5-dichlorophenyl	155
3-methylindol-1-yl	CH ₂	1,2-Ph	1,2-c-propyl	4-((1-hydroxy-1-methyl)ethyl)phenyl	156
3-methylindol-1-yl	CH ₂	1,2-Ph	1,2-c-propyl	4-(hydroxymethyl)phenyl	157

R ¹ R ² R ³ -Het	A	X	B	R ¹⁹	Cpd
3-methylindol-1-yl	CH ₂	1,2-Ph	1,2-c-propyl	3-(hydroxymethyl)phenyl	158
3-methylindol-1-yl	CH ₂	1,2-Ph	1,2-c-propyl	4-(methylsulfonyl)phenyl	159
3-methylindol-1-yl	CH ₂	1,2-Ph	1,2-c-propyl	3-(methylsulfonyl)phenyl	160
3-methylindol-1-yl	CH ₂	1,2-Ph	1,2-c-propyl	4-(propylsulfonyl)phenyl	161
3-methylindol-1-yl	CH ₂	1,2-Ph	1,2-c-propyl	4-((bis-trifluoromethyl)hydroxymethyl)phenyl	162
3-methylindol-1-yl	CH ₂	1,2-Ph	1,2-c-propyl	4-(benzyloxy)phenyl	163
3-methylindol-1-yl	CH ₂	1,2-Ph	1,2-c-propyl	4-((1-methoxy-1-methyl)ethyl)phenyl	164
3-methylindol-1-yl	CH ₂	1,2-Ph	1,2-c-propyl	4-dimethylaminophenyl	165
3-methylindol-1-yl	CH ₂	1,2-Ph	1,2-c-propyl	cyclohexyl	166
3-methylindol-1-yl	CH ₂	1,2-Ph	1,2-c-propyl	cyclopentyl	167
3-methylindol-1-yl	CH ₂	1,2-Ph	1,2-c-propyl	4-morpholinyl	168
3-methylindol-1-yl	CH ₂	1,2-Ph	1,2-c-propyl	2-naphthyl	169
3-methylindol-1-yl	CH ₂	1,2-Ph	1,2-c-propyl	2-thiazolyl	170
3-methylindol-1-yl	CH ₂	1,2-Ph	1,2-c-propyl	1-imidazolyl	171
3-methylindol-1-yl	CH ₂	1,2-Ph	1,2-c-propyl	2-furanyl	172
3-methylindol-1-yl	CH ₂	1,2-Ph	1,2-c-propyl	3-(2-chloro)-furanyl	173
3-methylindol-1-yl	CH ₂	1,2-Ph	1,2-c-propyl	2-pyridinyl	174
3-methylindol-1-yl	CH ₂	1,2-Ph	1,2-c-propyl	2-(4-chloro)pyridinyl	175
3-methylindol-1-yl	CH ₂	1,2-Ph	1,2-c-propyl	3-indolyl	176
3-methylindol-1-yl	CH ₂	1,2-Ph	1,2-c-propyl	4-nitrophenyl	177
3-methylindol-1-yl	CH ₂	1,2-Ph	1,2-c-propyl	4-cyanophenyl	178

R ¹ R ² R ³ -Het	A	X	B	R ¹⁹	Cpd
3-methylindol-1-yl	SO ₂	1,2-Ph	1,2-c-propyl	3,5-di-(CF ₃) phenyl	179
3-methylindol-1-yl	SO ₂	1,2-Ph	1,2-c-propyl	4-isopropyl phenyl	180
3-methylindol-1-yl	SO ₂	1,2-Ph	1,2-c-propyl	3,4-dichloro phenyl	181
3-methylindol-1-yl	SO ₂	1,2-Ph	1,2-c-propyl	3,4-difluoro phenyl	182
3-methylindol-1-yl	SO ₂	1,2-Ph	1,2-c-propyl	4-fluorophenyl	183
3-methylindol-1-yl	SO ₂	1,2-Ph	1,2-c-propyl	4-chlorophenyl	184
3-methylindol-1-yl	SO ₂	1,2-Ph	1,2-c-propyl	4-propylphenyl	185
3-methylindol-1-yl	SO ₂	1,2-Ph	1,2-c-propyl	2,5-dichloro-3-thienyl	186
3-methylindol-1-yl	SO ₂	1,2-Ph	1,2-c-propyl	2-styryl	187
3-methylindol-1-yl	SO ₂	1,2-Ph	1,2-c-propyl	3-chloro-4-fluorophenyl	188
3-methylindol-1-yl	SO ₂	1,2-Ph	1,2-c-propyl	4-methoxy phenyl	189
3-methylindol-1-yl	SO ₂	1,2-Ph	1,2-c-propyl	3-bromo phenyl	190
3-methylindol-1-yl	SO ₂	1,2-Ph	1,2-c-propyl	2,5-dimethyl phenyl	191
3-methylindol-1-yl	SO ₂	1,2-Ph	1,2-c-propyl	2-nitro-4-chloro phenyl	192
3-methylindol-1-yl	SO ₂	1,2-Ph	1,2-c-propyl	2-carbomethoxy phenyl	193
3-methylindol-1-yl	SO ₂	1,2-Ph	1,2-c-propyl	2,4-difluoro phenyl	194
3-methylindol-1-yl	SO ₂	1,2-Ph	1,2-c-propyl	4-butylphenyl	195
3-methylindol-1-yl	SO ₂	1,2-Ph	1,2-c-propyl	n-butyl	196
3-methylindol-1-yl	SO ₂	1,2-Ph	1,2-c-propyl	2,5-dimethoxy phenyl	197
3-methylindol-1-yl	SO ₂	1,2-Ph	1,2-c-propyl	3-trifluoromethyl phenyl	198
3-methylindol-1-yl	SO ₂	1,2-Ph	1,2-c-propyl	3,5-difluoro phenyl	199
1-(3-methyl) indolyl	SO ₂	1,2-Ph	1,2-c-propyl	3,5-dichloro phenyl	200

R¹R²R³-Het	A	X	B	R¹⁹	Cpd
3-methylindol -1-yl	SO ₂	1,2-Ph	1,2-c-propyl	4-((1-hydroxy-1-methyl)ethyl)phenyl	201
3-methylindol -1-yl	SO ₂	1,2-Ph	1,2-c-propyl	4-(hydroxymethyl)phenyl	202
3-methylindol -1-yl	SO ₂	1,2-Ph	1,2-c-propyl	3-(hydroxymethyl)phenyl	203
3-methylindol -1-yl	SO ₂	1,2-Ph	1,2-c-propyl	4-(methylsulfonyl)phenyl	204
3-methylindol -1-yl	SO ₂	1,2-Ph	1,2-c-propyl	3-(methylsulfonyl)phenyl	205
3-methylindol -1-yl	SO ₂	1,2-Ph	1,2-c-propyl	4-(propylsulfonyl)phenyl	206
3-methylindol -1-yl	SO ₂	1,2-Ph	1,2-c-propyl	4-((bis-trifluoromethyl)hydroxymethyl)phenyl	207
3-methylindol -1-yl	SO ₂	1,2-Ph	1,2-c-propyl	4-(benzyloxy)phenyl	208
3-methylindol -1-yl	SO ₂	1,2-Ph	1,2-c-propyl	4-((1-methoxy-1-methyl)ethyl)-phenyl	209
3-methylindol -1-yl	SO ₂	1,2-Ph	1,2-c-propyl	4-dimethylaminophenyl	210
3-methylindol -1-yl	SO ₂	1,2-Ph	1,2-c-propyl	cyclohexyl	211
3-methylindol -1-yl	SO ₂	1,2-Ph	1,2-c-propyl	cyclopentyl	212
3-methylindol -1-yl	SO ₂	1,2-Ph	1,2-c-propyl	4-morpholinyl	213
3-methylindol -1-yl	SO ₂	1,2-Ph	1,2-c-propyl	2-naphthyl	214
3-methylindol -1-yl	SO ₂	1,2-Ph	1,2-c-propyl	2-thiazolyl	215
3-methylindol -1-yl	SO ₂	1,2-Ph	1,2-c-propyl	1-imidazolyl	216
3-methylindol -1-yl	SO ₂	1,2-Ph	1,2-c-propyl	2-furanyl	217
3-methylindol -1-yl	SO ₂	1,2-Ph	1,2-c-propyl	3-(2-chloro)-furanyl	218
3-methylindol -1-yl	SO ₂	1,2-Ph	1,2-c-propyl	2-pyridinyl	219
3-methylindol -1-yl	SO ₂	1,2-Ph	1,2-c-propyl	2-(4-chloro)pyridinyl	220

R ¹ R ² R ³ -Het	A	X	B	R ¹⁹	Cpd
3-methylindol-1-yl	SO ₂	1,2-Ph	1,2-c-propyl	3-indolyl	221
3-methylindol-1-yl	SO ₂	1,2-Ph	1,2-c-propyl	4-nitrophenyl	222
3-methylindol-1-yl	SO ₂	1,2-Ph	1,2-c-propyl	4-cyanophenyl	223
2-naphthyl	CH ₂	1,2-Ph	CH=CH	3,5-di-(CF ₃) phenyl	224
2-naphthyl	CH ₂	1,2-Ph	CH=CH	4-isopropyl phenyl	225
2-naphthyl	CH ₂	1,2-Ph	CH=CH	2,3-dichloro phenyl	226
2-naphthyl	CH ₂	1,2-Ph	CH=CH	3,4-difluoro phenyl	227
2-naphthyl	CH ₂	1,2-Ph	CH=CH	4-chlorophenyl	228
2-naphthyl	CH ₂	1,2-Ph	CH=CH	4-fluorophenyl	229
2-naphthyl	CH ₂	1,2-Ph	CH=CH	2,5-dichloro-3-thienyl	230
2-naphthyl	CH ₂	1,2-Ph	CH=CH	3-chloro-4-fluoro phenyl	231
2-naphthyl	CH ₂	1,2-Ph	CH=CH	4-methoxy phenyl	232
2-naphthyl	CH ₂	1,2-Ph	CH=CH	butyl	233
2-naphthyl	CH ₂	1,2-Ph	CH=CH	3-trifluoro methylphenyl	234
2-naphthyl	CH ₂	1,2-Ph	CH=CH	4-((1-hydroxy-1-methyl)ethyl) phenyl	235
2-naphthyl	CH ₂	1,2-Ph	CH=CH	4-(methyl sufonyl)phenyl	236
2-naphthyl	CH ₂	1,2-Ph	CH=CH	4-(benzyloxy) phenyl	237
2-naphthyl	CH ₂	1,2-Ph	CH=CH	cyclohexyl	238
2-naphthyl	CH ₂	1,2-Ph	CH=CH	4-morpholinyl	239
2-naphthyl	CH ₂	1,2-Ph	CH=CH	2-thiazolyl	240
2-naphthyl	CH ₂	1,2-Ph	CH=CH	2-furanyl	241
2-naphthyl	CH ₂	1,2-Ph	CH=CH	2-pyridinyl	242
2-naphthyl	CH ₂	1,2-Ph	CH=CH	4-cyanophenyl	243
2-naphthyl	SO ₂	1,2-Ph	CH=CH	3,5-di-(CF ₃) phenyl	244
2-naphthyl	SO ₂	1,2-Ph	CH=CH	4-isopropyl phenyl	245
2-naphthyl	SO ₂	1,2-Ph	CH=CH	2,3-dichloro phenyl	246

R ¹ R ² R ³ -Het	A	X	B	R ¹⁹	Cpd
2-naphthyl	SO ₂	1,2-Ph	CH=CH	3,4-difluoro phenyl	247
2-naphthyl	SO ₂	1,2-Ph	CH=CH	4-chlorophenyl	248
2-naphthyl	SO ₂	1,2-Ph	CH=CH	4-fluorophenyl	249
2-naphthyl	SO ₂	1,2-Ph	CH=CH	2,5-dichloro-3-thienyl	250
2-naphthyl	SO ₂	1,2-Ph	CH=CH	3-chloro-4-fluorophenyl	251
2-naphthyl	SO ₂	1,2-Ph	CH=CH	4-methoxy phenyl	252
2-naphthyl	SO ₂	1,2-Ph	CH=CH	butyl	253
2-naphthyl	SO ₂	1,2-Ph	CH=CH	3-trifluoro methylphenyl	254
2-naphthyl	SO ₂	1,2-Ph	CH=CH	4-((1-hydroxy-1-methyl)ethyl) phenyl	255
2-naphthyl	SO ₂	1,2-Ph	CH=CH	4-(methyl sulfonyl)phenyl	256
2-naphthyl	SO ₂	1,2-Ph	CH=CH	4-(benzyloxy) phenyl	257
2-naphthyl	SO ₂	1,2-Ph	CH=CH	cyclohexyl	258
2-naphthyl	SO ₂	1,2-Ph	CH=CH	4-morpholinyl	259
2-naphthyl	SO ₂	1,2-Ph	CH=CH	2-thiazolyl	260
2-naphthyl	SO ₂	1,2-Ph	CH=CH	2-furanyl	261
2-naphthyl	SO ₂	1,2-Ph	CH=CH	2-pyridinyl	262
2-naphthyl	SO ₂	1,2-Ph	CH=CH	4-cyanophenyl	263
2-naphthyl	CH ₂ -O	1,2-Ph	CH=CH	3,5-di-(CF ₃) phenyl	264
2-naphthyl	CH ₂ -O	1,2-Ph	CH=CH	4-isopropyl phenyl	265
2-naphthyl	CH ₂ -O	1,2-Ph	CH=CH	2,3-dichloro phenyl	266
2-naphthyl	CH ₂ -O	1,2-Ph	CH=CH	3,4-difluoro phenyl	267
2-naphthyl	O-CH ₂	1,2-Ph	CH=CH	3,5-di-(CF ₃) phenyl	268
2-naphthyl	O-CH ₂	1,2-Ph	CH=CH	4-isopropyl phenyl	269
2-naphthyl	O-CH ₂	1,2-Ph	CH=CH	2,3-dichloro phenyl	270
2-naphthyl	O-CH ₂	1,2-Ph	CH=CH	3,4-difluoro phenyl	271
2-naphthyl	S	1,2-Ph	CH=CH	3,5-di-(CF ₃) phenyl	272

R ¹ R ² R ³ -Het	A	X	B	R ¹⁹	Cpd
2-naphthyl	S	1,2-Ph	CH=CH	4-isopropyl phenyl	273
2-naphthyl	S	1,2-Ph	CH=CH	2,3-dichloro phenyl	274
2-naphthyl	S	1,2-Ph	CH=CH	3,4-difluoro phenyl	275
2-(6-benzyloxy) naphthyl	SO ₂	1,2-Ph	CH=CH	2-thienyl	276
2-(6-benzyloxy) naphthyl	S	1,2-Ph	CH=CH	2-thienyl	277
2-(6-benzyloxy) naphthyl	SO ₂	1,2-Ph	1,2-c-propyl	2-thienyl	278
2-(6-benzyloxy) naphthyl	S	1,2-Ph	1,2-c-propyl	2-thienyl	279
2-(5-benzyloxy) naphthyl	SO ₂	1,2-Ph	CH=CH	2-thienyl	280
2-(5-benzyloxy) naphthyl	S	1,2-Ph	CH=CH	2-thienyl	281
2-(5-benzyloxy) naphthyl	SO ₂	1,2-Ph	1,2-c-propyl	2-thienyl	282
2-(5-benzyloxy) naphthyl	S	1,2-Ph	1,2-c-propyl	2-thienyl	283
2-(6-(4-trifluoro methyl)benzyloxy)) naphthyl	SO ₂	1,2-Ph	CH=CH	2-thienyl	284
2-(6-(4-trifluoro methyl)benzyloxy)) naphthyl	CH ₂	1,2-Ph	CH=CH	2-thienyl	285
2-(6-(4-trifluoro methyl)benzyl oxy))naphthyl	CH ₂	1,2-Ph	1,2-c-propyl	2-thienyl	286
2-(6-(4-trifluoro methyl)benzyl oxy))naphthyl	CH ₂	1,2-Ph	1,2-c-propyl	2-thienyl	287
1-(6-benzyloxy) naphthyl	SO ₂	1,2-Ph	CH=CH	2-thienyl	288
1-(6-benzyloxy) naphthyl	CH ₂	1,2-Ph	CH=CH	2-thienyl	289
2-(6-(3,4-difluoro benzyloxy)) naphthyl	SO ₂	1,2-Ph	CH=CH	2-thienyl	290
2-(6-(3,4-difluoro benzyloxy)) naphthyl	CH ₂	1,2-Ph	CH=CH	2-thienyl	291

R¹R²R³-Het	A	X	B	R¹⁰	Cpd
2-(6-(4-fluoro benzyloxy)) naphthyl	CH ₂	1,2-Ph	1,2-c-propyl	2-thienyl	292
2-(7-benzyloxy) naphthyl	SO ₂	1,2-Ph	CH=CH	2-thienyl	293
2-(6-(3,4-difluoro benzyloxy)) naphthyl	SO ₂	1,2-Ph	CH=CH	3,4-difluoro phenyl	294
2-(6-(3,4-difluoro benzyloxy)) naphthyl	CH ₂	1,2-Ph	CH=CH	3,4-difluoro phenyl	295
2-(6-(4-fluoro benzyloxy)) naphthyl	CH ₂	1,2-Ph	1,2-c-propyl	3,4-difluoro phenyl	296
2-(7-benzyloxy) naphthyl	SO ₂	1,2-Ph	CH=CH	3,5-di-(CF ₃) phenyl	297
2-(6-(3,4-difluoro benzyloxy)) naphthyl	SO ₂	1,2-Ph	CH=CH	3,5-di-(CF ₃) phenyl	298
2-(6-(3,4-difluoro benzyloxy)) naphthyl	CH ₂	1,2-Ph	CH=CH	3,5-di-(CF ₃) phenyl	299
2-(7-benzyloxy) naphthyl	SO ₂	1,2-Ph	1,2-c-propyl	3,4-difluoro phenyl	300
2-naphthyl	CH ₂	1,2-Ph	CH=CH	2-methoxy-5-bromophenyl	301
2-naphthyl	CH ₂	4-Cl-1,2-Ph	CH=CH	2-methoxy-5-bromophenyl	302
2-naphthyl	CH ₂	4-Cl-1,2-Ph	CH=CH	2-thienyl	303
2-naphthyl	SO	1,2-Ph	CH=CH	2-methoxy-5-bromophenyl	304
2-naphthyl	SO ₂	1,2-Ph	CH=CH	2-methoxy-5-bromophenyl	305
2-naphthyl	O	1,2-Ph	CH=CH	2-methoxy-5-bromophenyl	306
2-(5-benzyloxy) naphthyl	CH ₂	1,2-Ph	CH=CH	2-methoxy-5-bromophenyl	307
2-(5-benzyloxy) naphthyl	SO ₂	1,2-Ph	CH=CH	2-methoxy-5-bromophenyl	308
2-(5-benzyloxy) naphthyl	S	1,2-Ph	CH=CH	2-methoxy-5-bromophenyl	309
2-naphthyl	CH ₂	1,2-Ph	1,2-c-propyl	2-methoxy-5-bromophenyl	310
1,2-Ph	SO ₂	1,2-Ph	1,2-c-propyl	2-methoxy-5-bromophenyl	311

R ¹ R ² R ³ -Het	A	X	B	R ¹⁹	Cpd
2-naphthyl	S	1,2-Ph	1,2-c-propyl	2-methoxy-5-bromophenyl	312
2-naphthyl	CH ₂ -O	1,2-Ph	CH=CH	2-methoxy-5-bromophenyl	313
2-naphthyl	S	1,2-Ph	CH=CH	2-methoxy-5-bromophenyl	314
3-methyl indol-1-yl	SO ₂	1,2-Ph	1,2-c-propyl	2-methoxy-5-bromophenyl	315
3-methyl indol-1-yl	S	1,2-Ph	1,2-c-propyl	2-methoxy-5-bromophenyl	316
3-methyl indol-1-yl	CH ₂ -O	1,2-Ph	CH=CH	2-methoxy-5-bromophenyl	317
3-methyl indol-1-yl	S	1,2-Ph	CH=CH	2-methoxy-5-bromophenyl	318
3-methyl indol-1-yl	O-CH ₂	1,2-Ph	1,2-c-propyl	2-methoxy-5-bromophenyl	319
3-methyl indol-1-yl	SO	1,2-Ph	1,2-c-propyl	2-methoxy-5-bromophenyl	320
3-methyl indol-1-yl	CH ₂ -O	4-Cl-1,2-Ph	CH=CH	2-methoxy-5-bromophenyl	321
3-methyl indol-1-yl	S	4-Cl-1,2-Ph	CH=CH	2-methoxy-5-bromophenyl	322
3-methyl indol-1-yl	SO ₂	4-Cl-1,2-Ph	1,2-c-propyl	2-methoxy-5-bromophenyl	323
2-(7-fluoro) naphthyl	SO ₂	4-Cl-1,2-Ph	CH=CH	2-thienyl	347
2-(7-fluoro) naphthyl	O	4-Cl-1,2-Ph	CH=CH	2-thienyl	348
2-(7-fluoro) naphthyl	S	4-Cl-1,2-Ph	CH=CH	2-thienyl	349
2-(7-fluoro) naphthyl	CH ₂	4-Cl-1,2-Ph	CH=CH	2-thienyl	350
2-(7-fluoro) naphthyl	CH ₂	6-Cl-1,2-Ph	CH=CH	2-thienyl	351
2-(7-fluoro) naphthyl	CH ₂	4-Cl-1,2-Ph	1,2-c-Pr	2-thienyl	352
2-(7-fluoro) naphthyl	CH ₂	3-Cl-1,2-Ph	CH=CH	2-thienyl	353
2-(7-fluoro) naphthyl	SO ₂	4-Cl-1,2-Ph	CH=CH	2-methoxy-5-bromophenyl	354
2-(7-fluoro) naphthyl	O	4-Cl-1,2-Ph	CH=CH	2-methoxy-5-bromophenyl	355
2-(7-fluoro) naphthyl	S	4-Cl-1,2-Ph	CH=CH	2-methoxy-5-bromophenyl	356

R¹R²R³-Het	A	X	B	R¹⁹	Cpd
2-naphthyl	CH ₂	4,5-Cl ₂ -1,2-Ph	CH=CH	2-methoxy-5-bromophenyl	357
2-(7-fluoro)naphthyl	CH ₂	6-Cl-1,2-Ph	CH=CH	2-methoxy-5-bromophenyl	358
2-(7-fluoro)naphthyl	CH ₂	4-Cl-1,2-Ph	1,2-c-Pr	2-methoxy-5-bromophenyl	359
2-(7-fluoro)naphthyl	CH ₂	3-Cl-1,2-Ph	CH=CH	2-methoxy-5-bromophenyl	360
2-(7-fluoro)naphthyl	SO ₂	4-Cl-1,2-Ph	CH=CH	2-trifluoromethoxy-5-chlorophenyl	361
2-(7-fluoro)naphthyl	O	4-Cl-1,2-Ph	CH=CH	2-trifluoromethoxy-5-chlorophenyl	362
2-(7-fluoro)naphthyl	S	4-Cl-1,2-Ph	CH=CH	2-trifluoromethoxy-5-chlorophenyl	363
2-(7-fluoro)naphthyl	CH ₂	4-Cl-1,2-Ph	CH=CH	2-trifluoromethoxy-5-chlorophenyl	364
2-(7-fluoro)naphthyl	CH ₂	6-Cl-1,2-Ph	CH=CH	2-trifluoromethoxy-5-chlorophenyl	365
2-(7-fluoro)naphthyl	CH ₂	4-Cl-1,2-Ph	1,2-c-Pr	2-trifluoromethoxy-5-chlorophenyl	366
2-(7-fluoro)naphthyl	CH ₂	3-Cl-1,2-Ph	CH=CH	2-trifluoromethoxy-5-chlorophenyl	367
2-(7-fluoro)naphthyl	SO ₂	4-Cl-1,2-Ph	CH=CH	2-thienyl	368
2-(7-fluoro)naphthyl	O	4-Cl-1,2-Ph	CH=CH	2-thienyl	369
2-(7-fluoro)naphthyl	S	4-Cl-1,2-Ph	CH=CH	2-thienyl	370
2-(7-fluoro)naphthyl	CH ₂	4-Cl-1,2-Ph	CH=CH	2-thienyl	371
2-(7-fluoro)naphthyl	CH ₂	6-Cl-1,2-Ph	CH=CH	2-thienyl	372
2-(7-fluoro)naphthyl	CH ₂	4-Cl-1,2-Ph	1,2-c-Pr	2-thienyl	373
2-(7-fluoro)naphthyl	CH ₂	3-Cl-1,2-Ph	CH=CH	2-thienyl	374

R¹R²R³-Het	A	X	B	R¹⁹	Cpd
2-(7-fluoro) naphthyl	SO ₂	4-Cl-1,2-Ph	CH=CH	2-methoxy-5- bromophenyl	375
2-(6-fluoro) naphthyl	O	4-Cl-1,2-Ph	CH=CH	2-methoxy-5- bromophenyl	376
2-(6-fluoro) naphthyl	S	4-Cl-1,2-Ph	CH=CH	2-methoxy-5- bromophenyl	377
2-(6-fluoro) naphthyl	CH ₂	4-Cl-1,2-Ph	CH=CH	2-methoxy-5- bromophenyl	378
2-(6-fluoro) naphthyl	CH ₂	6-Cl-1,2-Ph	CH=CH	2-methoxy-5- bromophenyl	379
2-(6-fluoro) naphthyl	CH ₂	4-Cl-1,2-Ph	1,2-c-Pr	2-methoxy-5- bromophenyl	380
2-(6-fluoro) naphthyl	CH ₂	3-Cl-1,2-Ph	CH=CH	2-methoxy-5- bromophenyl	381
2-(7-chloro) naphthyl	SO ₂	4-Cl-1,2-Ph	CH=CH	2-thienyl	382
2-(7-chloro) naphthyl	O	4-Cl-1,2-Ph	CH=CH	2-thienyl	383
2-(7-chloro) naphthyl	S	4-Cl-1,2-Ph	CH=CH	2-thienyl	384
2-(7-chloro) naphthyl	CH ₂	4-Cl-1,2-Ph	CH=CH	2-thienyl	385
2-(7-chloro) naphthyl	CH ₂	6-Cl-1,2-Ph	CH=CH	2-thienyl	386
2-(7-chloro) naphthyl	CH ₂	4-Cl-1,2-Ph	1,2-c-Pr	2-thienyl	387
2-(7-chloro) naphthyl	CH ₂	3-Cl-1,2-Ph	CH=CH	2-thienyl	388
2-(6,7-difluoro) naphthyl	SO ₂	4-Cl-1,2-Ph	CH=CH	2-thienyl	389
2-(6,7-difluoro) naphthyl	O	4-Cl-1,2-Ph	CH=CH	2-thienyl	390
2-(6,7-difluoro) naphthyl	S	4-Cl-1,2-Ph	CH=CH	2-thienyl	391
2-(6,7-difluoro) naphthyl	CH ₂	4-Cl-1,2-Ph	CH=CH	2-thienyl	392
2-(6,7-difluoro) naphthyl	CH ₂	6-Cl-1,2-Ph	CH=CH	2-thienyl	393
2-(6,7-difluoro) naphthyl	CH ₂	4-Cl-1,2-Ph	1,2-c-Pr	2-thienyl	394
2-(6,7-difluoro) naphthyl	CH ₂	3-Cl-1,2-Ph	CH=CH	2-thienyl	395
2-(6,7-difluoro) naphthyl	SO ₂	4-Cl-1,2-Ph	CH=CH	2-methoxy-5- bromophenyl	396


R ¹ R ² R ³ -Het	A	X	B	R ¹⁹	Cpd
2-(6,7-difluoro) naphthyl	O	4-Cl-1,2-Ph	CH=CH	2-methoxy-5- bromophenyl	397
2-(6,7-difluoro) naphthyl	S	4-Cl-1,2-Ph	CH=CH	2-methoxy-5- bromophenyl	398
2-(6,7-difluoro) naphthyl	CH ₂	4-Cl-1,2-Ph	CH=CH	2-methoxy-5- bromophenyl	399
2-(6,7-difluoro) naphthyl	CH ₂	6-Cl-1,2-Ph	CH=CH	2-methoxy-5- bromophenyl	400
2-(6,7-difluoro) naphthyl	CH ₂	4-Cl-1,2-Ph	1,2-c-Pr	2-methoxy-5- bromophenyl	401
2-(6,7-difluoro) naphthyl	CH ₂	3-Cl-1,2-Ph	CH=CH	2-methoxy-5- bromophenyl	402
2-(5,7-difluoro) naphthyl	CH ₂	4-Cl-1,2-Ph	CH=CH	2-methoxy-5- bromophenyl	403
2-(5,7-difluoro) naphthyl	S	4-Cl-1,2-Ph	CH=CH	2-methoxy-5- bromophenyl	404
2-(5,7-difluoro) naphthyl	O	4-Cl-1,2-Ph	CH=CH	2-methoxy-5- bromophenyl	405
2-(5,7-difluoro) naphthyl	SO ₂	4-Cl-1,2-Ph	CH=CH	2-methoxy-5- bromophenyl	406
2-(6-fluoro) quinoliny	SO ₂	4-Cl-1,2-Ph	CH=CH	2-methoxy-5- bromophenyl	407
2-(6-fluoro) quinoliny	S	4-Cl-1,2-Ph	CH=CH	2-methoxy-5- bromophenyl	408
2-(6-fluoro) quinoliny	CH ₂	4-Cl-1,2-Ph	CH=CH	2-methoxy-5- bromophenyl	409
2-(6-fluoro) quinoliny	CH ₂	1,2-Ph	CH=CH	2-methoxy-5- bromophenyl	410
2-(6-fluoro) quinoliny	O	4-Cl-1,2-Ph	CH=CH	2-methoxy-5- bromophenyl	411
2-(6-fluoro) quinoliny	CH ₂	4-Cl-1,2-Ph	1,2-c-Pr	2-methoxy-5- bromophenyl	412
2-(5,7-difluoro)- quinoliny	SO ₂	4-Cl-1,2-Ph	CH=CH	2-methoxy-5- bromophenyl	413
2-(5,7-difluoro)- quinoliny	S	4-Cl-1,2-Ph	CH=CH	2-methoxy-5- bromophenyl	414
2-(5,7-difluoro)- quinoliny	CH ₂	4-Cl-1,2-Ph	CH=CH	2-methoxy-5- bromophenyl	415
2-(5,7-difluoro)- quinoliny	CH ₂	1,2-Ph	CH=CH	2-methoxy-5- bromophenyl	416
2-(5,7-difluoro)- quinoliny	O	4-Cl-1,2-Ph	CH=CH	2-methoxy-5- bromophenyl	417
2-(5,7-difluoro)- quinoliny	CH ₂	4-Cl-1,2-Ph	1,2-c-Pr	2-methoxy-5- bromophenyl	418

R ¹ R ² R ³ -Het	A	X	B	R ¹⁹	Cpd
3,4-dichloro phenyl	SO ₂	4-Cl-1,2-Ph	CH=CH	2-methoxy-5-bromophenyl	419
3,4-dichloro phenyl	S	4-Cl-1,2-Ph	CH=CH	2-methoxy-5-bromophenyl	420
3,4-dichloro phenyl	CH ₂	4-Cl-1,2-Ph	CH=CH	2-methoxy-5-bromophenyl	421
3,4-dichloro phenyl	CH ₂	1,2-Ph	CH=CH	2-methoxy-5-bromophenyl	422
3,4-dichloro phenyl	O	4-Cl-1,2-Ph	CH=CH	2-methoxy-5-bromophenyl	423
3,4-dichloro phenyl	CH ₂	4-Cl-1,2-Ph	1,2-c-Pr	2-methoxy-5-bromophenyl	424
3,4-dichloro phenyl	CH ₂	5-Cl-1,2-Ph	CH=CH	2-methoxy-5-bromophenyl	425
4-chloro phenyl	SO ₂	4-Cl-1,2-Ph	CH=CH	2-methoxy-5-bromophenyl	426
4-chloro phenyl	S	4-Cl-1,2-Ph	CH=CH	2-methoxy-5-bromophenyl	427
4-chloro phenyl	CH ₂	4-Cl-1,2-Ph	CH=CH	2-methoxy-5-bromophenyl	428
4-chloro phenyl	CH ₂	1,2-Ph	CH=CH	2-methoxy-5-bromophenyl	429
4-chloro phenyl	O	4-Cl-1,2-Ph	CH=CH	2-methoxy-5-bromophenyl	430
4-chloro phenyl	CH ₂	4-Cl-1,2-Ph	1,2-c-Pr	2-methoxy-5-bromophenyl	431
4-chloro phenyl	CH ₂	4-Cl-1,2-Ph	CH=CH	2-methoxy-5-bromophenyl	432
3,4-dichloro phenyl	SO ₂	4-Cl-1,2-Ph	CH=CH	2-thienyl	433
3,4-dichloro phenyl	S	4-Cl-1,2-Ph	CH=CH	2-thienyl	434
3,4-dichloro phenyl	CH ₂	4-Cl-1,2-Ph	CH=CH	2-thienyl	435
3,4-dichloro phenyl	CH ₂	1,2-Ph	CH=CH	2-thienyl	436
3,4-dichloro phenyl	O	4-Cl-1,2-Ph	CH=CH	2-thienyl	437
3,4-dichloro phenyl	CH ₂	4-Cl-1,2-Ph	CH=CH	2-thienyl	438
3,4-dichloro phenyl	CH ₂	5-Cl-1,2-Ph	CH=CH	2-thienyl	439
4-chloro phenyl	SO ₂	4-Cl-1,2-Ph	CH=CH	2-thienyl	440

$R^1R^2R^3\text{-Het}$	A	X	B	R^{19}	Cpd
4-chloro phenyl	S	4-Cl-1,2-Ph	CH=CH	2-thienyl	441
4-chloro phenyl	CH ₂	4-Cl-1,2-Ph	CH=CH	2-thienyl	442
4-chloro phenyl	CH ₂	1,2-Ph	CH=CH	2-thienyl	443
1-(5-chloro) indolyl	CH ₂	3,2-Pyr	CH=CH	2,4-(Me) ₂ -thiazol-5-yl	444
1-(5-chloro) indolyl	CH ₂	3,2-Pyr	CH=CH	2-thienyl	445
1-(6-(4-chloro) phenyl)indolyl	CH ₂	4-F-1,2-Ph	CH=CH	3-chloro-4-fluorophenyl	446
2-(6-difluoro methoxy) naphthyl	CH ₂	4-Cl-1,2-Ph	CH=CH	2-methoxy-5-bromophenyl	447
2-naphthyl	CH ₂	4-MeO-1,2-Ph	CH=CH	2-methoxy-5-bromophenyl	448
2-naphthyl	CH ₂	5-Cl-1,2-Ph	CH=CH	2-methoxy-5-bromophenyl	449
2-(6-chloro naphthyl)	CH ₂	4-Cl-1,2-Ph	CH=CH	2-methoxy-5-bromophenyl	450
1-(5-phenyl methoxy) indolyl	CH ₂	4-F-1,2-Ph	CH=CH	2-methoxy-5-bromophenyl	451
2-(benzo[b] thiophenyl)	CH ₂	4-F-1,2-Ph	CH=CH	2-methoxy-5-bromophenyl	452
5-(1-benzyl) indolyl	CH ₂	4-F-1,2-Ph	CH=CH	2-methoxy-5-bromophenyl	453
1-(6-(4-chloro) phenyl)indolyl	CH ₂	4-F-1,2-Ph	CH=CH	2-methoxy-5-bromophenyl	454

5

Table II



I-b

(Compounds 324-346 and 455-542)

5

R ¹ R ² R ³ -Het	A	X	B	Cpd
2-naphthyl	S(O) ₂	1,2-phenyl	CH=CH	324
2-naphthyl	S	1,2-phenyl	CH=CH	325
4-methylthiophenyl	CH ₂	1,2-phenyl	CH=CH	326
3-methylindol-1-yl	CH ₂	1,2-phenyl	CH=CH	327
3-chloro-4-fluorophenyl	CH ₂	1,2-phenyl	CH=CH	328
4-chlorophenyl	CH ₂	1,2-phenyl	CH=CH	329
2-naphthyl	CH ₂	1,2-phenyl	CH=CH	330
2-naphthyl	S(O) ₂	1,2-phenyl	1,2-c-propyl	331
2-naphthyl	S(O) ₂	1,2-phenyl	CH ₂ -CH ₂	332
2-naphthyl	S	1,2-phenyl	CH=CH	333
3,4-dichlorophenyl	S(O) ₂	1,2-phenyl	CH ₂ -CH ₂	334
3,4-dichlorophenyl	CH ₂	1,2-phenyl	CH=CH	335
2-(6-benzyloxy)naphthyl	CH ₂	1,2-phenyl	CH=CH	336
2-(6-benzyloxy)naphthyl	CH ₂	1,2-phenyl	1,2-c-propyl	337
2-(6-benzyloxy)naphthyl	SO ₂	1,2-phenyl	1,2-c-propyl	338
2-(6-benzyloxy)naphthyl	CH ₂ -O	1,2-phenyl	1,2-c-propyl	339
2-(6-benzyloxy)naphthyl	O-CH ₂	1,2-phenyl	1,2-c-propyl	340
2-(6-benzyloxy)naphthyl	SO ₂	1,2-phenyl	CH=CH	341
2-(6-benzyloxy)naphthyl	CH ₂ -O	1,2-phenyl	CH=CH	342
2-(6-benzyloxy)naphthyl	O-CH ₂	1,2-phenyl	CH=CH	343
2-(6-benzyloxy)naphthyl	S	1,2-phenyl	CH=CH	344
2-(7-benzyloxy)naphthyl	SO ₂	1,2-phenyl	CH=CH	345
2-(6-(4-trifluoromethyl)benzyloxy)naphthyl	CH ₂	1,2-phenyl	CH=CH	346
2-(6-fluoro)naphthyl	SO ₂	4-Cl-1,2-Ph	CH=CH	455
2-(6-fluoro)naphthyl	S	4-Cl-1,2-Ph	CH=CH	456
2-(6-fluoro)naphthyl	CH ₂	4-Cl-1,2-Ph	CH=CH	457
2-(6-fluoro)naphthyl	CH ₂	1,2-Ph	CH=CH	458
2-(6-fluoro)naphthyl	O	4-Cl-1,2-Ph	CH=CH	459
2-(6-fluoro)naphthyl	CH ₂	4-Cl-1,2-Ph	1,2-c-Pr	460
2-(7-fluoro)naphthyl	SO ₂	4-Cl-1,2-Ph	CH=CH	461
2-(7-fluoro)naphthyl	S	4-Cl-1,2-Ph	CH=CH	462
2-(7-fluoro)naphthyl	CH ₂	4-Cl-1,2-Ph	CH=CH	463
2-(7-fluoro)naphthyl	CH ₂	1,2-Ph	CH=CH	464
2-(7-fluoro)naphthyl	O	4-Cl-1,2-Ph	CH=CH	465
2-(7-fluoro)naphthyl	CH ₂	4-Cl-1,2-Ph	1,2-c-Pr	466
2-(6-chloro)naphthyl	SO ₂	4-Cl-1,2-Ph	CH=CH	467
2-(6-chloro)naphthyl	S	4-Cl-1,2-Ph	CH=CH	468
2-(6-chloro)naphthyl	CH ₂	4-Cl-1,2-Ph	CH=CH	469
2-(6-chloro)naphthyl	CH ₂	1,2-Ph	CH=CH	470
2-(6-chloro)naphthyl	O	4-Cl-1,2-Ph	CH=CH	471

R ¹ R ² R ³ -Het	A	X	B	Cpd
2-(6-chloro)naphthyl	CH ₂	4-Cl-1,2-Ph	1,2-c-Pr	472
2-(7-chloro)naphthyl	SO ₂	4-Cl-1,2-Ph	CH=CH	473
2-(7-chloro)naphthyl	S	4-Cl-1,2-Ph	CH=CH	474
2-(7-chloro)naphthyl	CH ₂	4-Cl-1,2-Ph	CH=CH	475
2-(7-chloro)naphthyl	CH ₂	4-Cl-1,2-Ph	CH=CH	476
2-(7-chloro)naphthyl	CH ₂	4-Cl-1,2-Ph	CH=CH	477
2-(7-chloro)naphthyl	CH ₂	4-Cl-1,2-Ph	CH=CH	478
2-(6,7-difluoro)naphthyl	SO ₂	4-Cl-1,2-Ph	CH=CH	479
2-(6,7-difluoro)naphthyl	S	4-Cl-1,2-Ph	CH=CH	480
2-(6,7-difluoro)naphthyl	CH ₂	4-Cl-1,2-Ph	CH=CH	481
2-(6,7-difluoro)naphthyl	CH ₂	4-Cl-1,2-Ph	CH=CH	482
2-(6,7-difluoro)naphthyl	CH ₂	4-Cl-1,2-Ph	CH=CH	483
2-(6,7-difluoro)naphthyl	CH ₂	4-Cl-1,2-Ph	1,2-c-Pr	484
2-(6,7-difluoro)naphthyl	CH ₂	4-Cl-1,2-Ph	CH=CH	485
2-(6,7-difluoro)naphthyl	CH ₂	4-Cl-1,2-Ph	CH=CH	486
2-(6,7-difluoro)naphthyl	CH ₂	4-Cl-1,2-Ph	CH=CH	487
2-(6,7-difluoro)naphthyl	CH ₂	1,2-Ph	CH=CH	488
2-(6,7-difluoro)naphthyl	CH ₂	4-Cl-1,2-Ph	CH=CH	489
2-(6,7-difluoro)naphthyl	CH ₂	4-Cl-1,2-Ph	1,2-c-Pr	490
3-methyl-5-fluoro indol-1-yl	SO ₂	4-Cl-1,2-Ph	CH=CH	491
3-methyl-5-fluoro indol-1-yl	S	4-Cl-1,2-Ph	CH=CH	492
3-methyl-5-fluoro indol-1-yl	CH ₂	4-Cl-1,2-Ph	CH=CH	493
3-methyl-5-fluoro indol-1-yl	CH ₂	1,2-Ph	CH=CH	494
3-methyl-5-fluoro indol-1-yl	CH ₂	4-Cl-1,2-Ph	CH=CH	495
3-methyl-5-fluoro indol-1-yl	CH ₂	4-Cl-1,2-Ph	CH=CH	496
2-(6-fluoro)quinolinyl	SO ₂	4-Cl-1,2-Ph	CH=CH	497
2-(6-fluoro)quinolinyl	S	4-Cl-1,2-Ph	CH=CH	498
2-(6-fluoro)quinolinyl	CH ₂	4-Cl-1,2-Ph	CH=CH	499
2-(6-fluoro)quinolinyl	CH ₂	4-Cl-1,2-Ph	CH=CH	500
2-(6-fluoro)quinolinyl	O	4-Cl-1,2-Ph	CH=CH	501
2-(6-fluoro)quinolinyl	CH ₂	4-Cl-1,2-Ph	CH=CH	502
2-(6-difluoromethoxy)- naphthyl	SO ₂	4-Cl-1,2-Ph	CH=CH	503
2-(6-difluoromethoxy)- naphthyl	SO ₂	4-Cl-1,2-Ph	CH=CH	504
2-(6-difluoromethoxy)- naphthyl	SO ₂	4-Cl-1,2-Ph	CH=CH	505

R ¹ R ² R ³ -Het	A	X	B	Cpd
2-(6-difluoromethoxy)-naphthyl	SO ₂	4-Cl-1,2-Ph	CH=CH	506
2-(6-difluoromethoxy)-naphthyl	SO ₂	4-Cl-1,2-Ph	CH=CH	507
2-(6-difluoromethoxy)-naphthyl	SO ₂	4-Cl-1,2-Ph	CH=CH	508
2-(7-difluoromethoxy)-naphthyl	SO ₂	4-Cl-1,2-Ph	CH=CH	509
2-(7-difluoromethoxy)-naphthyl	S	4-Cl-1,2-Ph	CH=CH	510
2-(7-difluoromethoxy)-naphthyl	CH ₂	4-Cl-1,2-Ph	CH=CH	511
2-(7-difluoromethoxy)-naphthyl	CH ₂	4-Cl-1,2-Ph	CH=CH	512
2-(7-difluoromethoxy)-naphthyl	O	4-Cl-1,2-Ph	CH=CH	513
2-(7-difluoromethoxy)-naphthyl	CH ₂	4-Cl-1,2-Ph	CH=CH	514
2-(6-methoxy)naphthyl	SO ₂	4-Cl-1,2-Ph	CH=CH	515
2-(6-methoxy)naphthyl	S	4-Cl-1,2-Ph	CH=CH	516
2-(6-methoxy)naphthyl	CH ₂	4-Cl-1,2-Ph	CH=CH	517
2-(6-methoxy)naphthyl	CH ₂	4-Cl-1,2-Ph	CH=CH	518
2-(6-methoxy)naphthyl	O	4-Cl-1,2-Ph	CH=CH	519
2-(6-methoxy)naphthyl	CH ₂	4-Cl-1,2-Ph	CH=CH	520
2-(6-fluoro)naphthyl	CH ₂	4-Cl-1,2-Ph	CH=CH	521
2-(6-fluoro)naphthyl	CH ₂	4-Cl-1,2-Ph	CH=CH	522
2-(6-fluoro)naphthyl	CH ₂	4-Cl-1,2-Ph	CH=CH	523
2-(6-fluoro)naphthyl	CH ₂	4-Cl-1,2-Ph	CH=CH	524
2-(6-fluoro)naphthyl	CH ₂	4-Cl-1,2-Ph	CH=CH	525
2-(6-fluoro)naphthyl	CH ₂	4-Cl-1,2-Ph	CH=CH	526
2-(7-fluoro)naphthyl	CH ₂	4-Cl-1,2-Ph	CH=CH	527
2-(7-fluoro)naphthyl	CH ₂	4-Cl-1,2-Ph	CH=CH	528
2-(7-fluoro)naphthyl	CH ₂	4-Cl-1,2-Ph	CH=CH	529
2-(7-fluoro)naphthyl	CH ₂	4-Cl-1,2-Ph	CH=CH	530
2-(7-fluoro)naphthyl	CH ₂	4-Cl-1,2-Ph	CH=CH	531
2-(7-fluoro)naphthyl	CH ₂	4-Cl-1,2-Ph	CH=CH	532
2-naphthyl	CH ₂	4,5-Cl ₂ -1,2-Ph	CH=CH	533
2-naphthyl	CH ₂	4-Cl-1,2-Ph	CH=CH	534
3,4-dichlorophenyl	CH ₂	4-Cl-1,2-Ph	CH=CH	535
2-naphthyl	CH ₂	4-Cl-1,2-Ph	CH=CH	536
4-chlorophenyl	CH ₂	4-Cl-1,2-Ph	CH=CH	537
1-(5-phenylmethoxy)indolyl	CH ₂	4-F-1,2-Ph	CH=CH	538

R ¹ R ² R ³ -Het	A	X	B	Cpd
2-(benzo[b]thiophenyl)	CH ₂	4-F-1,2-Ph	CH=CH	539
5-(1-benzyl)indolyl	CH ₂	4-F-1,2-Ph	CH=CH	540
1-(6-(4-chloro)phenyl) indolyl	CH ₂	4-F-1,2-Ph	CH=CH	541
1-(5-chloro)indolyl	CH ₂	3,2-Pyr	CH=CH	542

5

wherein D= -O(CH₂)₃-O, Qn= 7-chloroquinolin-2-yl, 1,2-Ph = 1,2-benzenediyl, Rs = -CH₂SCH₂CH₂Ph, Pyr = pyridinediyl, c-pr = cyclopropyl and Bn = benzyl.

19. A pharmaceutical composition which is
 10 comprised of a compound in accordance with any one of claims 1 to 18 in combination with a pharmaceutically acceptable carrier.

20. A method of treating or preventing a prostaglandin mediated disease which is comprised of administering to a mammalian
 15 patient in need of such treatment a compound in accordance with claim 1 in an amount which is effective for treating or preventing a prostaglandin mediated disease.

21. A method in accordance with claim 19 wherein the
 20 prostaglandin mediated disease is selected from the group consisting of:
 pain, fever or inflammation associated with rheumatic fever, influenza or other viral infections, common cold, low back and neck pain, skeletal pain, post-partum pain, dysmenorrhea, headache, migraine, toothache, sprains and strains, myositis, neuralgia,
 25 ~~synovitis, arthritis, including rheumatoid arthritis, degenerative joint diseases (osteoarthritis), gout and ankylosing spondylitis, bursitis,~~
 burns including radiation and corrosive chemical injuries, sunburns, pain following surgical and dental procedures, immune and autoimmune diseases;
 30 cellular neoplastic transformations or metastatic tumor growth;
 diabetic retinopathy, tumor angiogenesis;

- 5 prostanoid-induced smooth muscle contraction associated
with dysmenorrhea, premature labor, asthma or eosinophil related
disorders;
- Alzheimer's disease;
 glaucoma;
- 10 bone loss;
 osteoporosis;
 promotion of bone formation;
 Paget's disease;
 cytoprotection in peptic ulcers, gastritis, regional enteritis,
- 15 ulcerative colitis, diverticulitis or other gastrointestinal lesions; GI
bleeding and patients undergoing chemotherapy;
 coagulation disorders selected from hypoprothrombinemia,
haemophilia and other bleeding problems;
- kidney disease;
- 20 thrombosis;
 occlusive vascular disease;
 presurgery;
 and anti-coagulation.
- 25 22. A method in accordance with claim 20 wherein the
prostaglandin mediated disease is selected from the group consisting of:
pain, fever or inflammation.
23. A method in accordance with claim 20 wherein the
- 30 prostaglandin mediated disease is dysmenorrhea.
24. A method in accordance with claim 20, wherein the
compound is co-administered with other agents or ingredients.
- 35 25. A method in accordance with claim 24 wherein the
compound I is co-administered with another agent or ingredient
selected from the group consisting of: an analgesic selected from
acetaminophen, phenacetin, aspirin, a narcotic;

- 5 a COX-2 selective NSAID and a conventional NSAID;
caffeine;
an H₂-antagonist;
aluminum or magnesium hydroxide;
simethicone;
10 a decongestant selected from phenylephrine,
phenylpropanolamine, pseudophedrine, oxymetazoline, ephinephrine,
naphazoline, xylometazoline, propylhexedrine, or levo-desoxyephedrine;
an antiitussive selected from codeine, hydrocodone,
caramiphen, carbetapentane and dextramethorphan;
15 another prostaglandin ligand selected from misoprostol,
enprostil, rioprostil, ornoprostol and rosaprostol; a diuretic; and
a sedating or non-sedating antihistamine.

26. Use of a compound, salt, hydrate or ester as
defined in any one of claims 1 to 18 in the manufacture of a
20 medicament for treatment or prevention of a prostaglandin
mediated disease.

27. A compound, salt, hydrate or ester as defined in
any one of claims 1 to 18 for use in the treatment or prevention of
a prostaglandin mediated disease.

- 25 28. A prostaglandin antagonist pharmaceutical
composition comprising an acceptable prostaglandin antagonistic
amount of a compound, salt, hydrate or ester as defined in any one
of claims 1 to 18, in association with a pharmaceutically
acceptable carrier.



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification ⁶ : C07C 57/42, 59/68, 59/84, 311/51, C07D 209/10, 307/64, 307/79</p>	A3	<p>(11) International Publication Number: WO 99/47497</p> <p>(43) International Publication Date: 23 September 1999 (23.09.99)</p>		
<table style="width: 100%; border: none;"> <tr> <td style="width: 50%; vertical-align: top; padding: 5px;"> <p>(21) International Application Number: PCT/CA99/00212</p> <p>(22) International Filing Date: 12 March 1999 (12.03.99)</p> <p>(30) Priority Data: 60/077,990 13 March 1998 (13.03.98) US 19815856.1 21 July 1998 (21.07.98) GB</p> <p>(71) Applicant (for all designated States except US): MERCK FROSST CANADA & CO. [CA/CA]; 16711 Trans-Canada Highway, Kirkland, Quebec H9H 3L1 (CA).</p> <p>(72) Inventors; and (75) Inventors/Applicants (for US only): GAREAU, Yves [CA/CA]; (CA). LABELLE, Marc [CA/CA]; (CA). JUTEAU, Helene [CA/CA]; (CA). GALLANT, Michel [CA/CA]; (CA). LACHANCE, Nicolas [CA/CA]; (CA). BELLEY, Michel [CA/CA]; 16711 Trans-Canada Highway, Kirkland, Quebec H9H 3L1 (CA).</p> <p>(74) Agent: MURPHY, Kevin, P.; Swabey Ogilvy Renault, Suite 1600, 1981 McGill College, Montreal, Quebec H3A 2Y3 (CA).</p> </td> <td style="width: 50%; vertical-align: top; padding: 5px;"> <p>(81) Designated States: AE, AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, UA, US, UZ, VN, YU, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p> <p>Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p> <p>(88) Date of publication of the international search report: 28 October 1999 (28.10.99)</p> </td> </tr> </table>			<p>(21) International Application Number: PCT/CA99/00212</p> <p>(22) International Filing Date: 12 March 1999 (12.03.99)</p> <p>(30) Priority Data: 60/077,990 13 March 1998 (13.03.98) US 19815856.1 21 July 1998 (21.07.98) GB</p> <p>(71) Applicant (for all designated States except US): MERCK FROSST CANADA & CO. [CA/CA]; 16711 Trans-Canada Highway, Kirkland, Quebec H9H 3L1 (CA).</p> <p>(72) Inventors; and (75) Inventors/Applicants (for US only): GAREAU, Yves [CA/CA]; (CA). LABELLE, Marc [CA/CA]; (CA). JUTEAU, Helene [CA/CA]; (CA). GALLANT, Michel [CA/CA]; (CA). LACHANCE, Nicolas [CA/CA]; (CA). BELLEY, Michel [CA/CA]; 16711 Trans-Canada Highway, Kirkland, Quebec H9H 3L1 (CA).</p> <p>(74) Agent: MURPHY, Kevin, P.; Swabey Ogilvy Renault, Suite 1600, 1981 McGill College, Montreal, Quebec H3A 2Y3 (CA).</p>	<p>(81) Designated States: AE, AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, UA, US, UZ, VN, YU, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p> <p>Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p> <p>(88) Date of publication of the international search report: 28 October 1999 (28.10.99)</p>
<p>(21) International Application Number: PCT/CA99/00212</p> <p>(22) International Filing Date: 12 March 1999 (12.03.99)</p> <p>(30) Priority Data: 60/077,990 13 March 1998 (13.03.98) US 19815856.1 21 July 1998 (21.07.98) GB</p> <p>(71) Applicant (for all designated States except US): MERCK FROSST CANADA & CO. [CA/CA]; 16711 Trans-Canada Highway, Kirkland, Quebec H9H 3L1 (CA).</p> <p>(72) Inventors; and (75) Inventors/Applicants (for US only): GAREAU, Yves [CA/CA]; (CA). LABELLE, Marc [CA/CA]; (CA). JUTEAU, Helene [CA/CA]; (CA). GALLANT, Michel [CA/CA]; (CA). LACHANCE, Nicolas [CA/CA]; (CA). BELLEY, Michel [CA/CA]; 16711 Trans-Canada Highway, Kirkland, Quebec H9H 3L1 (CA).</p> <p>(74) Agent: MURPHY, Kevin, P.; Swabey Ogilvy Renault, Suite 1600, 1981 McGill College, Montreal, Quebec H3A 2Y3 (CA).</p>	<p>(81) Designated States: AE, AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, UA, US, UZ, VN, YU, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p> <p>Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p> <p>(88) Date of publication of the international search report: 28 October 1999 (28.10.99)</p>			
<p>(54) Title: CARBOXYLIC ACIDS AND ACYLSULFONAMIDES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT</p> <div style="text-align: center; margin: 20px 0;"> $\begin{array}{c} R^1R^2R^3-HET \\ \diagdown \\ A \\ \\ X-B \\ \diagup \quad \diagdown \\ \quad \quad O \\ \quad \quad \\ \quad \quad Z \end{array} \qquad (I)$ </div> <p>(57) Abstract</p> <p>Compounds of formula (I), as well as pharmaceutically acceptable salts, hydrates and esters thereof, are disclosed. The compounds are useful for treating or preventing prostaglandin mediated diseases. Pharmaceutical compositions containing such compounds and methods of treatment are also included.</p>				

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav	TM	Turkmenistan
BF	Burkina Faso	GR	Greece		Republic of Macedonia	TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's	NZ	New Zealand		
CM	Cameroon		Republic of Korea	PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

INTERNATIONAL SEARCH REPORT

national Application No

PCT/CA 99/00212

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C07C57/42 C07C59/68 C07C59/84 C07C311/51 C07D209/10
C07D307/64 C07D307/79

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07C C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 97 25328 A (RHONE-POULENC RORER S.A.) 17 July 1997 (1997-07-17) claims, RN 193982-03-5 ---	1,18
X	WO 97 10246 A (RHONE-POULENC RORER S.A.) 20 March 1997 (1997-03-20) claims, RN 183735-78-6 ---	1,18
X	WO 96 31505 A (PHARMACOEPIA, INC.) 10 October 1996 (1996-10-10) claims, RN 183735-78-6 ---	1,18
X	EP 0 459 243 A (BAYER AG.) 4 December 1991 (1991-12-04) claims, RN 139513-73-8 ---	1,8
	-/--	

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents :

A document defining the general state of the art which is not considered to be of particular relevance

E earlier document but published on or after the international filing date

L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

O document referring to an oral disclosure, use, exhibition or other means

P document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

& document member of the same patent family

Date of the actual completion of the international search

21 June 1999

Date of mailing of the international search report

07. 09. 1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

HAMMER

INTERNATIONAL SEARCH REPORT

International Application No

PCT/CA 99/00212

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 4 996 214 A (COUSINS ET AL.) 26 February 1991 (1991-02-26) column 4; example 1 RN 135199-34-7 ---	1,8
X	EP 0 028 063 A (GLAXO GROUP LTD.) 6 May 1981 (1981-05-06) claims, RN 79558-19-3 ---	1,18
A	EP 0 560 080 A (HODOGAYA CHEMICAL CO., LTD.) 15 September 1993 (1993-09-15) formula I, RN 152152-07-3 ---	1-18
X	WO 96 11902 A (ZENECA LTD.) 25 April 1996 (1996-04-25) claims, RN 179256-47-4 ---	1,18,19
X	WO 97 08934 A (ONTOGEN CORP.) 13 March 1997 (1997-03-13) claims, RN 188980-42-0 ---	1,18
X	CHEMICAL ABSTRACTS, vol. 99, no. 15, 10 October 1983 (1983-10-10) Columbus, Ohio, US; abstract no. 115553u, ATKINSON, D.C. ET AL.: "Substituted (2-phenoxyphenyl)acetic acids with antiinflammatory activity" page 21; column 2; XP002900537 abstract & J. MED. CHEM., vol. 26, no. 10, 1983, pages 1353-1360, ---	1,18
X	CHEMICAL ABSTRACTS, vol. 119, no. 6, 9 August 1993 (1993-08-09) Columbus, Ohio, US; abstract no. 55727y, YOKOTA, TOMOHIRO: "Skin-lightening preparations containing cinnamic acid derivatives" page 423; column 2; XP002900538 abstract & JP 05 078230 A (TOKKYO KOHO) 30 March 1993 (1993-03-30) ---	1,18

	-/--	

INTERNATIONAL SEARCH REPORT

national Application No

PCT/CA 99/00212

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	CHEMICAL ABSTRACTS, vol. 95, no. 19, 9 November 1981 (1981-11-09) Columbus, Ohio, US; abstract no. 161760z, IIZUKA KINJI ET AL.: "Highly selective inhibitors of thromboxane synthetase. 1. Imidazole derivatives" page 25; column 1; XP002900539 abstract & J. MED. CHEM., vol. 24, no. 10, 1981, pages 1139-1148, ---	1,18
X	CHEMICAL ABSTRACTS, vol. 91, no. 25, 17 December 1979 (1979-12-17) Columbus, Ohio, US; abstract no. 210985e, PLEVYAK, J.E. ET AL.: "Selective palladium-catalyzed vinylic substitutions with bromiodo aromatics" page 644; column 1; XP002900540 abstract & J. ORG. CHEM., vol. 44, no. 23, 1979, pages 4078-4080, ---	1,18
A	CHEMICAL ABSTRACTS, vol. 107, no. 21, 23 November 1987 (1987-11-23) Columbus, Ohio, US; abstract no. 190622c, GODA, YUKIHIRO ET AL.: "Inhibitors of the arachidonate cascade from Allium chinense and their effect on in vitro platelet aggregation" page 43; column 1; XP002900541 abstract & CHEM. PHARM. BULL., vol. 35, no. 7, 1987, pages 2668-2674, ---	1,20-28
A	CHEMICAL ABSTRACTS, vol. 117, no. 5, 3 August 1992 (1992-08-03) Columbus, Ohio, US; abstract no. 39800v, TSENG, CHENFANG ET AL.: "Inhibition of in vitro prostaglandin and leukotriene biosyntheses by cinnamoyl-beta-phenethylamine and N-acyldopamine derivatives" page 20; column 1; XP002900542 abstract & CHEM. PHARM. BULL., vol. 40, no. 2, 1992, pages 396-400, ---	1,20-28
	--- -/--	

INTERNATIONAL SEARCH REPORT

International Application No

PCT/CA 99/00212

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	CHEMICAL ABSTRACTS, vol. 109, no. 21, 21 November 1988 (1988-11-21) Columbus, Ohio, US; abstract no. 190191c, BUGGLE, K. ET AL.: "The reaction of diphenylsulfilimine with benzothiopyran-4-one 1,1-dioxides and benzothiopyran-2-ones" page 691; column 2; XP002900543 abstract & J. CHEM. RES., SYNOP., no. 2, 1988, page 49 ---	1,18
A	WO 92 02495 A (SCHERING AG.) 20 February 1992 (1992-02-20) claims ---	1,20-28
A	EP 0 223 593 A (GLAXO GROUP LTD.) 27 May 1987 (1987-05-27) claims ---	1,20-28
A	EP 0 157 420 A (TERUMO K.K.) 9 October 1985 (1985-10-09) claims ---	1,20-28
A	EP 0 536 713 A (E.R. SQUIBB & SONS, INC.) 14 April 1993 (1993-04-14) claims -----	1,20-28

INTERNATIONAL SEARCH REPORT

International application No.

PCT/CA 99/ 00212

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 20-25
because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claims 20-25
are directed to a method of treatment of the human/animal
body (PCT rule 39.1(iv)), the search has been carried out and based
on the alleged effects of the compounds.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such
an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all
searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment
of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report
covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is
restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

ANHANG

zum internationalen Recherchen-
bericht über die internationale
Patentanmeldung Nr.

ANNEX

to the International Search
Report to the International Patent
Application No.

ANNEXE

au rapport de recherche inter-
national relatif à la demande de brevet
international n°

PCT/CA 99/00212 SAE 226775

In diesem Anhang sind die Mitglieder
der Patentfamilien der in obenge-
nannten internationalen Recherchenbericht
angeführten Patentdokumente angegeben.
Diese Angaben dienen nur zur Unter-
richtung und erfolgen ohne Gewähr.

This Annex lists the patent family
members relating to the patent documents
cited in the above-mentioned inter-
national search report. The Office is
in no way liable for these particulars
which are given merely for the purpose
of information.

La présente annexe indique les
membres de la famille de brevets
relatifs aux documents de brevets cités
dans le rapport de recherche inter-
national visé ci-dessus. Les renseigne-
ments fournis sont donnés à titre indica-
tif et n'engagent pas la responsabilité
de l'Office.

In Recherchenbericht angeführtes Patentdokument Patent document cited in search report Document de brevet cité dans le rapport de recherche	Datum der Veröffentlichung Publication date Date de publication	Mitglied(er) der Patentfamilie Patent family member(s) Membre(s) de la famille de brevets	Datum der Veröffentlichung Publication date Date de publication
WD A1 9725328	17-07-1997	AU A1 13830/97 CA AA 2239254 CN A 1207102 CZ A3 9802166 EP A1 880522 FR A1 2743366 FR B1 2743366 PL A1 327942	01-08-1997 17-07-1997 03-02-1999 14-10-1998 02-12-1998 11-07-1997 06-02-1998 04-01-1999
WD A1 9710246	20-03-1997	AU A1 69920/96 FR A1 2738821 FR B1 2738821	01-04-1997 21-03-1997 21-11-1997
WD A1 9631505	10-10-1996	AU A1 54327/96 IL A0 117797	23-10-1996 04-08-1996
EP A2 459243	04-12-1991	DE A1 4037003 CA AA 2043310 EP A3 459243 JP A2 6345740 US A 5167693	05-12-1991 01-12-1991 04-03-1992 20-12-1994 01-12-1992
US A 4996214	26-02-1991	AU A1 82388/91 CA AA 2083710 EP A1 536310 JP T2 5508411 PT A 98078 ZA A 9104959 WO A1 9200279	23-01-1992 29-12-1991 14-04-1993 25-11-1993 30-06-1993 24-06-1992 09-01-1992
EP A1 28063	06-05-1981	AT E 7897 AU A1 62047/80 AU B2 543739 DE C0 3068213 DK A 3777/80 EP B1 28063 ES A1 494769 ES A5 494769 ES A1 8106124 ES A1 501436 ES A5 501436 ES A1 501437 ES A5 501437 ES A1 8202777 ES A1 8203318 FI A 802783 GB A1 2058785 GB B2 2058785 JP A2 56049336 NZ A 194844 ZA A 8005478	15-06-1984 12-03-1981 02-05-1985 19-07-1984 06-03-1981 13-06-1984 16-07-1981 14-08-1981 01-10-1981 16-02-1982 12-03-1982 01-04-1982 29-04-1982 16-05-1982 01-07-1982 06-03-1981 15-04-1981 25-05-1983 02-05-1981 29-07-1983 30-09-1981
EP A1 560080	15-09-1993	DE C0 69316250 DE T2 69316250 EP B1 560080 JP A2 5297637 US A 5346794 JP A2 5297639 JP A2 5249747 JP A2 5249746	19-02-1998 04-06-1998 14-01-1998 12-11-1993 13-09-1994 12-11-1993 28-09-1993 28-09-1993

WO A1	9611902	25-04-1996	AU A1	36162/95	06-05-1996
			EP A1	733033	25-09-1996
			GB A0	9420557	30-11-1994
			IL A0	115577	19-01-1996
			JP T2	9511529	18-11-1997
			US A	5811459	22-09-1998
			ZA A	9508622	12-04-1996
WO A1	9708934		WO A2	9708934	13-03-1997
			WO A1	9827065	25-06-1998
			AU A1	77358/96	27-03-1997
			AU A1	15667/97	15-07-1998
			EP A2	833629	08-04-1998
			EP A4	833629	16-09-1998
			US A	5753687	19-05-1998
			US A	5770620	23-06-1998
			CA AA	2224874	13-03-1997
JP A2	5078230	30-03-1993	keine - none - rien		
WO A1	9202495	20-02-1992	AT E	122036	15-05-1995
			AU A1	82212/91	02-03-1992
			CA AA	2088161	28-01-1992
			DE A1	4024347	30-01-1992
			DE C0	59105400	08-06-1992
			DK T3	541594	02-10-1995
			EP A1	541594	19-05-1993
			EP B1	541594	03-05-1995
			ES T3	2074721	16-09-1995
			IE B	67507	03-04-1996
			IL A0	98970	15-07-1992
			JP T2	6502390	17-03-1994
			PT A	98464	29-05-1992
			PT B	98464	31-10-1997
			ZA A	9105905	29-04-1992
EP A2	223593	27-05-1987	AT E	65992	15-08-1991
			AU A1	65505/86	21-05-1987
			AU B2	593039	01-02-1990
			DE C0	3680753	12-09-1991
			DK A0	5501/86	18-11-1986
			DK A	5501/86	20-05-1987
			EP A3	223593	18-01-1989
			EP B1	223593	07-08-1991
			FI A0	864692	18-11-1986
			FI A	864692	20-05-1987
			GB A0	8528398	24-12-1985
			GB A0	8627512	17-12-1986
			GB A1	2183234	03-06-1987
			GB B2	2183234	04-10-1989
			IL A0	80701	27-02-1987
			JP A2	62155250	10-07-1987
			NO A0	864599	18-11-1986
			NO A	864599	20-05-1987
			PH A	23837	23-11-1989
			PT A	83762	01-12-1986
			PT B	83762	07-12-1988
			ZA A	8608740	29-07-1987
EP A2	157420	09-10-1985	DE C0	3584846	23-01-1992
			EP A3	157420	19-11-1987
			EP B1	157420	11-12-1991
			EP B1	399569	24-08-1994
			JP A2	61122270	10-06-1986
			JP B4	4073431	20-11-1992
			US A	4673684	16-06-1987
			JP A2	61106555	24-05-1986
			JP B4	4073430	20-11-1992
			JP A2	61078756	22-04-1986
			JP B4	63055508	02-11-1988
			JP A2	61022057	30-01-1986
			JP B4	4024328	24-04-1992
			JP A2	61022056	30-01-1986
			JP B4	63055510	02-11-1988
			DE C0	3587912	29-09-1994
			DE T2	3587912	02-02-1995
			EP A1	399569	28-11-1990
			JP A2	60214766	28-10-1985
			JP B4	1038780	16-08-1989
EP A1	536713	14-04-1993	CA AA	2079705	08-04-1993
			JP A2	5255274	05-10-1993
			US A	5827868	27-10-1998